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Mitochondria play critical roles in the generation of cellular energy, apoptosis, calcium
buffering, and mitochondrial dysfunction is strongly implicated in common
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. However, we still
have a very poor understanding of the consequences of mitochondrial dysfunction in
neurons in vivo. This thesis investigates mitochondrial dysfunction in patients with
neurodegenerative disease and in a novel Drosophila model of neuronal mitochondrial
dysfunction.
I found that a single nucleotide polymorphism (SNP) in the gene mitochondrial transcription
factor A (TFAM, SNP rs2306604 A>G) is associated with Parkinson’s disease dementia
(PDD), but not with dementia with Lewy bodies (DLB). I have shown that mitochondrial
DNA levels are significantly reduced in the frontal cortex of PDD patients, compared to
controls. Furthermore, I have characterised the expression of TFAM and representative
components of the mitochondrial electron transport (ETC) chain at the protein level in
patients with Parkinson’s disease with and without dementia to determine whether
rs2306604 A>G affects TFAM or ETC protein expression.
In order to investigate mitochondrial dysfunction in a genetically tractable model system I
have used a novel model of neuronal-specific mitochondrial dysfunction in Drosophila. I
have used overexpression of TFAM, or expression of a mitochondrially-targeted restriction
enzyme mitoXhoI, to cause mitochondrial dysfunction specifically in neurons. I have
analysed the changes in mitochondrial DNA and mitochondrial gene expression in this
model as well as characterising the behavioural and synaptic phenotypes.
Using this model I performed microarray analysis to characterise the mitochondrial
retrograde response in the Drosophila nervous system. This analysis revealed that neuronal
mitochondrial dysfunction alters the expression of over 300 genes. I have validated the
4changes in expression of several of these genes in vivo. I have also characterised the
involvement of the transcription factor hypoxia inducible factor alpha (HIFα) in the
mitochondrial retrograde response in Drosophila. I found that HIFα regulates the
expression of several retrograde response genes and that modulation of HIFα expression
ameliorates some of the phenotypes associated with mitochondrial dysfunction.
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1. Introduction
1.1. Dementia facts and figures
Dementia is one of the largest and most devastating current global health challenges.  The
World Alzheimer Report 2013 states that dementia affects 35 million people worldwide
and that this frequency is expected to double by 2030 and triple by 2050 (Prince et al.,
2013).
The global annual costs of dementia in 2010 were estimated to be of US $ 604 billion,
equivalent to 1% of the World’s Gross Domestic Product (Prince et al., 2013).  Dementia
costs will increase proportionally to the number of people affected by the disease and is
therefore estimated to double to a cost of US $ 1,117 billion by 2030. In the UK, there are
currently over 800,000 people living with dementia, costing the UK economy £23 billion per
year (Kane and Cook, 2013).
1.2. Alzheimer’s Disease (AD)
Alzheimer’s disease (AD) was first described by psychiatrist and neuropathologist Alois
Alzheimer in 1906. He had been treating a patient with progressive memory loss, and while
carrying out an autopsy upon her death he noticed severe atrophy in her cerebral cortex, as
well as neurofibrillary tangles and neuritic plaques (Ramirez-Bermudez, 2012). These
histopathological features are today recognised as the pathological hallmarks of the
disease.
AD is the most prevalent form of dementia, accounting for 50-75% of all dementia cases in
the elderly. Age is a well-known risk factor for all forms of dementia and, in fact, the most
common cases of Alzheimer’s disease are late-onset (LOAD), with symptoms developing
above the age of 65. Early-onset cases (EOAD), which develop earlier than the age of 65,
are less prevalent and are commonly familial, therefore clustering within families.
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Epidemiological studies have identified additional risk factors for the disease relating to
general lifestyle, and a family history of the disease. Indeed, history of AD in the family
leads to a 3-4 fold increased risk of developing the disease, suggesting the existence of
genetic risk factors associated with AD. A well-established genetic associate of AD is the
lipid-binding apolipoprotein E (ApoE), a polymorphic protein with three isoforms: E2, E3
and E4. The presence of at least one copy of the ApoE E4 variant has been established as a
genetic risk factor for AD (Hutton et al., 1998).
1.2.1. Clinical symptoms and diagnosis of AD
Since AD is a progressive disease, symptoms tend to worsen over time.  The earliest sign of
AD is memory loss and changes in mood, which will worsen over progression of the disease
and will be accompanied by increased disorientation and confusion.  Additional symptoms
developed over progression of the disease may include trouble with sleep, poor vision,
delusions and hallucinations, problems with language and weight loss amongst others.
Ultimately, at the latest stages of the disease, patients will require full-time care as they
lose the ability of looking after themselves.
Clinically, a diagnosis of probable AD is made upon a thorough investigation of the
symptoms and medical history of the patient, as well as neuropsychological assessments
that establish a progressive loss of memory, executive function and cognitive impairment.
However, a definitive diagnosis of AD can only be reported upon histological examination
of the post-mortem brain specimen of the individual.
At autopsy, AD brains typically present substantial cerebral cortical atrophy, usually
involving the frontotemporal association cortex. Atrophied brain tissue in AD also tends to
result in symmetrical dilation of the lateral ventricles, and atrophy of the hippocampus is
usually associated with dilation of the temporal horn of the lateral ventricle.
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1.2.2. Neuropathology of AD
Microscopically, AD is characterised by the presence of extracellular cortical ‘plaques’
containing amyloid beta (Aβ) and intracellular ‘tangles’ containing hyperphosporylated tau
protein in the brain, granulo-vacuolar degeneration, and eosinophilic rod-like inclusions
(Perl, 2010) (Figure 1.1A,B).
Cortical plaques are mainly composed of Aβ, which is a 4-kDa protein with a beta-pleated
sheet configuration. It is derived from the fragmentation of the highly conserved
transmembrane amyloid precursor protein (APP) which, upon the action of secretases, is
cleaved into a 42–amino acid chain (Aβ 1–42), which is deposited within senile plaques and a
40–amino acid chain (Aβ 1–40), which tends to localise in cerebral cortical and cerebellar
blood vessels (Prelli et al., 1988).
Neurofibrillary tangles are usually present as paired helical filaments, the main component
of which is a hyperphosphorylated version of the microtubule-associated protein tau. The
extent and distribution of these tangles within the brain has been shown to be indicative of
the severity and duration of the disease (Arriagada et al., 1992; Bierer et al., 1995).
Although neurofibrillary tangles are considered to be a clinical hallmark for AD, they are
also observed in other neurodegenerative diseases, including post-traumatic dementia,
dementia pugalistica, amyotrophic lateral sclerosis/parkinsonism dementia complex of
Guam and post-encephalitic parkinsonism, as well as, the lysosomal storage disorder,
Niemann-Pick disease, type C (Perl, 2010). In 1991, Heiko Braak established a staging
method for tracking AD progression through tau pathology.  The presence of neurofibrillary
tangles in the transentorhinal region of the brain is typical of Braak stages I and II, whilst
stages III and IV are representative of tangle presence in the limbic regions including the
hippocampus. Finally, Braak stages V and VI are indicative of more severe pathology, with
tangles being present also in the neocortical regions (Braak and Braak, 1991).
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1.2.3. The amyloid cascade hypothesis
The ‘amyloid cascade hypothesis’, first proposed in 1992 (Hardy and Higgins, 1992),
identified Aβ as the main causative factor in AD pathology, stating that its aggregation
following APP cleavage leads to a neurotoxic cascade, resulting in neurofibrillary tangles,
cell loss, vascular damage and dementia (Figure 1.1 C).
The amyloid cascade hypothesis was partly based on the observations that mutations in
APP cause hereditary, EOAD (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al.,
1991; Naruse et al., 1991; van Duijn et al., 1991). Furthermore, a few years later, mutations
in presenilin genes PSEN1 and PSEN2 were also identified as causative mutations of familial
AD (Cruts et al., 1996). PSEN1 and PSEN2 are major components of the γ-secretase
complex, and are therefore responsible for APP cleavage. Therefore, the association of
PSEN1/2 mutations in AD, further re-established the role of APP cleavage in AD and further
supported the amyloid cascade hypothesis. Subsequently, the hypothesis led to a series of
studies and investment from the pharmaceutical industry that targeted Aβ removal as a
treatment for AD.
In 2012, a whole-genome sequence data analysis on 1,795 Icelanders was published,
revealing the identification of a protective variant of APP. The A673T substitution in APP
was found to have a strong protective effect against AD and against cognitive decline in the
elderly.  This substitution was then identified as being adjacent to a protease β-site in APP,
thereby resulting in reduced processing of the APP protein within the β-site and a lower
production of Aβ1–42 and Aβ1–40. This study was therefore also suggested as being proof of
the amyloid cascade hypothesis (Jonsson et al., 2012).
Additionally, a recent study using a three-dimensional human neural cell culture model of
AD provided further supporting evidence for the amyloid cascade hypothesis as
phosphorylated tau was shown to accumulate in ReNcell VM human neural stem cells
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expressing familial AD mutations, following accumulation of Aβ aggregates (Choi et al.,
2014). Similarly, a recent study showed that Aβ aggregates formed upon
intracerebroventricular injection of Aβ oligomers, induced tau phosphorylation and
formation of neurofibrillary tangles in non-human primates (Forny-Germano et al., 2014).
However, whilst Aβ aggregates and tau hyperphosphorylation are recognised as being
conducive to neuronal dysfunction in AD, the exact mechanism by which the two factors
interact to cause this neuronal deficit is not well elucidated. Several studies have suggested
that Aβ aggregation precedes, and induces tau hyperphosphorylation and that glycogen
synthase kinase-3β (GSK-3β) is required to mediate this response. Indeed, studies have
suggested that Aβ aggregates result in elevated activity of the serine/threonine kinase GSK-
3β, (Takashima et al., 1993; Takashima et al., 1996) which has been previously identified as
a tau kinase I, potentially phosphorylating tau in several sites that are found to be
hyperphosphorylated in AD tangles. GSK-3β levels are in fact found to be upregulated in
the hippocampus of AD patients (Blalock et al., 2004). Furthermore, GSK-3β is an important
negative regulator of the Wnt signalling pathway, and dysfunctional Wnt signalling has
been associated with neuronal degeneration and synaptic impairment in AD. Treatment
with Lithium, a GSK-3β inhibitor, has been shown to be neuroprotective and preventive of
AD neurodegeneration, both in vitro and in vivo (Alvarez et al., 1999; Zhang et al., 2011).
Additionally, expression of Wnt ligands, leading to permanent activation of the Wnt
pathway also exerts a neuroprotective effect (Cerpa et al., 2009). This suggests that the
downstream effects of the amyloid cascade might be prevented via inhibition of GSK-3β
and activation of the Wnt signalling pathway.
Other studies, however, argue that whilst the amyloid cascade hypothesis might hold true
for the familial form of AD, the sporadic cases might be due to more than just accumulation
of amyloidogenic proteins (Hardy and Mayer, 2011). Since the sporadic form of AD is
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responsible for the vast majority of cases, it is imperative that other factors linked to AD,
apart from the amyloid cascade hypothesis, are better investigated and looked at as
potential therapeutic targets.
Figure 1.1 Neuropathology of Alzheimer’s Disease
(A) Aβ positive senile plaques and (B) tau-positive neurofibrillary tangles and neuropil threads in a
typical AD brain (Haass and Selkoe, 2007). (C) The amyloid cascade hypothesis identifies Aβ as the
main causative factor in AD. Autosomal dominant mutations in presenilins PSEN1, PSEN2 and
amyloid precursor protein APP are associated with early onset familial AD (EOAD).  The presence of
these mutations leads to APP being cleaved into the neurotoxic Aβ 1–42, leading to Aβ aggregation,
formation of tau paired helical filaments (PHF) and eventually resulting in neuronal death.  Adapted




1.2.4. Current AD treatment
Medications currently administered to AD patients are aimed at alleviating certain
symptoms and improving cognition, behaviour and everyday function.
The nucleus basalis of Meynert, the origin of cortically-projecting cholinergic neurons, is
highly involved in the early stages of AD pathology.  AD is, in fact, associated with a decline
in acetylcholine synthesis capacity and cholinesterase inhibitor drugs are the most
administered drug in AD treatment, acting to increase levels of acetylcholine in the brain
(Farlow and Cummings, 2007).
Out of five total medications approved by the US Food and Drug Administration (FDA), four
are cholinesterase inhibitors and the fifth is an N-methyl-D-aspartate (NMDA) receptor
antagonist (Schneider, 2013). Tacrine was the first ever cholinesterase inhibitor to be
approved for AD treatment but is nowadays very rarely administered due to risks of
hepatotoxicity. Currently, the cholinesterase inhibitors Donepezil, Rivastigmine and
Galantamine are most commonly used to treat symptoms in mild to moderate AD and are
shown to be effective in improving memory, confidence, motivation and general daily
living. Memantine is a commonly used NMDA receptor antagonist, acting to reduce
excessive excitatory activity (Corbett and Ballard, 2012). It is used in more severe cases of
AD, and is associated with improved cognitive testing and behaviour. AD behavioural
symptoms are also often treated with neuropsychiatric medication including
antidepressants, anxiolytic medications and neuroleptic drugs (Corbett and Ballard, 2012).
Since all current treatments for AD only provide symptomatic benefit and do not modulate
the actual course of the disease, current studies are looking for agents that decrease Aβ
production and/or aggregation or increase Aβ clearance from the brain.
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More recently, because of a series of failures of Aβ-based compounds in clinical trials, tau
has emerged as a therapeutic target. However, only one anti-tau treatment has made it
into clinical phase III trials thus far. Additional tau-targeting therapies are still in
development stages, including immunotherapies and inhibition of GSK-3β.  Preliminary
studies in humans with lithium have been fairly promising, but lithium administration is
controversial and risky and therefore progress on this potential treatment has been slow
(Macdonald et al., 2008). Similarly, treatment with the tau aggregate inhibitor, methylene
blue, was encouraging but did not lead to major conclusions (Gura, 2008).
Therapies aimed at improving neuronal function have also been investigated. Treatment
with nerve growth factors has been proposed as a beneficial therapeutic method, and
candidates such as ladostigil have made it to phase II clinical trials (Weinreb et al., 2011).
Similarly, a 5-HT6 receptor antagonist, aimed at improving cholinergic neurotransmission
and cognition, has also made it to trials (Maher-Edwards et al., 2010). Treatments using
antihypertensives, antibiotics and brain insulin receptors are also currently being
investigated (Corbett and Ballard, 2012).
Since finding effective treatments for AD has proven difficult and many drugs have failed to
pass all clinical trials, it is imperative for new potential therapeutic avenues to be explored.
More importantly, emerging evidence strongly suggests that the initial changes occurring in
AD must be addressed as potential therapeutic targets. Eliminating plaques and tangles
from the brain once they have already developed might be too late to allow for a full
recovery.
1.3. Parkinson’s Disease (PD)
Parkinson’s disease (PD) was first described in 1817 in ‘An assay on the shaking palsy’
written by the English doctor James Parkinson (Parkinson, 1817). Today, it is the second
most common age-related neurodegenerative disorder following AD. It is estimated to
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affect 1% of the population aged over 60, equivalent to approximately 127,000 individuals
in the UK, and up to 5% of the population aged over 85 (de Lau and Breteler, 2006; Reeve
et al., 2014). Whilst the vast majority of PD cases are sporadic and idiopathic, 5% of all
cases are familial early-onset, with symptoms presenting prior to the age of 60.  Such cases
can be due to autosomal dominant or recessive mutations, affecting mostly protein
metabolism or mitochondrial function (Reeve et al., 2014).
1.3.1. Clinical symptoms, neuropathology and etiology of PD
Symptomatically, Parkinsonian disorders are characterised by the presence of bradykinesia,
tremor, rigidity and postural instability. Pathologically, parkinsonian disorders are
characterised by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc)
which project to the putamen, leading to reduced activity in the dopaminergic nigrostriatal
pathway. This neuronal loss correlates with the loss of the black pigmentation in SNpc, due
to less neuromelanin being generated as a by-product of dopamine (Figure 1.2A). Pigment
loss is also observed in the locus ceruleus in PD, correlating with a loss of noradrenergic
neurons.
PD is distinguished by the presence of neuronal inclusions composed of the presynaptic
protein α-synuclein. These are referred to as Lewy bodies when found in neuronal
perikarya, or Lewy neurites when found in neuronal processes (Figure 1.2B). Classical Lewy
bodies are found within the brain stem region of the brain, however occasionally Lewy
bodies are encountered in less affected brain regions such as the cortex and the amygdala.
These are referred to as cortical Lewy bodies (Ikeda et al., 1978) and are thought to
precede the classical Lewy bodies, thereby being termed ‘pre-Lewy bodies’.
Within Lewy bodies, α-synuclein is arranged as straight filaments that are 10-15 nm in
diameter. Such filaments, consisting of a beta-sheet conformation, have been observed in
vitro with wild-type and mutant α-synuclein (Conway et al., 2000). Native α-synuclein is
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thought to be relatively unfolded and conformational changes may lead to its fibrillation
(Perrin et al., 2000). A central hydrophobic region within the α-synuclein structure has been
shown to be crucial in fibril formation and is also a characteristic feature that distinguishes
α-synuclein from its beta (β) and gamma (γ) synuclein homologues (Giasson et al., 2001).
β-and γ-synuclein lack any fibrillation capacity and have, in fact, never been observed in
Lewy bodies or associated to any other pathologic structures. The factors that make α-
synuclein gain this fibrillar conformation are unknown, however post-translational
modifications such as phosphorylation, truncation and oxidative damage are thought to
play a role in the process (Giasson et al., 2000; Fujiwara et al., 2002; Tofaris et al., 2003;
Anderson et al., 2006).
α-synuclein pathology is also present in some AD patients, with most pathology being
restricted to the amygdala. These amygdala-only patterns are thought to differ from the α-
synuclein distribution observed in PD and therefore are thought to represent a separate
disease process (Iseki, 2004; Leverenz et al., 2008; Dickson et al., 2010).
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Figure 1.2 Neuropathology of Parkinson’s disease
(A) Horizontal sections from the midbrain showing loss of pigment in the SNpc of a PD patient, P,
compared to a healthy control, C (Mackenzie, 2001). (B) α-synuclein positive Lewy neurite (left) and
Lewy body (right) in the SNpc of a PD patient (Haass and Selkoe, 2007). (C) L-dopa (L-3,4-
dihydroxyphenylalanine) is the most commonly used dopamine-replacement therapy in PD, acting to
improve motor symptoms. Upon further degeneration, however, treatment with L-dopa will also





1.3.2. Genetic causes of PD
α-synuclein was identified as the main constituent of Lewy bodies in 1997 (Spillantini et al.,
1997). In the same year, the Ala53Thr missense mutation in the SNCA gene, encoding α-
synuclein, was shown to result in a dominantly inherited form of PD with Lewy pathology
(Polymeropoulos et al., 1997). Subsequently, other substitutions in the gene, including
Ala30Pro, Glu46Lys, His50Gln, and Gly51Asp, were also associated with PD
(Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004; Appel-Cresswell et
al., 2013; Lesage et al., 2013; Proukakis et al., 2013).  Duplications of the SNCA gene have
also been attributed to familial, late-onset PD (Singleton et al., 2003; Chartier-Harlin et al.,
2004; Ibanez et al., 2004; Fuchs et al., 2007; Nishioka et al., 2009), and additional copies of
SNCA have also been linked to a more severe Lewy body disease and a greater frequency of
dementia (Singleton et al., 2003; Ross et al., 2008).
However, the most common genetic cases of PD are linked to dominantly-inherited
missense mutations in LRRK2, a large gene comprising 51 exons which is located close to
the centromere on chromosome 12. It encodes leucine rich repeat kinase 2, a kinase with
well-established roles in striatal neurotransmission, neuronal arborisation, endocytosis,
autophagy and immunity (Cookson, 2012). Dominantly inherited substitutions in LRRK2
including Asn1437His, Arg1441Cys/Gly/His, Tyr1699Cys, Gly2019Ser and Ile2020Thr have
been linked to an idiopathic PD-like clinical phenotype (Paisan-Ruiz et al., 2004; Zimprich et
al., 2004; Kachergus et al., 2005; Aasly et al., 2010). LRRK2 PD is typically associated with
nigral neuronal loss and gliosis, along with Lewy body or neurofibrillary tangle pathology.
The Gly2019Ser mutation in LRRK2 has been shown to induce neuronal dysfunction via
alteration of mitochondrial dynamics in vitro (Niu et al., 2012), and is associated with
reduced mitochondrial membrane potential and adenosine triphosphate (ATP) levels in PD
patients (Mortiboys et al., 2010). Expressing a LRRK2 mutant in C. elegans also resulted in
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enhanced mitochondrial dysfunction and susceptibility to oxidative stress (Saha et al.,
2009).
The role of mitochondrial-associated genes in PD is further discussed in section 1.12.2.
1.3.3. Current PD treatment
Due to the predominant dopaminergic deficit, symptomatic PD therapy for motor
symptoms is mainly focused on regenerating levels of dopamine in the brain.
Neuroprotective or disease-modifying therapies aim to slow or block the loss of dopamine
neurons. Thus far there is no proven neuroprotective treatment, though drugs such as
monoamine oxidase (MAO)-B inhibitors, creatine and isradipine are currently under
investigation (Obeso et al., 2010).
To date, the most frequently administered drug for symptomatic treatment of PD is L-dopa.
Following its introduction as an anti-parkinsonian agent in 1968 (Cotzias, 1968), L-3,4-
dihydroxyphenylalanine (Levodopa or L-dopa) is now the most commonly used
dopaminergic drug. Even though it is the most efficacious drug treatment known for PD, its
benefits are quite short-lived and long-term administration can lead to sensitisation of the
dopaminergic system, resulting in motor-response complications including involuntary
movements known as levodopa-induced dyskinesias (LIDs) (Figure 1.2C). Whilst L-dopa
provides a mainly phasic dopaminergic stimulation, other dopamine agonists used in
treating PD (e.g. pramipexole, ropinirole, pergolide) provide a more tonic stimulation and
present different affinities for different dopamine receptors (Poletti and Bonuccelli, 2013).
Additionally, other neurotransmitter systems such as acetylcholine, serotonin and
noradrenaline are also implicated in PD and might provide alternative avenues for
therapeutic targets.
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Apart from the characteristic motor symptoms, PD cases are also characterised by
additional non-motor symptoms which can be categorised into three groups:
neuropsychiatric (including psychotic episodes, amnesia, anxiety, depression, fatigue),
autonomic (including urinary incontinence and excessive sweating) and sensory (including
pain and numbness). Since most non-motor symptoms are frequently found in conjunction
with motor symptoms, most methods of treatment are anti-parkinsonian therapies.
Analgesics might be used to treat pain and alpha-blockers might be used for dysautonomic
symptoms whilst anti-anxiety agents might be used to treat neuropsychiatric symptoms.
Overall, treatment for non-motor symptoms is also predominantly symptomatic and no
neuroprotective treatments are yet available.
1.4. Dementia with Lewy bodies (DLB) and Parkinson’s disease
dementia (PDD)
A frequently encountered non-motor symptom of PD which is of great distress to the
patients and their carers is a decline in cognitive function.
84% of PD patients are estimated to develop cognitive decline throughout their disease,
with 60% of men and 45% of women with PD developing Parkinson’s disease dementia
(PDD) by the age of 75 (Buter et al., 2008). In fact, PD patients are at a six-fold increased
risk of developing dementia compared to controls of the same age. The most commonly
diagnosed cognitive changes occurring in PD patients include impairments in executive
function and deficits in attention and visuospatial recognition. Some cases are also
associated to an impairment in memory, which might be a consequence of a deficit in
executive function (Irwin et al., 2013). It has therefore been suggested that impairments in
executive function in PD are due to dopaminergic loss in the frontal cortex, whilst
subsequent neuropathology in the temporal and parietal cortices correlate to deficits in
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visuospatial recognition and semantic memory, and represent an increased risk of PDD
(Williams-Gray et al., 2009).
Since the cognitive decline within a PD diagnosis appears to be gradual, recent
developments have led to the establishment of a clinical diagnosis of PD-MCI (PD with mild
cognitive impairment), which is defined as cognitive impairment within PD patients who
are still functionally independent (Emre et al., 2007; Litvan et al., 2012). MCI tends to affect
executive function, attention or memory and represents a risk factor for developing full-
blown PDD, which is associated with further cognitive decline in the visuospatial domain
(Gasca-Salas et al., 2014). PDD is diagnosed on two levels – possible or probable PDD.
Probable PDD diagnosis requires the presence of both PDD core features (diagnosis of PD
as well as dementia syndrome) and impairment in at least two of four cognitive domains
(executive function, attention, memory, visuospatial function), usually supported by the
presence of behavioural symptoms. Possible PDD, on the other hand, is associated with
the presence of the two core features and impairment in at least one cognitive domain
(Emre et al., 2007).
Structural and cellular changes correlating with these cognitive alterations have yet to be
elucidated. However, atrophy in the hippocampus, amygdala, caudate nucleus, cingulate
gyrus, and the temporal and prefrontal lobes, has been observed to correlate with
dementia, in PD, in vivo (Hwang et al., 2013).  Furthermore, the role of cortical Lewy bodies
has been well established in PD cognitive decline.  Several groups have correlated presence
of cortical Lewy bodies to cognitive severity (Hurtig et al., 2000; Mattila et al., 2000), whilst
others have argued that a co-existing AD-like pathology is required to cause decline in
cognition (Harding and Halliday, 2001). Indeed, a recent study has suggested that whilst α-
synuclein pathology in cortical areas tends to correlate significantly with a decline in
cognitive ability, the presence of Aβ plaques and phospho-tau tangles are also indicative of
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cognitive impairement, suggesting that multiple pathologies might play a role in cognitive
decline (Howlett et al., 2014). Cognitive symptoms in PDD and AD may also be quite similar;
however PDD is usually distinguished by the presence of hallucinations, depression, sleep
disturbance and cognitive fluctuations.
Age is recognised as being a prominent risk factor for PDD, and studies show that age of PD
onset does not play a role in risk of dementia development (Aarsland et al., 2007).
Therefore patients tend to develop PDD at a similar age, regardless of when they first
developed motor symptoms (Kempster et al., 2010). On the other hand, the severity of
motor symptoms is correlated to cognitive decline (Braak et al., 2005).  Furthermore, male
gender, low levels of education and visual hallucinations as well as prominent axial rigidity
and bradykinesia are thought to be risk factors for PDD (Irwin et al., 2013). Diagnosis of
PDD is, however, not always clear-cut due to the similarities it shares with the more
common form of dementia; dementia with Lewy bodies (DLB).
DLB is a relatively recently established form of dementia which exhibits symptoms
associated with both AD and PD. As a result of combined symptoms and pathologies,
researchers believe that DLB cases are under-diagnosed and may in reality make up to 10-
15% of all dementia cases in the elderly, making DLB the second most common form of
degenerative dementia following AD. As in AD, DLB patients also tend to exhibit cortical
amyloid plaques and neurofibrillary tangles (Howlett et al., 2014). The presence of tau
aggregates is linked to an increased chance of Lewy body formation especially in
susceptible brain areas such as the amygdala, and in fact, as previously mentioned, Lewy
bodies are also found in numerous cases of familial or sporadic AD (Lippa et al., 1998;
Hamilton, 2000).
The third report of the DLB consortium published in 2005 aimed to highlight the similarities
and the importance of establishing better boundaries between PDD and DLB (McKeith et
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al., 2005). Pathologically, both PDD and DLB are characterised by widespread α-synuclein in
the brain stem, neocortex and the limbic and forebrain regions. PDD patients tend to suffer
more neuronal loss in the SNpc than DLB patients, whilst α-synuclein pathology might be
greater in the striatum in DLB patients compared to PDD (Lippa et al., 2007).
Neuropsychological profiles exhibited are also very similar in the two syndromes, though
DLB patients tend to suffer more psychoses and hallucinations, and more conceptual and
attentional errors than PDD patients (Lippa et al., 2007).
These two syndromes are distinguished diagnostically purely via the temporal sequence of
appearance of symptoms. The ‘one year rule’ states that if cognitive symptoms arise within
the same year as the motor symptoms, the diagnosis should be DLB, whilst in PDD,
cognitive symptoms should appear longer than a year after the onset of motor symptoms.
In fact, most PDD patients tend to develop dementia 10 years or more after the onset of
motor symptoms. Nevertheless, the ‘one year rule’ has been criticised by some suggesting
that the two types of dementia are simply different stages within a common spectrum of
Lewy body disease. The consortium therefore concluded that whilst distinct PDD and DLB
may be used in diagnosing more clear-cut cases and in particular areas of research, studies
in clinical research, development of therapeutics and genetics might require the use of the
collective term Lewy body disease (LBD) or α-synucleinopathy (McKeith et al., 2005).
The consortium also revisited the criteria used for DLB diagnosis which had previously been
established in the first publication of Consensus criteria for clinical and pathologic diagnosis
of DLB (McKeith et al., 1996). The most recent criteria require a central feature of
progressive cognitive decline leading to concordant memory impairment and additional
core features including a fluctuating cognitive impairment with varying levels of attention
and alertness, prominent visual hallucinations and parkinsonism. In addition to cognitive
decline, the presence of one core feature is indicative of possible DLB whilst the presence
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of two core features is required for a diagnosis of probable DLB (McKeith et al., 2004;
McKeith et al., 2005). Other features that may be present in DLB include rapid eye
movement (REM) sleep behaviour disorder, neuroleptic sensitivity, severe autonomic
dysfunctions, delusions, depression and occurrence of syncope and loss of consciousness
(McKeith et al., 2005).
DLB patients exhibit both cortical and subcortical neuropsychological impairments with a
prominent dysfunction in visuospatial processing. In fact this is a feature that helps to
distinguish between DLB and AD patients, as DLB patients tend to have a better verbal
memory but a more pronounced visuospatial impairment. Similarly to PDD, DLB patients
suffer from psychiatric manifestations such as visual hallucinations, associated with a
decline in cortical acetylcholine (Perry et al., 1991), a prominent number of Lewy bodies in
the anterior and inferior temporal lobe (Harding et al., 2002), as well as delusions, apathy
and anxiety early on in the course of the disease. Unlike PDD cases, however, 25% of DLB
cases might progress through the disease without ever exhibiting any extrapyramidal
symptoms, suggesting that parkinsonism is not always present in this form of dementia. In
fact the absence of motor symptoms upon clinical visits, might be a major factor leading to
the previously mentioned under-diagnosis of DLB (McKeith et al., 2000b) or a differential
diagnosis of AD, vascular dementia, atypical parkinsonian syndromes or Creutzfeldt-Jakob
disease. In DLB, when present, extrapyramidal signs tend to show an axial bias towards
greater postural instability and facial impassivity compared to tremor, and this is consistent
with a ‘non-dopaminergic’ motor involvement (McKeith et al., 2004).
The ongoing debate regarding similarities and distinctions between DLB and PDD prompted
the formation of a DLB/PDD working group which, following the third report of the DLB
consortium, published a report discussing boundary issues in PDD and DLB. This group
concluded that PDD and DLB are indeed more similar than they are different, and that the
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main distinction lies in the onset of cognitive symptoms in relation to motor deficits. They
therefore reiterate that whilst the one-year rule should aim to distinguish between the two
for clinical classification, the umbrella term of LBD should be used in understanding
underlying molecular mechanisms. More importantly, the group suggests that since
cholinergic deficits are a prominent feature in both these syndromes, and they are more
severe than in other dementias, such as AD, biomarkers for cholinergic abnormalities
should be investigated for use in diagnosis of these disorders. Furthermore, the need for
the development of clinical biomarkers for α-synuclein and Lewy bodies, as well as the
need of more communication between groups researching movement disorders and
dementia is emphasized (Lippa et al., 2007).
1.4.1. Lewy body staging
In 1984, Kosaka and colleagues were the first to publish a standardized scoring system for
brain pathology assessment in DLB (Kosaka et al., 1984). This was the first publication
suggesting that the clinical manifestation of the disease correlates with the anatomical
distribution of the pathological features. In 1996, the Consortium on DLB International
Workshop published more detailed instructions on how to score disease progression
following Kosaka’s suggestions, based on the presence of pathology in the brainstem,
limbic and neocortical regions (McKeith et al., 1996).
Following the identification of α-synuclein as a central factor in DLB and PD
neurodegeneration, Braak and colleagues published a proposed staging scheme for PD
based on the distribution of α-synuclein, utilising α-synuclein immunohistochemistry (IHC).
According to the Braak scheme, PD progresses in six neuropathological stages, with the
pathology starting in the dorsal motor nucleus of the vagus in the medulla and the anterior
olfactory nucleus and progressing onto the locus ceruleus and the substantia nigra, basal
forebrain, amygdala and the medial temporal lobe and finally reaching the cortical areas
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(Braak et al., 2003) (Figure 1.3A-C). The DLB consortium, subsequently published a revised
version of the diagnostic protocol and established α-synuclein pathology as the preferred
method of evaluating pathology (McKeith et al., 2005). Moreover, the consortium
recommended a semi-quantitative scoring method for Lewy body pathology in the cerebral
cortex thereby establishing a cortical severity model with Lewy body staging ranging from
stage 1 to 4. Stage 1 represents a sparse presence of Lewy bodies and Lewy neurites whilst
stage 4 represents numerous Lewy bodies and Lewy neurites in the cerebral cortex.
The most recent protocol published by the BrainNet Europe Consortium aims to
consolidate the criteria established by Braak and McKeith, proposing a method whereby
Braak stages 1-3 correspond to the McKeith brainstem stage, whilst the limbic stage
incorporates Braak stages 3-5 and finally Braak stage 6 corresponds to the neocortical stage
(Alafuzoff et al., 2009) (Figure 1.3D).
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Figure 1.3 The different stages of Lewy body pathology
(A) Braak stages 1 and 2 correspond to lesions in the olfactory bulb, the anterior olfactory nucleus
and/or the dorsal motor nuclei of the vagal and glossopharyngeal nerves in the brainstem as well as
the locus coeruleus, magnocellular nucleus of the reticular formation, and lower raphe nuclei. (B) In
Braak stages 3 and 4, the pathology reaches basal forebrain, SNpc, the hypothalamus, portions of the
thalamus and the mesocortex, and the first clinical symptoms of PD appear. (C) In the later Braak
stages 5 and 6, pathology reaches neocortical high-order association areas, first-order association
areas and primary fields (Goedert et al., 2013). (D) The proposed BrainNet Europe protocol for
assigning α-synuclein pathology.  dmV: Dorsal motor nucleus of vagus, irx: intermediate reticular
zone, LC: locus coeruleus, R: raphe, SN: substantia nigra, nbM: nucleus basalis of Meynert, AC:
amygdala, CA2: cornu ammonis of hippocampus, region 2 TOcx: temporo-occipital cortex, LN: Lewy
neurites (Alafuzoff et al., 2009).
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1.4.2. Current PDD and DLB treatment
As in most other dementias, treatments for DLB and PDD are symptomatic.  In the cases of
these particular dementia types, treatment strategies might be especially problematic as
they might enhance psychotic side effects to which these patients are sensitive.
The only treatment currently licensed in PDD is the use of rivastigmine, the cholinesterase
inhibitor commonly used in AD treatment, which has been shown to cause substantial long-
term improvement in areas of memory, language, praxis and executive function (McKeith
et al., 2000a; Emre et al., 2004). An additional cholinesterase inhibitor, donepezil, has also
shown improvement in cognition and general status in PDD patients in several clinical trials
(Ishikawa et al., 2014). Atomoxetine, a selective noradrenaline reuptake inhibitor, is also at
advanced stage clinical trials, after having shown to improve cognitive function in animal
models (Athauda and Foltynie, 2015).
The NMDA receptor antagonist memantine has also been tested in PDD clinical trials, and
showed improvement in cognitive function, sleep and general quality of life (Broadstock et
al., 2014). However, additional studies on memantine found insufficient improvement on
symptoms upon drug treatment and the Movement Disorder Society concluded in 2011
that although deemed safe, memantine does not exhibit strong enough evidence as a
candidate for PDD treatment (Seppi et al., 2011).
Cholinesterase inhibitors, such as rivastigmine and donepezil have also been tested on DLB
patients and improvements in neuropsychiatric symptoms and in cognitive screening tests
were reported (Broadstock et al., 2014). In 2011, the British Association of
Psychopharmacology concluded that cholinesterase inhibitors are effective in treating
neuropsychiatric symptoms of PDD and DLB patients (O'Brien and Burns, 2011). As in PDD,
treatment of DLB patients with memantine gave inconclusive results, although one study
did suggest an improvement in Clinical Global Impression and Neuropsychiatric Inventory
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(Emre et al., 2010). L-dopa has also been tested to reduce motor symptoms in DLB,
however the treatment was not as efficient as it is in PD, and was associated with an
increased risk of psychotic symptoms (Ballard et al., 2011).
A neuroprotective therapeutic strategy which is currently under investigation is
immunisation against α-synuclein. Monoclonal antibodies against α-synuclein have been
proven to promote clearance of toxic α-synuclein in animal models, leading to the
development of antibodies such as PRX002 and AFFITOPE® PD01 which are currently being
tested in clinical trials (Athauda and Foltynie, 2015).
Epigallocatechin gallate (EGCG), a catechin found in tea with antioxidant properties, is also
being tested for therapeutic use in neurodegeneration. EGCG is thought to act via the
inhibition of formation of α-synuclein oligomers (Lorenzen et al., 2014).
Additionally, since there is substantial evidence linking coffee-drinking to a reduced risk of
PD, caffeine treatment has been recently investigated as a potential therapeutic strategy
(Rivera-Oliver and Diaz-Rios, 2014). Pilot studies have suggested that caffeine leads to a
benefit in motor impairments in PD and clinical trials underway also aim to test any
benefits on cognition.
1.5. Mitochondrial dysfunction is a common factor in
neurodegenerative diseases
As discussed above, most neurodegenerative diseases exhibit common overlapping
pathologies and a variable degree of comorbidity, however there is no single factor known
to be responsible for the causation of all neurodegenerative diseases. Age is established as
the greatest risk factor in the development of neurodegeneration, and it is therefore
essential for us to better elucidate the cellular changes occurring in ageing in order to
better comprehend the cellular alterations leading to neurodegeneration. A key player in
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the ageing paradigm, the mitochondrion, has therefore become a critical target in this field
of research.
There are now increasing lines of consistent evidence linking mitochondrial dysfunction to
neurodegeneration, and it is suggested that changes in bioenergetic homeostasis,
influenced greatly by mitochondrial function, lie at the centre of the various facets of
neurodegeneration, including loss of neuronal tissue, systemic malfunction, and an
eventual deterioration of neuronal transduction and communication. Mitochondria play a
major role in the apoptotic pathway and oxidative stress, which are both components in
the pathway leading to neuronal death. In addition, mitochondrial dysfunction and
oxidative stress are known to be strongly associated to ageing. Most neurodegenerative
diseases display mitochondrial deficits early on in disease progress that may lead to a
bioenergetic decline and thereby contribute to the development of the pathologies
(Correia et al., 2012; Wirz et al., 2014).
In AD, the pathology-associated proteins Aβ and APP are known to interact directly with
mitochondria (Pinho et al., 2014) and studies suggest that the key regulator of
mitochondrial biogenesis, peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC1-α), is down-regulated in Huntington’s disease (HD), (Cui et al., 2006). In PD,
mutations in the autosomal recessive genes parkin, PINK1 and DJ1 lead to increased
oxidative stress and mitochondrial dysfunction (Albrecht, 2005; Andres-Mateos et al., 2007;
Dodson and Guo, 2007; Devi et al., 2008; Ramsey and Giasson, 2008; Kaye et al., 2014) and
in amyotrophic lateral sclerosis (ALS), mutant superoxide dismutase (SOD) has been shown
to be localised in the outer mitochondrial membrane, intermembrane space and matrix
(Higgins et al., 2003; Pasinelli et al., 2004; Vijayvergiya et al., 2005). It is therefore
imperative that further research is carried out into better understanding the role of
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mitochondrial dysfunction in neurodegenerative disease, potentially leading to the
development of mitochondrial-targeted therapeutic approaches.
1.6. Mitochondrial structure and function
Mitochondria were first observed as cellular structures in the 1840s and were given the
name by which they are commonly known today in 1898 by Benda (Benda, 1898).  In the
early 1910s it was established that cellular respiration occurs in mitochondria (Warburg,
1913). These findings led to the search for a respiratory pigment, paving the way for the
discovery of what it known today as the oxidative phosphorylation (OXPHOS) respiratory
chain. The late 1920s to late 1940s saw a great surge of progress in respiratory research,
with the discovery of ATP as a ‘molecular unit of energy currency’ (Lohmann, 1929) and the
citric acid cycle as the energy-generating cycle for all aerobic organisms (Krebs, 1937). In
1946, Claude isolated mitochondria for the first time using differential centrifugation
(Claude, 1946), and the following decade saw mitochondria being identified as crucial in
cellular respiration. In 1949, Kennedy and Lehninger found that fatty acid oxidation, as well
as the citric acid cycle and ATP generation via nicotinamide adenine dinucleotide (NADH),
occur exclusively in mitochondria (Kennedy and Lehninger, 1949) and in the early 1950s,
the first electron micrograph of mitochondria revealed details of the morphology of the
organelle (Palade, 1953). The late 1950s saw more research focused on understanding the
mechanism regulating cellular respiration and in 1961 Mitchell helped to unravel the
mystery with the theory of chemiosmotic coupling, which suggested that energy derived
from oxidation of fuels pumps protons across the inner mitochondrial membrane, creating
a ‘proton motive force’ (Mitchell, 1961). This concept was dismissed at first, but after being
proven true by further experiments, finally led Mitchell to win a Nobel prize in 1978.
Mitochondrial structure is closely related to its function. The organelles are enclosed by an
outer mitochondrial membrane (OMM), which regulates entry of large proteins into the
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organelle via a large protein complex known as translocase of the outer membrane (TOM).
An inter-membrane space separates the outer and inner phospholipid membranes. The
inner mitochondrial membrane (IMM) is composed of several membrane infoldings known
as cristae. OXPHOS, and therefore ATP generation, occurs within the IMM, and the cristae
enable an enhanced surface area for optimal ATP production. A translocase of the inner
membrane (TIM) complex allows transport of proteins from the IMM to the mitochondrial
matrix which is the innermost space between the cristae, and is where mitochondrial DNA
(mtDNA) is found (Figure 1.4A).
1.6.1. Mitochondrial origin
It is postulated that approximately two billion years ago there was a significant increase in
the oxygen tension of the Earth’s atmosphere, and primitive eukaryotes had to evolve
mechanisms to deal with this sudden change (Kurland and Andersson, 2000). According to
the endosymbiotic theory of the origins of complex life, this event lead to the origin of
eukaryotic aerobes, when entities capable of aerobic respiration were introduced into
ancestral eukaryotes via an endosymbiotic α-proteobacterium (Margulis, 1981). Over the
past years, several evolutionary biologists have further investigated this theory and put
forth their interpretations and developments to the theory. Researchers in the field are still
very much puzzled by the series of events which lead to the existence of complex
multicellular organisms. Some still find validity in Margulis’ endosymbiotic theory, and
simply state that it needs to be adapted into the modern world of microbial genomics
(Zimorski et al., 2014). Others argue that there is no evidence which suggests that
mitochondria evolved in order to deal with a sudden increase in atmospheric oxygen.
Martin and Muller suggested an alternative ‘hydrogen hypothesis’ postulating that the
primitive eukaryote originated from a symbiotic relationship between an anerobic
autotrophic archaeon which possessed hydrogen-dependent metabolism, and a
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eubacterium (future mitochondrion) capable of anaerobic respiration which generated
hydrogen and carbon dioxide during the process (Martin and Muller, 1998). Evolutionary
biologist Nick Lane further argues that complex life originated in the presence of natural
proton gradients, possibly in alkaline hydrothermal vents, and led to the evolution of
membranes capable of carrying out membrane bioenergetics that we all utilise today (Lane,
2006; Lane, 2014). Mitochondria as they are known today, contain their own genome in the
form of mtDNA. According to the endosymbiotic theory, the α-proteobacterium which was
engulfed by the ancestral eukaryote, carried its own genome with it, leading to the
existence of mtDNA enclosed in mitochondria, isolated from its nuclear counterpart.
Indeed, detailed phylogenetic studies using the mitochondrial genome of protists, the
nuclear genome of S. cerevisiae and the genome of the α-proteobacterium Rickettsia
prowazekii revealed that coding sequences in mitochondrial genes are descendent of α-
proteobacterial homologues (Andersson et al., 2003).
Over time, the mitochondrial genome has reduced greatly in size, partly due to gene
transfer from the mitochondria to the nucleus. The vast majority of mitochondrially-
associated proteins are today encoded by the nuclear genome, suggesting that throughout
the course of evolution, genes were transferred from the genome of the endosymbiont to
that of the host.
So, why do mitochondria still carry their own genome? What is the advantage of a
eukaryotic cell having two separate genomes, rather than all mitochondrial-associated
genes being present on the nuclear genome? The current most widely accepted hypothesis
was first put forward by John Allen in 1993 (Allen, 1993), who states that there must be
great benefits offered by the presence of mtDNA within the mitochondrion for so many
years and that these benefits must be related to the main function of mitochondria –
respiration. The theory suggests that ATP production and ultimately energy supply is
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dependent on demand and that each mitochondrion with its electron transport chain (ETC)
must react individually to its needs, with speed of respiration adjusted accordingly. It
therefore makes more sense for mitochondria to control their own gene expression since
respiratory supply and demand might differ between mitochondria in a network and it
would be too inefficient for the nuclear DNA to respond to each mitochondrion’s individual
needs – especially since mitochondria act as a network that is under constant turnover. In
summary, the issue might be metabolic – mitochondrial gene expression might be under
the direct regulation of components of the ETC or the reduction /oxidation (redox) status of
the organelle.
1.6.2. The mitochondrial respiratory chain
The respiratory chain in mitochondria is composed of five different multimeric complexes
(Figure 1.4B): reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase-
ubiquinone oxidoreductase (complex I), succinate dehydrogenase-ubiquinone
oxidoreductase (complex II), ubiquinol-cytochrome c oxidoreductase (complex III),
cytochrome c oxidase (complex IV) and ATP synthase (complex V) located on the IMM.
Two small electron carriers; ubiquinone/coenzyme Q and cytochrome c, help to transport
electrons obtained from energy substrates NADH and flavine adenine dinucleotide (FADH2)
along the different complexes to reach the electron acceptor, oxygen. This involves a
sequential series of redox reactions, generating an electrochemical gradient, as protons are
pumped into the intermembrane space, thereby resulting in the mitochondrial membrane
potential. ATP synthase is composed of two functional domains; F0 is a proton pore found
embedded in the mitochondrial membrane while F1 is located in the mitochondrial matrix
and is composed of alternating alpha and beta subunits, arranged around a rotary central
gamma subunit. The proton-motive force generated by the ETC triggers the transport of
protons through the F0 region of the complex, towards the rotating F1 gamma subunit
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which then causes conformational changes in associated catalytic binding sites, thereby
leading to ATP synthesis. This mechanism was first explained by Paul Boyer in the late
1970s (Kayalar et al., 1977), and in 1994, the F1 catalytic subunit of ATP synthase was
crystallised by John E. Walker (Abrahams et al., 1994). In 1997 Boyer and Walker shared the
Nobel prize in chemistry for their findings.
Once produced inside the mitochondrion, ATP will be translocated into the cytosol to feed
energy to the cell, via the adenine nucleotide transporter (ANT) found on the IMM. This
process, by which ATP is generated via the ETC is termed OXPHOS.
In the nervous system, mitochondrial ATP generation is crucial for numerous functions
including the transport and release of synaptic vesicles, assembly of the actin cytoskeleton
in presynaptic development, as well as, the generation of axonal and synaptic membrane
potentials. Furthermore, ATP production is especially important to maintain ionic
homeostasis during electrical signalling, as this process requires the action of Na+/K+ and
Ca2+ plasma membrane ion pumps which are ATP consuming.
Therefore, mitochondrial ATP generation is a crucial process, however, it is prone to
damage by a series of factors. Chemical treatment, Ca2+ overload and oxidative damage
may all lead to inhibition or dysfunction of mitochondrial metabolism. In turn, this may lead
to cell death, either via insufficient levels of ATP or through triggered cell death by
mitochondrial released pro-apoptotic factors.
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Figure 1.4 Mitochondrial DNA encodes components of the mitochondrial respiratory chain
(A) Mammalian mitochondrial DNA (mtDNA), found in the mitochondrial matrix, is a 16 kb circular
genome which encodes for components of Complex I-V of the respiratory chain. (B) The ETC, located
on the inner mitochondrial membrane (IMM) consists of five complexes.  13 of the proteins required
for the assembly of the complexes are encoded by the mtDNA, whilst the rest are encoded by




1.6.3. Mitochondrial generation of reactive oxygen species
Reactive oxygen species (ROS) are produced by mitochondria during the oxidative
phosphorylation process and their production is the main factor leading to oxidative
damage in a range of pathologies. ROS, however, are also known to be involved in
retrograde redox signalling, where they might serve a highly beneficial purpose
(Gutterman, 2005; Murphy, 2009). The main ROS generated by mitochondria is superoxide
(O2•−), produced by a one-electron reduction of molecular O2. Subsequently, O2•− can
dismutate to form hydrogen peroxide H2O2, which can in turn undergo further reactions to
form the hydroxyl radical HO . O2•− is first produced from complex I, due to a high proton
motive force in the organelle, a high NADH/NAD+ ratio in the mitochondrial matrix and a
reduced coenzyme Q (CoQ) pool. Specifically, there are two main mechanisms which
explain O2•− production in Complex I (Murphy, 2009).
I. At complex I, a flavin mononucleotide (FMN) co-factor accepts electrons from
NADH and passes them onto a series of Fe-S centres onto the CoQ reduction site.
O2 will then react with the fully reduced FMN to generate O2•−. The proportion of
reduced FMN in mitochondria is determined by the NADH/NAD+ ratio. Therefore in
a situation where the respiratory chain is inhibited via mutations or other forms of
damage, a low respiration rate will cause an increase in NADH/NAD+ ratio leading
to subsequent O2•− generation by FMN. In situations where mitochondria are
undergoing normal respiration and the NADH/NAD+ ratio is relatively low,
generation of O2•− is highly depreciated.
II. There is also considerable O2•− generation at complex I via a reverse electron
transport mechanism. This occurs when there is considerable electron supply
acting to reduce CoQ in the presence of a large proton motive force, causing
electrons to ‘reverse’ back into complex I, reducing NAD+ to NADH at the FMN. The
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rate of O2•− generation via this mechanism is highly dependent on a high proton
motive force, and is therefore highly sensitive to any changes in pH which could
decrease this force.
It is not entirely understood whether these two processes occur individually or
simultaneously to generate O2•−at complex I.
An additional ETC complex which is thought to be crucial in generating ROS is complex III,
which passes electrons from the CoQ pool onto cytochrome c. Generation of superoxide at
this complex is thought to depend on the stability of the ubisemiquione radical in the Qo
site of CoQ, which may be modulated via changes in proton motive force, loss of
cytochrome c or the redox state of CoQ. It is further important to note that O2•− at complex
III is only substantial when the Q i site at CoQ is directly inhibited via antimycin. Therefore
under normal physiological conditions, the amount of superoxide generated at complex III
is negligible compared to that produced at complex I (Andreyev et al., 2005).
Apart from complexes I and III, an additional seven mitochondrial sites have been identified
as having potential in generating ROS. These are cytochrome b5 reductase and monoamine
oxidases, located on the OMM, dihydroorotate dehydrogenase and dehydrogenase of
alpha-glycerophosphate located on the outer surface of the IMM, succinate dehydrogenase
located on the inner surface of the IMM, aconitase found in the mitochondrial matrix and
alpha-Ketoglutarate dehydrogenase complex which is found on the matrix-facing side of
the IMM. The role of these sites in ROS production in physiological in vivo conditions is
however poorly understood (Andreyev et al., 2005).
ROS generation is an inevitable process that also serves a physiologically relevant purpose,
as mentioned throughout this thesis. The generation of ROS by itself is not a precursor to
oxidative stress. Rather, oxidative stress results from an imbalance between ROS
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generation and detoxification. Multiple cellular mechanisms serve to combat oxidative
stress (Cadenas and Davies, 2000; Andreyev et al., 2005). One of the predominant lines of
defence against mitochondrial ROS is manganese superoxide dismutase (MnSOD), an
enzyme located inside the mitochondrial matrix serving to dismutate superoxide to H2O2,
thereby preventing any damage to the Fe-S clusters present within the mitochondria. H2O2
can itself be quite toxic and therefore needs to be neutralised by an additional enzyme,
catalase, which converts H2O2 into H2O and O2. Glutathione peroxidase (GPxI) is another
major role player in ROS detoxification. It is present in the mitochondrial matrix and the
intermembrane space and also acts to detoxify H2O2 into H2O and O2 by utilising
glutathione (GSH). In the process GSH is reduced to glutathione disulphide (GSSG) which
can then be converted back to GSH via glutathione reductase using NADPH. The GPX
scavenging system is thought to be more prevalent in cases of severe oxidative stress
rather than in the neutralisation of normal physiological ROS levels. During severe oxidative
stress, there is a decrease in GSH concentration, concomitant with an increase in GSSG
concentration (Andreyev et al., 2005).
Several reviews written on the subject have discussed the link between mitochondrial
dysfunction, oxidative stress and neurodegenerative disease as well as general ageing
(Barja, 2014; Hayashi and Cortopassi, 2015; Pinto and Moraes, 2015) and several of these
findings are mentioned throughout this chapter (sections 1.11 and 1.12). The exact
mechanisms underlying these associations are, however, still relatively unknown and
further work is required to better understand how diminishing oxidative stress in
mitochondria could serve as a therapeutic strategy.
1.6.4. Mitochondrial dynamics
Mitochondria function as a dynamic network undergoing fission and fusion, mitochondrial
turnover and transport (Figure 1.5). Mitochondrial distribution and motility throughout
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neurons is especially heterogeneous, since neurons are polarised cells with areas of
differing energy requirements.  Areas with high ATP level demands such as presynaptic and
postsynaptic terminals, nodes of Ranvier, active growth cones and axonal branches
therefore tend to contain a higher number of mitochondria than other neuronal domains
(Morris and Hollenbeck, 1993; Ruthel and Hollenbeck, 2003; Zhang et al., 2010). A recent
study has shown that a resting cortical neuron uses up to 4.7 billion molecules of ATP per
second (Zhu et al., 2012) and it is therefore not surprising that mitochondrial transport and
distribution tend to be directly correlated to synaptic activity, with more mitochondria
being detained in the presynaptic terminals and postsynaptic dendritic spines during
periods of continuous synaptic activity. Mitochondrial transport towards active synapses is
regulated by either ATP/adenosine diphosphate (ADP) levels, or via intracellular Ca2+
concentration. Indeed, mitochondria are known to slow down to a potentially stationary
state in areas of a low ratio of ATP/ADP concentration (Sheng, 2014). This is because ATP
has a low capacity for intracellular diffusion and therefore low energy areas require a local
‘docked’ pool of mitochondria for immediate ATP generation. Elevated levels of Ca2+ are
also known to inhibit mitochondrial transport and optimal calcium levels at synapses are
maintained by mitochondria which sequester intracellular Ca2+ (Sheng, 2014). In fact, two-
thirds of mitochondria in an axonal network are thought to be stationary over an extended
period of time (Kang et al., 2008).
Since neurons are particularly dependent on efficient mitochondrial dynamics, they are
highly dependent on well-functioning transport, fusion, fission and turnover machinery.
Mitochondrial fusion is known to be important in the exchange of contents between
different mitochondria, thereby enabling a shuffling of components between healthy and
damaged mitochondria allowing for an overall healthy and functional network.
Mitochondrial fission on the other hand, is crucial in generating mitochondria containing
damaged components, which can be easily segregated for degradation. Furthermore,
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fission is highly related to transport as once mitochondria have undergone fission, the
smaller daughter organelles can move along the axon at a faster pace, quickly getting to
the area where required (Figure 1.5A).
Studies investigating the role of dynamin related protein-1 (Drp1), a mitochondrial
dynamin-like GTPase required for mitochondrial membrane fission, show that defects in
the process lead to accumulation of mitochondria in the soma and a diminished
mitochondrial content in dendrites (Li et al., 2004). Studies in Drosophila also show that
Drp1 is essential for the presence of mitochondria at neuromuscular junctions (NMJs)
(Verstreken et al., 2005). Mutations in the gene encoding for mitofusin, MFN2, which is
required for mitochondrial fusion have also been shown to disrupt anterograde and
retrograde mitochondrial transport (Baloh et al., 2007). Deficiencies in fusion are therefore
correlated to impaired distribution of mitochondria as well as fragmentation of the
organelles. Furthermore, mitofusin has been shown to associate with the motor MIRO-
Milton complex; composed of the motor adaptor complex Milton interacting with the RHO
family GTPase MIRO found in the OMM. This association has also been shown to be
necessary for axonal mitochondrial transport (Misko et al., 2010).
Phosphatase and tensin homolog-induced putative kinase 1 (PINK1), a mitochondrially
targeted serine/threonine kinase, and Parkin, a cytosolic E3 ubiquitin ligase, are proteins
involved in mitochondrial turnover by mitophagy (mitochondrial specific autophagy).
Damaged mitochondria with a reduced mitochondrial membrane potential exhibit an
accumulation of PINK1 on the OMM, which triggers Parkin recruitment to the
mitochondrion causing ubiquitination of OMM proteins and targeting the organelle for
autophagy (Figure 1.5C). Recent studies also suggest that apart from a role in mitophagy,
the PINK1-Parkin pathway may also play a role in selective turnover of mitochondrial
respiratory chain subunits (Vincow et al., 2013). Furthermore, the PINK1-Parkin complex
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has also been shown to be associated with mitochondrial transport. More specifically,
PINK1 has been shown to phosphorylate MIRO, activating its degradation, thereby
arresting mitochondrial anterograde transport, in a Parkin dependent manner (Weihofen et
al., 2009). This suggests that PINK1 and Parkin might also regulate mitochondrial transport,
inhibiting damaged mitochondria from moving along the network, thereby allowing
segregation and subsequent autophagy of the organelle.
The PINK1-Parkin pathway has been shown to promote mitochondrial fission and inhibit
fusion, by downregulating MFN2 and OPA1, which encodes the protein optic atrophy 1,
required for fusion of the IMM (Yang et al., 2008; Yu et al., 2011). These findings have
however been contradicted in several mammalian cell studies, in which loss of PINK1
correlated with an increase in mitochondrial fragmentation (Dagda et al., 2009; Lutz et al.,
2009) Recent studies have also suggested that Parkin ubiquitinates mitofusin proteins,
possibly inhibiting damaged mitochondria from fusing with healthy ones as an additional
mode of segregation followed by mitophagy (Gegg et al., 2010; Ziviani et al., 2010).
Efficient mitochondrial transport, fission and fusion machinery are therefore required to
work together in a synergistic manner facilitating mitochondrial function (Figure 1.5D), and
when these processes are compromised, the ability of neurons to survive stressful stimuli
and eliminate damaged cells may depreciate. Indeed, as will be discussed in sections 1.12.1
(AD) and 1.12.2 (PD), there are numerous studies linking deficits in mitochondrial dynamics
to neurodegeneration.
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Figure 1.5 Mitochondrial dynamics
(A) Mitochondrial fission is mediated by dynamin-related protein 1 (Drp1) and mitochondrial fission-
1 protein (Fis1).  Fusion of the outer mitochondrial membrane (OMM) is mediated by Mitofusins
(Mnf) 1 and 2 whilst fusion of the inner mitochondrial membrane (IMM) is mediated by protein optic
atrophy type 1 (OPA1). (B) In neurons, mitochondria move towards the synapse via anterograde
transport and back to the nucleus via retrograde transport. (C) PINK1/Parkin mediate mitochondrial
quality control via mitochondria–specific autophagy (mitophagy). (A-C adapted from (Perier and Vila,
2012). (D) Mitochondrial quality control is mediated by fusion, which mixes healthy and damaged
mitochondrial components, fission, which allows segregation of the damaged mitochondria and





1.7. The mitochondrial genome
1.7.1. mtDNA replication
The presence of DNA in mitochondria was first reported in 1963 when Margit and Sylvan
Nass were studying chick embryo mitochondria under the electron microscope. They
observed fibres within the mitochondria which contained DNA-like characteristics and
proposed that mitochondria contained their own DNA, separate from the nuclear
counterpart (Nass and Nass, 1963). A year later, in 1964, mtDNA was purified from baker’s
yeast (Schatz et al., 1964) and in 1966, a study reported the differentiation of nuclear and
mitochondrial protein systems due to a differing susceptibility to antibiotic treatment
(Clark-Walker and Linnane, 1966). A timeline of the main discoveries related to mtDNA in
yeast is depicted in Figure 1.6.
The mitochondrial genome copy number in an organism is highly variable and regulated in
a cell-specific manner (Phillips et al., 2014). It is estimated that there are thousands of
mitochondria in most mammalian somatic cells, each containing 1 to 10 copies of mtDNA,
and mammalian oocytes contain at least 100,000 copies of mtDNA per cell (Shoubridge and
Wai, 2007). The mitochondrial genome, which in mammals is 16.6kb, encodes 13
polypeptides, all of which are components of the complexes of the mitochondrial
respiratory chain. The energetic levels of the cell are therefore dependent on the presence
of an adequate mtDNA copy number, which is sufficient to maintain the metabolic
requirements of the cell.
The mtDNA replication machinery is nuclear encoded. The mitochondrial DNA polymerase
(pol γ) has a catalytic and accessory subunit, termed pol γ-α and pol γ-β respectively, which
are responsible for the synthesis of the new mtDNA strand. The mtDNA is unwound in the
5’ to 3’ direction by the mtDNA helicase, which in mammals is known as Twinkle. mtDNA
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single stranded binding protein (SSBP) consequently acts to stabilize the single strand,
thereby preventing rewinding of the strands (Figure 1.7).
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Figure 1.6 A timeline of the main discoveries in yeast mtDNA
A timeline depicting the main findings associated with mtDNA in yeast, leading to the publishing of the complete sequence of yeast mtDNA in 1998
(Williamson, 2002).
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Figure 1.7 Mammalian mtDNA replication machinery
The factors required for mtDNA replication are all transcriptionally regulated by nuclear
respiratory factor 1 (NRF1). MtDNA is synthesised via the mtDNA polymerase, pol γ (α and β
subunits) whilst the mammalian mtDNA helicase, Twinkle, unwinds the double strand. The
mtDNA single strand binding protein (SSBP) stabilises the single strand, whilst TOPO
(topoisomerase) controls mtDNA winding.  Mitochondrial transcription factor A (TFAM)
binding to mtDNA is essential for mtDNA replication. Deoxyribonucleotides (dNTPs) required
for mtDNA synthesis are supplied by TP (thymidine phosphorylase), TK2 (thymidine kinase 2),
DGUOK (deoxyguanosine kinase) and p53R2 (ribonucleotide reductase subunit). Other factors
including MPV17 (a mitochondrial membrane protein) and HSP40 (a mitochondrial
chaperone) have an unclear function but are required for mtDNA replication. ANT1 imports
ADP and exports ATP out of the mitochondrial matrix. Adapted from (Tyynismaa and
Suomalainen, 2009).
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In mammalian mtDNA, the circular genome consists of a heavy strand, so called because it
contains a higher proportion of guanine, and a light strand.  Both the heavy strand and the
light strand carry an origin of replication, termed the OH and the OL respectively (Figure
1.8).
The strand-displacement model of mtDNA replication, which was first proposed by Clayton
in 1982 (Clayton, 1982) states that DNA synthesis is initiated at the leading, heavy (H)
strand from the OH, and proceeds at the lagging, light (L) strand from the OL, once two-
thirds of the genome has been replicated by the leading strand (Figure 1.8A). This results in
a displacement-loop (D-loop), unidirectional, continuous, and asymmetric replication
mechanism. This model of mtDNA replication has been widely supported by both in vitro
and in vivo studies (Wanrooij et al., 2007; Fuste et al., 2010; Wanrooij et al., 2012).
However, later studies have challenged the validity of this model and have proposed
alternative theories.
Studies using two-dimensional agarose gel electrophoresis identified the presence of
replication intermediates suggesting the presence of coupled leading and lagging strand
synthesis (Holt et al., 2000). The strand-coupled model proposes a bidirectional,
discontinuous and symmetric mechanism in which replication is initiated in a region of
about 10kb in size, downstream of the 3’ end of the D-loop in the control region (Figure
1.8C) (Holt et al., 2000; Yang et al., 2002; Reyes et al., 2005). Later studies further
investigated the nature of the replication intermediates and identified them as RNA
segments which become incorporated into the newly synthesised lagging strand, to be later
maturated into DNA. This was proposed as the RITOLS (RNA Incorporated Through Out the
Lagging Strand) model of mtDNA replication (Figure 1.8B) (Yang et al., 2002; Yasukawa et
al., 2006).
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Therefore, there has been no conclusive study establishing the presence of a sole mode of
mtDNA replication and it is unclear whether different mechanisms of mtDNA replication
may be used depending on the organism or particular physiological conditions. Further
study and detailed investigation is required to understand the mechanism and the
regulation of mtDNA replication.
65
Figure 1.8 Models of mtDNA replication
(A) The strand-displacement model of mtDNA replication suggests that replication is initiated at the OH on the heavy strand and proceeds on the light strand once the OL is
exposed, leading to a continuous unidirectional mode of replication.  (B) The RITOLS model suggests the incorporation of RNA segments into the newly synthesised lagging
strand. (C) The strand-coupled model suggests a bidirectional, discontinuous, symmetric mode of replication. Continuous and dashed lines represent the 5’ to 3’ direction
of DNA and RNA synthesis respectively (McKinney and Oliveira, 2013).
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1.7.2. Mitochondrial transcription
Mitochondrial transcription is dependent on factors encoded by the nuclear genome.
Mitochondrial RNA polymerase (MTRPOL), mitochondrial transcription factor B 2 (TFB2M)
and mitochondrial transcription factor A (TFAM) must interact and are the core proteins in
the transcription machinery.
MtDNA contains three promoters; one on the light strand (LSP) which controls the
expression of one protein-coding transcript (ND6), eight tRNAs and RNA primers required
for mtDNA replication initiation, and two on the heavy strand – HSP1 controls the
expression of two tRNAs and two rRNAs, whilst HSP2 controls the expression of the
remaining 12 tRNAs and 12 protein-encoding genes (Shi et al., 2012). Transcription
termination is regulated by the mitochondrial transcription termination factors 1-4 (MTERF
1-4) (Linder et al., 2005).
A recent study has suggested that the transcription process is initiated via a pre-initiation
transcription complex, which has been identified and isolated (Morozov et al., 2014). This
study suggests that TFAM, once bound to the N-terminal domain of MTRPOL results in the
bending of promoter DNA around MTRPOL forming a pre-initiation complex, which then
triggers the recruitment of TFB2M, inducing promoter melting and the assembly of a
complete initiation complex. A later study also used electron microscopy to model the
complete mitochondrial transcription initiation complex (Yakubovskaya et al., 2014).
TFAM is a nuclear encoded protein, containing a mitochondrial targeting sequence which is
cleaved upon its import into the mitochondrion, leading to the formation of the mature
protein. TFAM contains two high-mobility group (HMG) box domains, each of which is
composed of three alpha-helices and two inter-connected peptide loops. When the two
HMG boxes in TFAM bind to the mtDNA, they cause a kink in the structure which induces
bending (Figure 1.9). The basic linker domain found in between HMG 1 and 2 will stabilise
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the binding by making additional contacts with the phosphodiester backbone. The C-
terminal tail found behind HMG 2 serves to activate TFAM transcriptional activity and is
also involved in TFAM dimerization and positive cooperativity – a process by which TFAM
binding to mtDNA triggers binding of further TFAM molecules along the chain (Kaufman et
al., 2007).
Therefore, TFAM is necessary for mtDNA transcription in mammals, and is also required to
bind to and bend mtDNA into particular conformations (Shi et al., 2012). Recent studies
have further investigated the role of TFAM in mtDNA packaging, showing that TFAM
creates a U-turn in mtDNA which results in the compaction of mtDNA (Ngo et al., 2011).
The compact structure is also known to interact with other proteins to form nucleoprotein
complexes known as nucleoids (Garrido et al., 2003). Super resolution imaging studies in
human fibroblasts have revealed that each nucleoid, of which TFAM is a main component,
has a diameter of around 100 nm and carries one copy of mtDNA (Kukat et al., 2011).
68
Figure 1.9 Mitochondrial transcription factor A (TFAM) binding to mtDNA is required for
transcription
The model depicted in the diagram proposes a mechanism for TFAM transcriptional activity at the
LSP. (A) TFAM will bind to mtDNA in the region marked by the black bar, whilst mitochondrial
transcription factor B2 (TFB2M) and mitochondrial RNA polymerase (MTRPOL) bind to the regions
indicated by the yellow and grey bars respectively. (B) HMG1 will bind to the mtDNA first inducing a
kink. (C) The linker segment will then stabilise the first kink, leading to the binding of HMG2, which
introduces a second kink, therefore forming a U-turn in the mtDNA. (D) Transcription is then initiated
upon recruitment of TFB2M and MTRPOL (Rubio-Cosials et al., 2011).
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Several in vitro studies have been carried out to further investigate the requirements for
TFAM in mammalian mitochondrial transcription (Fisher and Clayton, 1988; Parisi and
Clayton, 1991).  It has been concluded that TFAM binding to a specific site upstream of the
LSP, is necessary for transcription to occur, as alterations within this site (Dairaghi et al.,
1995b; Gaspari et al., 2004) or depletion of TFAM (Shi et al., 2012) lead to transcription
abolishment. Absolute TFAM requirement for transcription can be relaxed in conditions
that induce DNA breathing, i.e. the spontaneous re-opening and closing of the double helix,
such as low salt concentrations or negative supercoiling. Such conditions also lead to non-
specific initiation of transcription at various other sites along the template (Shi et al., 2012).
The requirement for TFAM in maintenance of mtDNA and regulation of copy number has
also been demonstrated in several animal models. Homozygous TFAM-/- mice are
embryonic lethal, have reduced cytochrome c oxidase (COX) expression and abnormal
mitochondrial morphology. Moreover, mtDNA copy number in these animals is greatly
reduced (Larsson et al., 1998). Heterozygous TFAM-/+ animals are viable with a 50%
reduction in TFAM levels and a concomitant reduction in mtDNA levels (Larsson et al.,
1998).
TFAM binding regulates mtDNA copy number, and there are currently two models
attempting to explain how this is achieved (Campbell et al., 2012). The first model is
transcription-mediated and suggests that TFAM over-expression increases LSP activity,
thereby increasing expression of the RNA priming sequence which triggers mtDNA
replication (Shutt et al., 2010). This model is obviously dependent on the concentration of
TFAM present relative to DNA, since saturating levels of TFAM are known to interfere with
transcription. Indeed over-expression of TFAM, resulting in high TFAM: mtDNA ratios are
thought to interfere with optimal DNA coiling, restricting access to DNA thereby reducing
levels of transcription and mtDNA copy number (Dairaghi et al., 1995a; Pohjoismaki et al.,
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2006; Matsushima et al., 2010; Shutt et al., 2010). Furthermore, at higher levels of TFAM,
transcription would occur preferentially at the HSP1 promoter, which would not trigger
replication (Shutt et al., 2010). The second model argues that TFAM covers the whole of
the mtDNA (a dimer per 35 bp), not just the promoter region, and that the transcriptional
activity of TFAM is not required to control mtDNA copy number (Ekstrand et al., 2004;
Freyer et al., 2010). In fact, over-expressing TFAM lacking the C-terminal region, therefore
lacking transcriptional competence, in human cell lines, has been shown to increase mtDNA
copy number (Kanki et al., 2004). Similarly, over-expression of human TFAM in a TFAM
knockout mouse increases the mtDNA copy number, but has no effect on mitochondrial
transcript level and does not improve respiratory chain function and mitochondrial mass
(Ekstrand et al., 2004). As previously mentioned, the C-terminal region in the TFAM
structure is required for transcriptional activity, and since this region sequence differs in
human and mouse TFAM, hTFAM cannot be used to activate transcription in a mouse and
vice versa (Ekstrand et al., 2004). This model therefore suggests that the role of TFAM as a
transcription factor is not required in the regulation of mtDNA copy number.
How is TFAM activity regulated? TFAM is known to be degraded by mitochondrial Lon
protease (Matsushima et al., 2010) – an enzyme that degrades oxidised or mis-folded
proteins. It is not known what triggers this TFAM degradation – the protease might
recognise unfolded TFAM, or it might be targeting oxidatively-altered mtDNA, reducing
TFAM binding (Canugovi et al., 2010).
Recently, Lu et al. showed that TFAM is phosphorylated, possibly via phosphate kinase A
within its HMG1 domain, leading to its dissociation from mtDNA and its subsequent
degradation by Lon (Lu et al., 2013). Furthermore, an additional study also demonstrated
that TFAM is directly phosphorylated by extracellular-signal-regulated kinase (ERK)1/2 at
Serine 177, similarly reducing its binding to the mtDNA promoter region and thereby
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inhibiting its transcriptional activity (Wang et al., 2014). Other studies also demonstrate
that TFAM might be post-translationally modified via acetylation at a single lysine residue.
The authors speculate that since TFAM exhibits histone-like properties, its acetylation
might be a way of regulating mtDNA gene expression, similar to nuclear gene regulation by
histone acetylation (Dinardo et al., 2003).
Due to its crucial role in mtDNA stability, transcription and regulation of copy number,
over-expression of TFAM has been shown to ameliorate cell function and viability in several
pathology models including Type II diabetes, heart disease, PD, AD and general ageing
(Ikeuchi et al., 2005; Hayashi et al., 2008; Suarez et al., 2008; Gauthier et al., 2009; Keeney
et al., 2009; Xu et al., 2009; Campbell et al., 2012; Piao et al., 2012). Clearly, this is
dependent on the structure of TFAM, with a compatible C-terminal tail allowing for
transcription initiation, and ratios of TFAM: mtDNA, whereby an optimal balance allows for
sustainable rates of transcription and replication without compromising mtDNA integrity.
1.7.3. MtDNA inheritance
MtDNA is maternally inherited, and therefore, mtDNA mutations and any associated
pathologies are also derived from the maternal line. In mammals, mitochondria are
randomly distributed during oogenesis in females, thereby producing oocytes with
different amounts of mutant or wild-type mtDNA (Figure 1.10). A mother carrying only
normal (wild-type) mtDNA will only pass on wild-type mtDNA to her progeny, and in this
case all mitochondria will carry identical copies of mtDNA – this is known as homoplasmy.
However, in cases where the mother is carrying mutant mtDNA, mitochondria in the
progeny may harbour both wild-type and mutant mtDNA; a situation known as
heteroplasmy. Therefore, in any cell, levels of heteroplasmy can vary greatly and over time
somatic segregation might favour an increase in the frequency of one genotype to the
other. The level of heteroplasmy is crucial because pathogenic mutations must surpass a
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threshold level in order for symptoms to develop and a disease to develop (Taylor and
Turnbull, 2005). The threshold level required for pathogenesis is dependent on the tissue
type. Highly oxygen demanding tissue types such as the brain, heart and muscle, will have a
lower threshold level for presence of mtDNA mutations as they will be particularly
susceptible to mutations in mtDNA affecting the respiratory chain.
Figure 1.10 Inheritance of mtDNA
MtDNA is maternally inherited and during the production of primary oocytes. MtDNA molecules are
randomly distributed to the individual oocytes. This leads to varying levels of mtDNA mutational load,
with some oocytes carrying a low level and thereby giving rise to unaffected offspring and other
oocytes having higher levels of mutations, surpassing the pathological threshold, therefore leading to
affected offspring (Taylor and Turnbull, 2005).
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1.8. Mutations in mtDNA
The mitochondrial genome, being less protected and having fewer repair mechanisms than
its nuclear counterpart, is particularly susceptible to damage. Mutations in mtDNA may
lead to mitochondrial dysfunction either via direct alterations in the protein-encoding
genes of the genome, or via mutations in the genes affecting translation. Mutations in
mtDNA can be inherited or occur spontaneously. The most well-known syndromes
associated with large mtDNA deletions are; Pearson’s syndrome, a rare disease
characterised by sideroblastic anemia and exocrine pancreas dysfunction, Kearns-Sayre
syndrome, a multisystemic mitochondrial myopathy, and progressive external
ophtalmoplegia (PEO), a mitochondrial myopathy characterised by drooping of the eyelids
(ptosis) and paralysis of the extraocular muscles (ophthalmoplegia) (Zeviani et al., 1988;
Moraes et al., 1989; Rotig et al., 1990). Point mutations in rRNA or tRNA genes in the
mitochondrial genome result in defects in the overall synthesis of mitochondrial proteins.
Mitochondrial encephalopathy lactic acidosis, and stroke-like episodes (MELAS) syndrome
is associated with an A to G transition, A3243G, in the mTERF binding site on tRNA, whilst
an A8344G transition is associated with myoclonus epilepsy and ragged-red fibers (MERRF)
(Wallace et al., 1988a; Goto et al., 1990; Shoffner et al., 1990; Larsson et al., 1992). Finally,
point mutations may also occur in the protein-encoding genes in the mitochondrial
genome. Leber’s hereditary optic neuropathy (LHON), characterised by the degeneration of
retinal ganglion cells, is a maternally inherited disease caused by one of three mutations:
G3460A, G11778A and T14484C, affecting ND1, ND4 and ND6 respectively (Wallace et al.,
1988b; Wallace et al., 1988a; Howell et al., 1991; Johns et al., 1992). Similarly, Leigh
syndrome, also known as juvenile subacute necrotizing encephalomyelopathy, results from
a mutation T8993C in the ATP6 gene (Shoffner et al., 1992). MtDNA mutations, however,
only account for 20-25% of cases of Leigh syndrome (Thorburn and Rahman, 1993). The
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majority of cases are associated with a mutation in SURF1, a nuclear DNA encoded gene
which is required for assembly and function of COX.
1.9. Mutations in nuclear DNA
Mutations in nuclear genes encoding mitochondrial targeted proteins will also affect
mitochondrial function and OXPHOS. This might occur via defects in proteins regulating
mitochondrial replication – autosomal dominant PEO is attributed to mutations in the
catalytic subunit of pol γ, the mtDNA helicase Twinkle and ANT (Copeland, 2008).
Mutations in genes encoding for TK2 and dGUOK, which are required for synthesis of dNTPs
for mtDNA replication (Figure 1.7), are also associated with depletion of mtDNA levels
(Mandel et al., 2001; Saada et al., 2001). Similarly, mutations in TP, resulting in a decrease
in enzyme activity and an accumulation of thymidine, lead to depletion or deletions in
mtDNA in patients with mitochondrial neuro gastro-intestinal encephalomyopathy
(MNGIE), possibly via an aberrant regulation of thymidine availability for DNA synthesis
(Nishino et al., 1999).
1.10. Animal models of mtDNA dysfunction
Mutations in Drosophila pol γ-α (tamas) and pol γ-β have been shown to lead to loss of
mtDNA and developmental lethality (Iyengar et al., 1999; Iyengar et al., 2002). Similarly,
homozygous pol γ-α knockout mice are embryonic lethal whilst heterozygous mice develop
normally despite showing a slight reduction in mtDNA levels (Hance et al., 2005).
Moreover, mice expressing a proofreading-deficient version of pol γ-α, known as ‘mutator
mice’, exhibit an increased level of mtDNA mutations, have a shorter lifespan and exhibit
premature ageing phenotypes (Trifunovic et al., 2004). Indeed, studies have identified the
presence of mtDNA deletions as the driving force behind the premature phenotypes
observed (Vermulst et al., 2008). However, other studies have argued that whilst there
might be an increase of mtDNA deletions in pol γ mutator mice, the association with a
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premature ageing phenotype might be correlative, rather than causal. Quantitative
measurement of mtDNA deletions in mutator mice via analysis by single molecule PCR has
revealed that, in reality, the frequency of mtDNA deletions in these mice is too low to
significantly contribute to a change in physiology, such as premature ageing. Indeed, it is
argued that current experimental data is not sufficient to conclude that mtDNA deletions
drive premature ageing and that further work is required to investigate this association in
mutator mice models (Khrapko and Vijg, 2009; Kraytsberg et al., 2009).
Overexpression of tamas in Drosophila has also been shown to cause mtDNA depletion
resulting in a variety of phenotypes (Lefai et al., 2000). Overexpressing tamas in muscle
resulted in substantial pupal lethality, with a few surviving adults having a significantly
reduced lifespan concomitant with a reduced mtDNA level and a decrease in levels of TFAM
(Martinez-Azorin et al., 2013). Overexpression of tamas in the fly nervous system also
caused an increase in pupal lethality, albeit to a lower level than that observed in the
muscle. Adults also exhibit a decreased lifespan, a reduced mtDNA level and lower levels of
TFAM (Martinez-Azorin et al., 2008). Contrastingly, overexpression of tamas in Drosophila
Schneider cells did not phenocopy these observations, and mtDNA levels and growth rate
were unchanged (Lefai et al., 2000), suggesting that variable levels of pol-γ are tolerated
more in vitro than they are when expressed in the whole organism.
Recently, downregulation of tamas in Drosophila dopaminergic neurons was shown to
result in premature ageing, lower respiratory chain activity and neuronal cell loss, which
was fully rescued upon expression of the alternative oxidase AOX, allowing for an
alternative ETC route, bypassing complex III/IV deficiency (Humphrey et al., 2012).
In mammals, dominant mutations in the mtDNA helicase, Twinkle, are associated with
adult onset PEO. Expression of these PEO patient mutations in mice resulted in ‘deletor
mice’ exhibiting respiratory chain deficiency in skeletal muscles and specific neuronal
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populations, as well as a reduced level of mtDNA levels in the brain. Furthermore,
mitochondrial myopathy was observed in these mice at about 12 months of age, with a
progressively increasing rise of mtDNA deletions with age. These ‘deletor mice’ however,
unlike the ‘mutator mice’ previously discussed, do not exhibit any signs of premature
ageing. Therefore, Twinkle and pol γ might influence ageing via separate mechanisms.
Alternatively, high levels of mtDNA mutations, resulting specifically from PolgA mutations,
might be required for a premature ageing phenotype (Tyynismaa et al., 2005).
Overexpression of wild-type mtDNA helicase in both mice and Drosophila led to an
increased mtDNA copy number, but the animals did not exhibit any particular phenotypes
(Tyynismaa et al., 2004; Sanchez-Martinez et al., 2012). Expression of a mtDNA helicase
variant carrying a K388A mutation, which disrupts helicase activity, in Drosophila, however,
led to a decreased mtDNA number and lethality at the third larval instar stage (Sanchez-
Martinez et al., 2012). Expression of two mtDNA helicase mutations which are commonly
associated with human autosomal dominant PEO: A442P and W441C, also resulted in a
decrease in mtDNA copy number and a decrease in lifespan, although the results were
more significant in the A442P mutants than W441C. Expression of the K388A and A442P
mutations elicit defects in the mitochondrial OXHPOS process and a concomitant increase
in apoptosis, suggesting that these mutations lead to a deregulation of mitochondrial-
assisted programmed cell death and a reduction in cell proliferation (Sanchez-Martinez et
al., 2012).
Similarly, mutations in the lopo gene in Drosophila, encoding mtDNA SSBP, result in
developmental lethality, loss of respiratory function and reduced cell proliferation (Maier
et al., 2001). Moreover, mutations in specific amino acids within mtDNA SSBP, which inhibit
its DNA-binding activity and its interaction with pol γ, result in a loss of pol γ activity and
defects in DNA synthesis.
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Furthermore, as previously mentioned in Section 1.7.2, inactivation of TFAM in mouse
dopaminergic neurons leads to a reduction in mtDNA levels. These ‘Mito-park’ mice
develop parkinsonian-like phenotypes, with neuronal loss in SNpc, loss of dopamine in the
striatum, abnormal mitochondrial aggregates as well as reduced movement and tremors
(Ekstrand et al., 2007).
An additional model of mtDNA dysfunction was recently developed by the Moraes group,
utilising a mitochondrially targeted endonuclease (mito-PstI) to create double stranded
breaks in mtDNA in dopaminergic neurons. This model, known as ‘PD-mito-PstI’ develops a
reduction in mtDNA copy number resulting in OXPHOS deficiency and a disrupted
mitochondrial membrane potential.  The ‘PD-mito-PstI’ mouse develops similar PD-like
phenotypes to those observed in the ‘Mito-park’ mouse, including depletion in dopamine
levels, motor symptoms and a reduction in dopaminergic neurons in the SNpc (Pickrell et
al., 2011).
Taken together, these studies all demonstrate the importance of mitochondrial integrity in
a functional nervous system and further validate the role of mtDNA dysfunction in
neurodegenerative diseases.
1.11. Mitochondrial retrograde signalling
As discussed above, the nuclear genome plays a crucial role in the regulation of
mitochondrial structure and function. The nucleus, therefore, must efficiently
communicate with the mitochondria, ensuring a constant flow of information – this process
is referred to as nucleus-to-mitochondria ‘anterograde signalling’. In the early 1990s,
pioneering work by the Butow laboratory also led to the identification of a mitochondria-
to-nucleus communication pathway referred to as ‘retrograde signalling’ (Liao and Butow,
1993; Butow and Avadhani, 2004). Research carried out on the mitochondrial retrograde
signalling pathway suggests that dysfunctional mitochondria communicate with the nucleus
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to deliver information regarding their metabolic, oxidative and respiratory statuses. Such
communication could ultimately lead to changes in nuclear gene expression, acting to
ameliorate metabolic conditions (Figure 1.11). Therefore, mitochondrial retrograde
signalling is defined as a cellular response to a change in mitochondrial function.
The mitochondrial retrograde signalling pathway was first identified in yeast, where mtDNA
depletion was found to induce the upregulation of nuclear-encoded transcription factors,
resulting in altered mitochondrial metabolism with upregulated fatty acid β-oxidation and
activation of the glyoxylate cycle (Parikh et al., 1987; Butow et al., 1988). Later studies
identified three retrograde response genes in yeast: RTG1, RTG2 and RTG3 (Liao and
Butow, 1993; Jia et al., 1997; Rothermel et al., 1997; Sekito et al., 2000; Liu et al., 2003).
RTG1 and RTG3 encode the subunits of a heterodimeric transcription factor, which bind to
the sequence GTCAC (R box) in the promoters of target genes of the retrograde signalling
response, stimulating transcription. RTG1-RTG3 are usually located in the cytoplasm, where
RTG3 is heavily phosphorylated, but are translocated to the nucleus upon the induction of
the retrograde response (Rothermel et al., 1995; Rothermel et al., 1997; Sekito et al.,
2000). This requires a partial dephosphorylation of RTG3; a process which requires the
presence of RTG2 (Sekito et al., 2000).
Retrograde signalling is conserved in mammals, although the molecular mechanisms might
differ in different species, likely due to varying metabolic demands. Retrograde signalling in
mammals was first observed in several ρ° (devoid of mtDNA) cell lines which showed
increased mRNA levels for several mitochondrial proteins (Marusich et al., 1997; Wang and
Morais, 1997). Further studies in mammalian cell lines, including C2C12 skeletal myoblasts
(rhabdomyoblasts) (Biswas et al., 1999) and human lung carcinoma A549 cells (Amuthan et
al., 2002), further established the presence of a mitochondrial stress response. Treatment
with ethidium bromide or the ionophore CCCP (carbonyl cyanide m-chlorophenyl
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hydrazone), resulted in altered mitochondrial membrane potential and increased levels of
cytosolic free Ca2+, which in turn activates the phosphatase calcineurin. Ultimately, the
induced mitochondrial stress in both cell types resulted in the upregulation of nuclear-
encoded genes involved in Ca2+ transport and storage such as Ryanodine Receptor I or II,
calreticulin and calsequestrin (Biswas et al., 1999; Amuthan et al., 2001).
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Figure 1.11 Mitochondrial retrograde signalling
MtDNA damage or the presence of mutations in mtDNA can lead to mitochondrial dysfunction,
including a bioenergetic deficit due to functional changes in respiratory chain complexes.
Mitochondria can relay this information back to the nucleus via a retrograde signalling pathway,
which will elicit an anterograde response, acting to repair the damage or induce cell death (Wright et
al., 2010).
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Recently, studies have also been carried out in Drosophila, in order to uncover more details
regarding the mechanisms of retrograde pathways which are activated upon mitochondrial
dysfunction (Mandal et al., 2005; Liao et al., 2006; Freije et al., 2012). Downregulation of
Complex IV (COX) subunit Va (CoVa) in the developing Drosophila retina, activates a
retrograde pathway specifically involving AMP-activated protein kinase and tumor-
suppressor protein p53 (Mandal et al., 2010). Activated p53 will transcriptionally activate
archipelago, an F-box protein which will in turn ubiquitinylate Cyclin E, resulting in
proteasomal degredation and a block in the cell cycle from G1 to S phase (Mandal et al.,
2010; Freije et al., 2012). However, cell viability is maintained, suggesting that the
retrograde signal acts to alter the metabolic state whilst favouring cell survival. Indeed,
disruption of ETC genes has been reported to extend lifespan, via a retrograde signal, in
Drosophila (Copeland et al., 2009; Liu et al., 2011) and mice (Liu et al., 2005; Dell'agnello et
al., 2007; Lapointe and Hekimi, 2008).
Furthermore, studies in mammalian cells also identified an additional retrograde response,
which was termed the mitochondrial unfolded protein response (UPRmt). In a healthy
mitochondrion, mitochondrial chaperones localised in the mitochondrial matrix act to
regulate protein import and folding of proteins and complex assembly, whilst proteases in
the matrix and inner membrane degrade any misfolded proteins (Tatsuta and Langer,
2008). However, several disruptions in the mitochondrial environment, such as mutations
in assembly proteins, harsh environmental conditions or high levels of reactive oxygen
species (ROS), might lead to the accumulation of unfolded or misfolded proteins, triggering
a UPRmt (Haynes and Ron, 2010). This stress response induces an upregulation of nuclear
encoded mitochondrial chaperones and proteases (Martinus et al., 1996; Zhao et al., 2002).
The UPRmt response has also been shown to be activated upon mitochondrial stress caused
by mtDNA depletion, downregulation of ETC components, depletion of mitochondrial
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proteases and induction of high ROS levels in C. elegans (Yoneda et al., 2004; Haynes et al.,
2010; Durieux et al., 2011; Nargund et al., 2012).
Recently, the theory of ‘mitonuclear protein imbalance’ was put forward by Houtkooper et
al. (Houtkooper et al., 2013). This suggests that there is a stochiometric imbalance between
proteins encoded by mitochondrial and nuclear genomes, and that this imbalance might be
involved in regulating lifespan. Mitochondrial dysfunction induces this mitonuclear protein
imbalance which will in turn trigger a UPRmt, positively correlating with an increased
lifespan in C. elegans (Houtkooper et al., 2013). In another Drosophila study, knockdown of
complex I components resulted in a muscle mitochondrial phenotype while concomitantly
inducing a redox – dependent upregulation of UPRmt regulating genes. Expression of the
insulin-like growth factor binding protein, ImpL2, was also upregulated, suggesting a
decrease in insulin signalling and an increase in mitophagy. This ultimately preserved
muscle activity and prolonged lifespan (Owusu-Ansah et al., 2013). Activation of the
retrograde signal in C. elegans, has also been shown to extend lifespan, and similarly to
Drosophila, knockdown of subunit 4 of Complex IV of the ETC (COX) has been reported to
increase lifespan whilst activating a UPRmt (Durieux et al., 2011). Interestingly, this study
also found that mitochondrial dysfunction in the nervous system triggered a UPRmt in the
intestine in C. elegans, suggesting that the mitochondrial stress response could lead to a
non-cell autonomous signal.
In mammals, retrograde signalling is known to involve the mechanistic target of rapamycin
(mTOR) complex and PGC1α, which act to regulate mitochondrial biogenesis, thus
maintaining adequate cellular bioenergetics (Jones et al., 2012; Chae et al., 2013; Lerner et
al., 2013). Mitochondrial dysfunction might trigger a retrograde response, which acts on
mTOR and PGC1-α to re-establish functional mitochondria and promote cell survival. In
neurodegenerative diseases, which are characterized by neuronal cell death, this would
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lead to neuroprotection, whilst in cancer, promoting cell survival might further exacerbate
the pathology. Indeed, the mitochondrial retrograde response has been reported to be
implicated in cellular proliferation and survival in a wide variety of tumours. Inhibition of
mitochondrial ATPase has been shown to trigger a ROS-mediated retrograde response that
inhibits apoptosis via upregulation of the anti-apoptotic protein Bcl-xl, promoting
tumorigenesis (Formentini et al., 2012). Mutations in the mitochondrial-encoded ATP6 and
COI genes are also both associated with decreased mitochondrial respiration and enhanced
tumour growth, following increased ROS levels (Petros et al., 2005; Shidara et al., 2005;
Arnold et al., 2013), and several other studies suggest that somatic mtDNA mutations lead
to increased ROS levels which are attributed to enhanced tumour metastasis (Ishikawa et
al., 2008; Chang et al., 2009; Hung et al., 2010). Moreover, recent studies in cybrid cell lines
have suggested that the introduction of healthy mitochondria into cancerous cells can
attenuate the mitochondrial dysfunction phenotypes associated, and can restore ATP
generation and oxygen consumption whilst reducing ROS levels (Kaipparettu et al., 2013).
Taken together, these findings suggest that ROS-mediated retrograde signalling is
implicated in tumorigenesis, introducing a role for ROS-regulation in the therapeutic
intervention of cancer.
Mitochondria have also been reported to modify the epigenetics of the nuclear genome.  A
study has shown that peripheral blood DNA from subjects belonging to haplogroup J had
higher methylation levels than samples from individuals belonging to other haplogroups.
The same findings were observed in DNA from cybrid cells, where cybrids carrying DNA
from J haplogroup exhibited higher methylation levels than cybrids with other haplogroup
DNA (Bellizzi et al., 2012). J cybrids also generated lower levels of ATP and ROS, suggesting
that mtDNA can regulate epigenetic changes in the nuclear genome and that this might
possibly affect OXPHOS activity (Bellizzi et al., 2012).
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Differing DNA methylation levels were also observed in mouse embryonic stem cells
belonging to different mtDNA haplogroups (Kelly et al., 2012), and a human disease study,
identified altered DNA methylation levels in cardiac cells from patients with dilated
cardiomyopathy (Koczor et al., 2013). These findings therefore imply that a mitochondrial
retrograde signalling mechanism might also be acting to modulate the epigenetic gene
silencing of nuclear DNA, however, the mechanisms by which this control might occur are
not yet well elucidated. Recent studies have provided some mechanistic insight by
identifying the role of ROS in this epigenetic response. O’Hagan et al. found that exposure
to ROS resulted in the assembly of a protein complex at regions of damaged chromatin,
leading to the methylation of DNA (O'Hagan et al., 2011). A later study found that
mitochondrial ROS are able to activate DNA damage response kinases, which act in the
nucleus inhibiting histone demethylation (Schroeder et al., 2013). These discoveries further
establish ROS as important retrograde signalling molecules, which may also play a part in
the epigenetic changes induced by the mitochondria on the nucleus.
1.11.1. Mitochondrial retrograde signalling in disease
The presence of a compensatory mechanism in response to stress and mtDNA mutations,
begs the question of whether an age-related malfunction of this compensatory mechanism
might be implicated in the development of age-related disease.
Several animal models have demonstrated that mtDNA dysfunction leads to a retrograde
signal that triggers an adaptive compensatory response. In Drosophila, a mutation in the
ETC complex V ATP6 protein resulted in reduced OXPHOS activity but an upregulation in
the rate of glycolysis, ketogenesis and citric acid cycle bioenergetics that maintained
functional cellular activity while the flies were still young. However, once aged, the flies
exhibited locomotor deficits and premature death (Celotto et al., 2011).
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Furthermore, mitochondria isolated from platelets of AD and MCI patients had
differentially expressed levels of genes that regulate mitochondrial biogenesis and activity,
compared with controls (Silva et al., 2013). Mitochondrial malfunction has also been
reported in embryonic neurons in AD mouse models, prior to onset of AD pathology (Yao et
al., 2009). These findings therefore suggest that while a compensatory mechanism does
exist, in response to mitochondrial dysfunction, it might become inadequate over
prolonged periods of time, resulting in full-blown disease onset and cell death.
The previously mentioned mtDNA A3243G base substitution associated with MELAS, has
also recently been shown to potentially instigate a retrograde signalling pathway acting via
RXRA (retinoid X receptor α), ROS, JNK kinase (c-JUN N-terminal kinase), and the
transcriptional co-activator PGC1α to mediate the response (Chae et al., 2013). Chae et al.,
found that in a cybrid model cell line, expression of the A3243G mutation triggered
generation of reactive oxygen species which resulted in a decreased mRNA abundance of
OXPHOS and translation-related genes. This pathway therefore results in a transcriptional
feedback loop which further exacerbates the dysfunction in oxidative phosphorylation,
further aggravating mitochondrial dysfunction and contributing to disease progression.
Therefore, the mitochondrial retrograde signalling pathway plays a crucial part in
regulating the processes related to mitochondrial-associated pathologies and further
understanding of the mechanism is critical to develop potential therapeutic options.
1.12. Mitochondrial dysfunction in neurodegenerative diseases
1.12.1. Mitochondria and Alzheimer’s Disease
The AD mitochondrial cascade hypothesis was first proposed in 2004 by Swerdlow and
Kahn (Swerdlow and Khan, 2004). The premise is that, for each individual, a genetically
determined mitochondrial baseline function, along with environmental factors, will
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regulate a rate of decline in mitochondrial function which will in turn determine the
temporal onset of AD pathology (Figure1.12). This theorem further strengthens the ideas
put forth by numerous studies which concluded a link between mtDNA mutations,
mitochondrial dysfunction and AD (Parker et al., 1989; Wallace, 1992).
Unlike the amyloid cascade hypothesis, the mitochondrial cascade hypothesis clearly
distinguishes between LOAD and EOAD in terms of disease development. According to this
hypothesis, in LOAD, age-associated mitochondrial dysfunction leads to AD pathology,
whilst in EOAD, the APP processing leading to Aβ aggregation will be the hallmark of
disease onset. The proposal also further identifies the role of an ageing brain in AD
development. Mitochondrial function declines with ageing, which is compensated by
adaptive mechanisms. However, if compensatory mechanisms are not enough to
counteract the disease development, symptoms will present (Swerdlow et al., 2013).
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Figure1.12 The mitochondrial cascade hypothesis
The mitochondrial cascade hypothesis argues that for each individual, genetic and environmental
factors determine an age-associated mitochondrial decline, which initially leads to a compensatory
mechanism resulting in bioenergetic hypermetabolism. This, in turn, increases production rates of
Aβ and this leads to further bioenergetic decline.  When mitochondrial dysfunction is too severe,
compensatory mechanisms are not adequate and symptoms develop.  At this point, Aβ production
rates decline (Swerdlow et al., 2013).
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As previously stated, familial, EOAD cases account for less than 1% of all AD cases and are
mostly associated with mutations in APP and the presenilin genes PSEN1 and PSEN2.
Presenilin 1 and 2 complexes regulate the cleavage of APP by γ-secretase, into Aβ1–40 and
Aβ 1–42.  The toxicity of these peptides has been greatly studied, with Aβ 1–42 being identified
as the most neurotoxic, especially in its aggregated form (Deshpande et al., 2006). The
presenilin complex with γ-secretase has been shown to be localised to mitochondria,
further confirming the importance of the organelle in the pathogenesis of the disease
(Hansson et al., 2004). APP has also been found to bind to the OMM, where the APP
intracellular domain (AICD), is released into the mitochondrion once cleaved by the γ-
secretase complex (Pavlov et al., 2011). Moreover, Aβ is found in mitochondrial cristae,
where it localises after entering the organelle via the TOM complex (Hansson Petersen et
al., 2008). Indeed, in AD patients, Aβ accumulation is known to occur early on in the
disease and is especially found in lysosomes, endosomes and mitochondria (Lustbader et
al., 2004; Gouras et al., 2005; Manczak et al., 2006; LaFerla et al., 2007). Aβ binds to
mitochondrial proteins, altering mitochondrial morphology and function. Inhibiting this
interaction suppresses mitochondrial damage caused by Aβ and reduces cognitive
phenotypes in mouse models of AD, suggesting that mitochondrial targets are a major
contributor to AD progression (Lustbader et al., 2004; Du et al., 2008).
Aβ is thought to interfere with mitochondrial function by increasing viscosity of the
mitochondrial membrane, altering levels of the phosphate to oxygen ratio, reducing levels
of ETC activity, and increasing levels of ROS and release of cytochrome c (Aleardi et al.,
2005). Indeed, in human cortical neurons, treatment with Aβ oligomers (AβO), composed
of 15-20 monomers, resulted in a significant 89% drop in mitochondrial membrane
potential and a 70% loss in ATP levels within 2 hours post-treatment, followed by an
increase in caspase activation and release of cytochrome c and apoptosis initiating factor
after 8 hours (Deshpande et al., 2006).
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Aβ has also been shown to interfere with mitochondrial function via inhibition of the
respiratory chain (Canevari et al., 1999; Crouch et al., 2005). Aβ is known to inhibit complex
IV of the ETC, possibly via an interaction with the heme-containing COX unit (Atamna and
Boyle, 2006). In vivo treatment with sodium azide, a known COX inhibitor, results in
cognitive deficits and morphological changes in rat neurons (Szabados et al., 2004).
Additionally, manganese superoxide dismutase (MnSOD), an enzyme acting to reduce
superoxide levels in mitochondria, is also inhibited by Aβ causing an increase in oxidative
stress (Massaad et al., 2010).
Studies have also suggested that Aβ accumulation in AD is linked to increased
mitochondrial fission and a decrease in mitochondrial fusion, leading to a disruption in
mitochondrial dynamics and subsequent neuronal damage (Wang et al., 2008).
Somatic mtDNA mutations, such as the common 5 kb deletion (mtDNA-4977) have also
been linked to AD, particularly in the frontal cortex and basal ganglion (Corral-Debrinski et
al., 1994). These regions are especially susceptible since they carry the highest somatic
mtDNA mutation rate in the human body and they are highly energy demanding. The
mutation T414G in the control region of mtDNA causes an alteration in the TFAM binding
site which transcribes the ND6 gene, encoding NADH-ubiquinone oxidoreductase chain 6
(Michikawa et al., 1999a; Murdock et al., 2000). This mutation was found to be associated
with ageing in human skin fibroblasts (Michikawa et al., 1999b), and was later found to be
more predominant in AD brains compared to control brains (Coskun et al., 2004).  Somatic
mtDNA mutations have also been found to be more frequent in DSAD (Down’s Syndrome
with AD-like dementia) and mtDNA/nDNA ratio levels are reduced in both DSAD and AD
(Coskun et al., 2004; Coskun et al., 2010).
Interestingly, mtDNA mutations and levels were also found to correlate with Aβ
metabolism. In DSAD, an increase in the somatic mutation levels in the mtDNA control
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region and a decrease in mtDNA/nDNA levels, correlated with an increase in β-secretase
activity (Coskun et al., 2010). Furthermore, depleting levels of mtDNA correlated with an
increase in insoluble forms of Aβ 1-40. MtDNA mutations arise earlier than Aβ accumulation
in progression of the disease, and may therefore play a role in increasing Aβ pathology.
AD cybrid studies have also established a link in bioenergetic decline with disease
progression. Specifically AD-neuroblastoma cybrids exhibit reduced complex IV activity,
increased oxidative stress, Aβ peptide secretion and fluctuations in mitochondrial
membrane potential (Thiffault and Bennett Jr, 2005). Differentiated AD cybrids also
develop altered mitochondrial morphology and impaired mitochondrial transport along
neurites as well as increased autophagic vesicles and increased deposition of Aβ (Trimmer
and Borland, 2005; Cardoso et al., 2010). Whilst transmitochondrial cybrid studies have
proven extremely useful in studying the role of mitochondrial mutations in disease, it is
important to note that most ρ0 cells used in these studies are derived from aneuploid
tumor cell lines. Since aneuploidy could affect nuclear DNA-mtDNA ratios and consequently
nuclear DNA-mtDNA ETC subunit stoichiometry, it could significantly affect phenotypes
observed in such studies. Furthermore, most tumorigenic cell lines are highly anaerobic.
Therefore, in such cybrid models, the metabolic state of the original host cell might be an
exerting an effect which could influence the results obtained in the studies (Swerdlow,
2007).
Studies in animal models have also established a link between mitochondrial dysfunction
and AD. In a Drosophila model of AD, Aβ accumulates intraneuronally when expressed in
the giant fibre neuron system (Zhao et al., 2010). Such treatment with Aβ was sufficient to
cause age-dependent mitochondrial loss at the presynaptic terminal, concomitant with a
decrease in synaptic vesicle release and increased synaptic fatigue. Axonal mitochondrial
numbers were also reduced, whilst mean mitochondrial area was increased, suggesting a
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defect in mitochondrial fission. Anterograde and retrograde transport of mitochondria
along the axon was also observed to slow down, following presynaptic mitochondrial loss
upon treatment with Aβ. Impaired transport upon Aβ treatment has also been observed in
cultured hippocampal neurons (Rui et al., 2006; Vossel et al., 2010). Bruchpilot (Brp) is the
Drosophila homolog of the Elks/CAST proteins, which function in the assembly of
presynaptic active zones; areas within the presynaptic membrane where presynaptic
vesicles dock and fuse to release neurotransmitters (Kittel et al., 2006; Wagh et al., 2006).
Expression of the arctic mutant form of Aβ1-42 (Aβarc) in the giant fiber neuron system of
Drosophila has been shown to lead to an age-dependent decrease in Brp protein,
suggesting a decrease in the amount of active zones (Huang et al., 2013). In the squid giant
axon, treatment of the presynaptic region with Aβ also resulted in a reduction of docked
synaptic vesicles and a subsequent loss of synaptic transmission (Moreno et al., 2009).
The temporal sequence leading to full-blown AD pathogenesis is not well elucidated.
Though presynaptic mitochondrial alterations are a contributing factor, they might occur
much earlier than any real synaptic dysfunction. Therefore, whilst loss of mitochondrial
function and ATP deficiencies might be a result of neurodegeneration, they might also be
required to trigger the damage induced upon Aβ accumulation. Furthermore, recent
studies suggest that while AD pathology is necessary for cognitive decline to develop,
failure of the stress response system in the brain is also a requirement (Lu et al., 2014) and
other studies find compelling evidence suggesting that chromatin remodelling plays a
major role in the epigenetic regulation correlated to cognitive decline (Fischer et al., 2007;
Graff and Tsai, 2013; Ronan et al., 2013). Recent studies also suggest that Aβ is produced in
a soluble form via APP processing in response to mitochondrial dysfunction (Jimenez et al.,
2011). This response might initially serve a protective function, however, if sustained,
might result in accumulation of Aβ levels leading to oligomerisation (Eckert et al., 2008).
Analogously, α-synuclein might initially serve a neuroprotective purpose in PD, but later
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aggregates into Lewy bodies. This would lead to further mitochondrial dysfunction and
association bioenergetic deficits. In an aged individual, such deficits might rapidly result in
neuronal death.
1.12.2. Mitochondria and Parkinson’s Disease
In 1976, a chemistry student called Barry Kidston synthesised the drug 1-methyl-4-phenyl-
4-propionoxy-piperidine (MPPP) for recreational use. However, the drug was contaminated
with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and Kidston developed
parkinsonian symptoms as a result. A few years later, in 1982, another six people were
diagnosed with Parkinsonism after having intravenously injected the illicit drug MPPP.  The
neurologist J. William Langston identified MPTP as a major contaminant in the substance,
and further studied the effects of the drug on primates. This led to the discovery that MPTP
metabolite 1-methyl-4-phenylpyridinium (MPP+) is primarily toxic to the dopamine-
producing substantia nigra cells in the brain, where it interferes with complex I of the ETC.
Later studies further investigated the structure and function of mitochondrial respiratory
chain complexes in PD post-mortem tissue, and found a reduced complex I activity in the
SNpc of PD patient tissue (Schapira et al., 1990a; Schapira et al., 1990b; Hattori et al., 1991;
Mann et al., 1992; Janetzky et al., 1994; Hanagasi et al., 2005). Studies have also reported
the presence of multiple mtDNA deletions in the SNpc of PD patients. These somatic
mtDNA mutations accumulate to an extent which leads to respiratory chain deficiency and
eventual neuronal loss (Bender et al., 2006; Kraytsberg et al., 2006).
Furthermore, loss of activity of the previously discussed PINK1 and Parkin has been
suggested to be implicated in respiratory chain deficits, particularly in Complex I
dysfunction (Mortiboys et al., 2008; Morais et al., 2009; Amo et al., 2011). As previously
discussed, the PINK1-Parkin complex plays a role in mitochondrial turnover, fission and
fusion and transport. The mechanism underlying the PINK1 – Parkin interaction is not yet
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fully elucidated, and whilst certain studies suggest a direct binding between the two (Xiong
et al., 2009; Sha et al., 2010) or that PINK1 directly phosphorylates Parkin (Kim et al., 2008;
Narendra et al., 2010; Sha et al., 2010; Vives-Bauza et al., 2010), others suggest that they
localise in separate complexes (Thomas et al., 2011; Lazarou et al., 2012). Recent studies
also suggest that PINK1 targets Parkin to the mitochondrial membrane via phosphorylation
of specific substrates, such as the primary motor/adaptor complex component Miro (Wang
et al., 2011). Specific proteosomal degradation of Miro via Parkin, inhibits further
mitochondrial movement and quarantines damaged mitochondria for sequestration.
PARK2, the gene encoding for Parkin, has been associated with early-onset Parkinsonism
with reports of more than 120 mutations in over 600 affected families
(http://www.molgen.ua.ac.be/PDmutDB/). PARK2 mutations therefore account for most
cases of autosomal recessive PD, though the mechanism by which the mutation might lead
to parkinsonism is not well elucidated. Mutations in PINK1 and the oxidative stress sensor
DJ-1, are much less prevalent in association with PD (Spatola and Wider, 2014).
Lee et al., found that expressing mutations of Parkin known to be associated with early-
onset PD, in mouse embryonic fibroblasts led to impaired clearance of defective
mitochondria due to defects in recognition, transportation and ubiquitination of
dysfunctional mitochondria (Lee et al., 2010). Furthermore, knock-out of Parkin in mice
leads to a reduced number of mitochondrially-linked proteins and reduced respiration as
well as increased susceptibility to oxidative stress (Palacino et al., 2004). In Drosophila, loss
of Parkin led to reduced mitochondrial integrity and function (Narendra et al., 2009).
Studies in vitro (Yu et al., 2011) and in Drosophila (Yang et al., 2008) have also concluded
that Parkin and PINK1 regulate mitochondrial dynamics and function in dopaminergic
neurons.
Similarly, knock-down of PINK1 has been shown to decrease mitochondrial respiration and
ATP synthesis, as well as increase α-synuclein aggregation in in vitro models of PD (Liu et
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al., 2009). In murine models, PINK1 knock-out decreases mitochondrial respiration, and
increases mitochondrial dysfunction and susceptibility to oxidative stress (Gautier et al.,
2008). Furthermore, alterations in dPINK1 levels in Drosophila also affected mitochondrial
axonal transport with dPINK1 knock-down promoting anterograde transport, whilst dPINK1
over-expression inhibited transport in both the anterograde and retrograde direction (Liu
et al., 2012). DJ-1 knockdown has also been associated to increased oxidative damage and
dopaminergic degeneration, impaired mitochondrial respiration and morphology and an
increased mitochondrial dysfunction (Lavara-Culebras and Paricio, 2007; Irrcher et al.,
2010; Krebiehl et al., 2010) (Figure 1.13).
Figure 1.13 Mitochondria and Parkinson’s disease
A decrease in Complex I (C-I) activity as well as mutations in POLG (mtDNA polymerase γ) are
associated with PD. Proteins associated with PD (α-synuclein, parkin, DJ-1, PINK1, and LRRK2) are
also known to be localised in the mitochondria and mutations in genes encoding these factors
contribute to mitochondrial dysfunction and PD pathology.  Parkin is located in the outer
mitochondrial membrane where it inhibits cytochrome c release and might also associate with
TFAM. It is also known to physically interact with PINK1, mediating mitochondrial quality control and
the oxidative stress sensor DJ-1. LRRK2 is also localised to the mitochondria, and PD mutations are
known to augment its kinase activity, disrupting mitochondrial function. Additionally, overexpression
of α-synuclein has also been linked to mitochondrial dysfunction and toxicity of the mitochondrial
membrane transition pore. Adapted from (Lin and Beal, 2006).
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Whilst the role of ETC dysfunction in PD is well established, the presence of a mitochondrial
retrograde signalling response has not been thoroughly examined. The presence of a UPRmt
in dopaminergic neurons is plausible since the ETC toxins, such as paraquat, known to
induce parkinsonian phenotypes are also strong inducers of the UPRmt (Nargund et al.,
2012; Haynes et al., 2013). Furthermore, both the UPRmt and PINK1-dependent mitophagy
are dependent on mitochondrial import efficiency and are both activated by the same
stresses (Haynes et al., 2013). Therefore, it would be of great interest to understand how
these processes communicate with one another to efficiently regulate a response to
mitochondrial dysfunction, and most importantly, how these mechanisms are being
compromised in the context of neurodegenerative disease.
1.13. Summary
All forms of dementia lead to a devastating decline in cognitive ability and quality of life for
the patients.  Patients lose the ability to take care of themselves and eventually require full-
time care, leading to an immense emotional burden for both patients and their carers.
The pathogenic mechanisms leading to AD, PD, DLB and PDD are all complex and are
usually associated with varying levels of comorbidity. This complexity, the limited amount
of efficient animal models, and the substantial side effects associated with certain drugs
have led to a huge difficulty in providing efficient treatments for these diseases. Indeed, all
treatments available to date are symptomatic and offer limited, and mostly temporary,
benefit. The need for disease modifying therapies is crucial, especially at a time in which
the world population is ageing.
Mitochondria, being the prime source of cellular energy, are critically important in our
general body health and are especially crucial in maintaining adequate levels of energy in
our brain, which is the most energy-demanding organ of all. Mitochondrial dysfunction is
thought to be an early feature in forms of dementia, playing a role in cognitive decline and
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disease progression. Therefore, mitochondria have recently become an attractive
candidate for therapeutic studies since they might hold the secret to inhibiting the
degeneration of neurons prior to its onset. However, the mechanisms underlying the
association of mitochondrial dysfunction to neurodegeneration are not well known. Work
in this thesis aims to address the potential association of a single nucleotide polyphormism
(SNP) in TFAM with dementia.
Evidence suggesting the existence of a mitochondrial retrograde signalling pathway is also
substantial, however the role of this pathway in neuronal maintenance and in the onset of
neurodegenerative disease is not well elucidated.
Neurodegenerative diseases are progressive and most therapeutic strategies aimed at
improving cognition and brain function at the later stages of the disease have not been
very successful. The work outlined in this thesis therefore aims to better understand the
initial response of neurons to mitochondrial dysfunction, via an examination of
mitochondrial retrograde signalling in a Drosophila model of neuronal mitochondrial
dysfunction. Investigating this response could lead to the discovery of a mechanism and
therapeutic targets which inhibit the onset of neurodegeneration, thereby preventing the
devastating symptoms and pathologies associated with dementia.
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2. Investigating the association of TFAM SNP rs2306604 A>G with




The implications of mitochondrial dysfunction in neurodegeneration have been discussed
in chapter 1 (Sections 1.12.1 and 1.12.2).
The human TFAM gene contains seven exons and six introns and covers 11.7 kb in
chromosome region 10q 21.1. There are several linkage and candidate gene studies that
have associated a risk of LOAD to genes present on a broad region of chromosome 10
(Zubenko et al., 1998; Bertram et al., 2000; Myers et al., 2002; Liang et al., 2007; Liang et
al., 2009). Therefore, due its chromosomal location and function, TFAM has been of great
interest in AD association studies.
The genetic variant, TFAM rs2306604 with a IVS4 + 113A > G SNP in intron 4, has been
associated with AD in a 2007 meta-analysis of several small-scale studies and in a recent
French genome wide association study (GWAS) (Bertram et al., 2007; Laumet et al., 2010).
In both these studies, the A allele was associated with an increased risk of developing AD.
The non-synonymous coding variant of TFAM, rs1937 (exon 1 variant S12T G > C), also
referred to as rs11006128, has also been studied in association with the intronic variant
rs2306604 (IVS4 + 113A > G) in AD, and studies show that G/G genotype of the rs1937
variant and a TFAM haplotype, Grs1937-Ars2306604 are significantly associated with AD.
rs2306604 has a global minor allele frequency of A = 0.461 and an average European minor
allele frequency of A = 0.400. In silico studies have suggested that the presence of
rs2306604 (IVS4 + 113A > G) creates an alternative splice variant generating a truncated
TFAM protein (Günther et al., 2004). However, there are no in vivo studies affirming the
presence of this splice variant.
The intronic variant rs2306604 (IVS4 + 113A > G) has also been studied in association with
PD and was identified as a PD risk modifier in a 2010 study, with the G/G genotype leading
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to an increased risk of disease development (OR 1.789, 95% CI 1.162-2.755, p=0.008)
(Gaweda-Walerych et al., 2010). However, other studies, including GWAS and a meta-
analysis study found no significant association of rs2306604 (IVS4 + 113A > G) with PD risk
(Gaweda-Walerych and Zekanowski, 2013). These results suggest that this TFAM variant
might be conferring different risks for AD and PD and that TFAM polymorphisms might be
contributing to the development of dementia.
As previously described (section 1.4), up to 84% of PD patients develop cognitive
impairment throughout the progression of the disease leading to PDD, which is associated
with further alpha-synuclein pathology in the cortical areas, cholinergic deficits and co-
morbid AD pathology including amyloid plaques. PDD is highly similar to another form of
dementia; DLB. Indeed, as previously discussed, PDD and DLB patients exhibit similar
symptoms and neuropsychological and neuropathological profiles. The main recognised
distinguishing feature between the two dementias is the time of onset of cognitive
symptoms relative to motor symptoms, with PDD cases expected to exhibit motor
symptoms for longer than a year before developing cognitive impairments. DLB cases on
the other hand typically develop dementia within the same year of exhibiting motor
symptoms.
Importantly, the role of genetic factors in a predisposition to dementia in PD is not very
well understood. Similarly, there are no studies investigating genetic differences
distinguishing DLB and PDD development. Since definitions and diagnostic criteria for PDD
and PD-MCI have only been established fairly recently (Emre et al., 2007; Litvan et al.,
2012; Goldman et al., 2013), there have been no GWAS studies identifying genes
associated with cognitive impairment in PD. However, studies on smaller cohorts have
recorded an association of several genetic factors with cognitive impairment in PD.
Namely, triplications in the SNCA gene and the presence of a E46K mutation are attributed
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to an increased risk of cognitive impairment in PD (Singleton et al., 2003; Chartier-Harlin et
al., 2004; Ibanez et al., 2004; Zarranz et al., 2004; Somme et al., 2011), whilst cognitive
impairment in the presence of LRRK2mutations is thought to be less frequent than in cases
of sporadic PD, suggesting that the mutations confer a reduced risk of dementia in PD
(Goldwurm et al., 2006; Belarbi et al., 2010; Shanker et al., 2011; Ben Sassi et al., 2012).
Similarly, the presence of mutations in mitochondrial associated Parkin, have been found
to confer no added risk to cognitive impairment in PD (Caccappolo et al., 2011).
Additionally, a study investigating the presence of mtDNA polymorphisms in PD and PDD,
identified the presence of amino acid replacements in mtDNA-encoded complex I genes in
haplogroup super-cluster JTIWX in both PD and PDD. However, the presence of this super-
cluster was found to be even more frequent in PDD than in PD (Autere et al., 2004). Taken
together, these studies therefore suggest that there might be genetic risk factors enabling
a predisposition to the progression of dementia in PD.
In order to investigate whether TFAM rs2306604 A>G might also confer a predisposition to
dementia, the distribution of TFAM rs2306604 A>G, and gender bias associated with its
presence, in PD, PDD and DLB compared to healthy controls was studied.
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2.2. Chapter aims
TFAM is a nuclear encoded protein that plays a variety of roles in mitochondria, including
regulation of transcription, stability of mtDNA and regulation of mtDNA copy number.
TFAM variants have been investigated in association with AD and PD and in particular,
studies investigating an association of TFAM SNP rs2306604 A>G have provided contrasting
evidence for AD and PD with the A allele being recognised as a risk factor for AD and a
putative protective factor for PD.
In this chapter, I aim to investigate whether the intronic variant TFAM SNP rs2306604 A>G
is associated with the other forms of dementia; PDD and DLB in comparison to non-
demented PD cases and healthy controls. In particular, the prime objectives of this chapter
are:
 To investigate whether TFAM SNP rs2306604 A>G is associated with the
development of dementia in PD.
 To investigate whether the distribution of TFAM SNP rs2306604 A>G is significantly
different in the highly similar dementias PDD and DLB.
 To investigate whether the distribution of TFAM SNP rs2306604 A>G is significantly
different in males and females of the different diagnoses.
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2.3. Materials and Methods
2.3.1. Cohort description
Post-mortem tissue from frontal cortex Brodmann area 9 (BA9), and blood samples were
collected from multiple UK and Scandinavian clinical cohorts and tissue resources:
postoperative cognitive decline trial, King's College London, UK; Newcastle Brain Tissue
Resource, London Neurodegenerative Diseases Brain Bank and Thomas Willis Oxford Brain
Collection, as part of the Brains for Dementia Research initiative, UK, Multiple Sclerosis and
Parkinson’s Tissue bank, UK; Demvest clinical and pathological study in Stavanger, Norway,
and a dementia patient cohort in Malmö, Sweden. A total of 328 DNA samples were
prepared from brain or blood of individuals for TFAM rs2306604 SNP genotyping. 72 DNA
samples were obtained from DLB patients, 74 from PDD patients, 41 from PD patients and
141 from controls. Paraffin fixed, wax-embedded blocks, cut into sections of 7 µm and
mounted onto slides, were also available for subsets of the samples for IHC.
PD cases were diagnosed based upon the presence of PD following the UK brain bank
criteria (Hughes et al., 2001), whilst PDD cases were diagnosed according to DSM-IV criteria
and required the presence of PD symptoms for more than one year before the onset of
dementia (McKeith et al., 2005). Cases were diagnosed as DLB when cognitive impairment
was developed within the same year of motor symptoms, according to the McKeith
consensus criteria (McKeith et al., 2005). Controls presented no evidence of dementia-
associated pathology upon post-mortem examination.
All post-mortem tissue analysis described in this chapter received ethical approval from
Brains for Dementia Research, UK and the Multiple Sclerosis and Parkinson’s Tissue bank,
UK.
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Of the total 328 samples, 158 were tissue (BA9) samples: 48 Controls, 41 PD, 22 DLB and 47
PDD whilst the rest of the cases were blood samples: 93 Controls, 50 DLB and 27 PDD (full
list in Appendix 1). All 41 PD samples obtained were from brain tissue, and therefore no
blood samples were used for this diagnosis group. Out of the total 158 BA9 samples, 33
controls, 41 PD, and 39 PDD samples were utilised in this study.
2.3.2. Semi-quantitative pathology scoring
Lewy body neuropathology scoring was carried out according to (Ballard et al., 2006),
which is a 0 to 20 scoring system based on the previously published Lewy body scoring
system from (McKeith et al., 1996), which is modified to also represent pathology in
response to α-synuclein staining. For the purposes of this study, the scores were re-coded
as 0 (none), 1 (brainstem predominant), 2 (limbic), 3 (neocortical) as shown in Table 1.
Table 1. Scoring system used for Lewy body neuropathology.
Category Mc Keith scoring system
(McKeith et al., 1996)
Ballard scoring system




None - - 0
Brainstem 0 0-2 1
Limbic (transitional) 0-1 3-8 2
Neocortical 1-2 9-18 (mild)
19-20 (severe)
3
Tau neuropathology was scored according to (Braak and Braak, 1991) and recoded as 0
(Stage 0), 1 (stages I/II), 2 (stages III/IV), 3 (stages V/VI) as shown in Table 2. Aβ
neuropathology was scored according to the CERAD scoring system (Mirra et al., 1991) and
recoded as 0 (none), 1 (sparse), 2 (moderate) and 3 (frequent) as shown in Table 3.
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Table 2. Scoring system used for tau neurofibrillary tangle (NFT) neuropathology.
Braak and Braak Staging
(Braak and Braak, 1991)
Category Re-coded scores for this
study
0 None 0
I-II NFT in transentorhinal and
entorhinal cortex
1
III-IV NFT in limbic allocortex and
adjoining neocortex
2
V-VI NFT in neocortex 3
Table 3. Scoring system used for Aβ plaque neuropathology.
Frequency of Aβ plaques






2.3.3. Measurement of pH of tissue homogenate
Brain tissue pH is known to vary depending on agonal state, brain ischaemia as well as
repeated freeze/thaw cycles. It is therefore a routinely used indicator for quality of post-
mortem tissue (Monoranu et al., 2009). The pH of brain tissue homogenates used in this
study were measured as previously described by Kirvell et al. (Kirvell et al., 2006).  Briefly,
pH readings were taken using a pH meter (Thermo, Orion 3 star) calibrated at pH 4.0, 7.0
and 10.0 using standard buffer solutions (Thermo, Orion). The pH of dH2O was taken as a
baseline measurement to tare the readings. 50 mg of brain tissue was dissected and
homogenised in 2 mL distilled deionised water (dH2O) using an Ultra-Turrax tissue
homogeniser (IKA Werke, Germany). The pH of each sample was measured in triplicate and
the average reading was recorded.
2.3.4. DNA extraction
Genomic DNA was extracted using a commercially available kit (DNeasy blood and tissue
kit, Qiagen), following the ‘Animal tissue, spin column protocol’. 10 mg of BA9 tissue was
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cut and placed in a 1.5 ml microcentrifuge tube and 180 µl buffer ATL were added. 20 µl of
proteinase K were added and once thoroughly mixed, the sample was incubated at 56oC
overnight. 200 µl of Buffer AL were then added, followed by 200 µl of 100% ethanol. The
mixture was then spun through a DNeasy Mini Spin column and washed with washing
buffer AW1, followed by an additional spin and a wash with buffer AW2. DNA was finally
eluted with 200µl elution buffer AE. The concentration of the purified DNA samples was
subsequently quantified using the NanoDrop 1000 Spectrophotometer (Thermo Scientific)
and stored at -20oC.
2.3.5. Genotyping
The TFAM rs2306604 SNP was genotyped using a Taqman SNP genotyping assay (Applied
Biosystems, C__1953826_1). DNA at a concentration of 20ng/µl was diluted 1 in 10 fold in
DNAse-free water. A total of 5µl of DNA was then added per well in a 96-well reaction
plate. A Taqman primer/probe mixture (Context sequence: AATAAAATATGGTAGAATGTC
ATCA   [A/G] GTATTCTTCAGTTAGGCAGAAGTGG, with the VIC reporter dye linked to the 5’
end of the A allele probe, and the FAM reporter dye linked to the 5’ end of the G allele
probe) was prepared using a 1:2 dilution in Tris-EDTA pH7.4. A total of 1.25µl of the diluted
primer/probe mixture along with 12.5µl TaqMan Universal PCR MasterMix and 6.25µl
DNase-free water, were added to the 5µl DNA volume per well for a total reaction volume
of 25µl. A 25µL non-template control was also included per plate. The plate was then run
on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using the following
thermal cycling conditions:  a 10 min hold at 95oC followed by 40 cycles of (95oC for 15 sec
and 60oC for 1 min). A substantial increase in VIC-dye fluorescence indicated homozygosity
for allele A, an increase in FAM-dye fluorescence indicated homozygosity for allele B, whilst
an increase in fluorescence of both dyes indicated A/G heterozygosity. An example of such
an assay run is shown in Figure 2.1A.
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Samples obtained from the Multiple Sclerosis and Parkinson’s Tissue bank, UK at a later
stage in the study were genotyped by PCR followed by restriction enzyme digestion as in
(Alvarez et al., 2008a). A fragment of 230 bp was ampliﬁed with primers
TAAAATATGGTAGAATGTCCTC (forward) and AGATTCTTGATACTCCTGGT (reverse) at
conditions: 95oC for 2 min, followed by 40 cycles of 95oC for 15s, 50oC for 15s and 72oC for 1
min, and a final 10 min at 72oC. The forward primer introduces a target site for the
restriction enzyme DdeI in fragments containing the G-allele (Figure 2.1B). Therefore
following digestion with DdeI (New England Biolabs UK, Ltd.) at 37oC for 30 minutes, the
PCR product was run on a 2% gel. An example of such a gel is shown in Figure 2.1C.
2.3.6. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics version 19 and GraphPad
Prism version 5.0 (GraphPad Software Inc). When required, data were normalised by
logarithmic transformation and case outliers greater than two standard deviations from the
mean were not included in the analysis.
A Pearson correlative analysis was used to measure the linear correlation between post-
mortem delay of patients and levels of protein and mtDNA.
Genotype distribution in DLB, PD and PDD cases compared to controls was tested using
Pearson’s chi-squared test whilst 2x2 contingency of allele frequencies was compared using
Fischer’s exact test.
In all individual analyses, a null hypothesis was postulated which asserted that there is no
difference in frequency of TFAM SNP rs2306604 A>G amongst the different groups tested.
In all cases, a result was considered statistically significant, and the null hypothesis
rejected, when p value was lower or equal to 0.05 (p ≤0.05).
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2.4. Results
Demographic information was made available from the individual brain banks from which
the case samples were obtained, and is summarised in Table 4. There was no significant
difference between the mean age of death and brain pH of controls and PD, DLB, or PDD
patients. Post-mortem delay (PMD) of PD samples was significantly shorter than in the
other diagnostic groups, possibly due to the samples being sourced from a different brain
bank (Multiple Sclerosis and Parkinson’s Tissue bank, UK), however, correlation studies
confirmed that the difference in PMD did not influence levels of proteins or mtDNA
discussed below (data not shown).
Since only the samples obtained from the brain tissue were utilised for certain
experiments, including measurement of mtDNA levels and protein levels, demographic
information was also compared for the brain tissue samples only (Table 5).
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Table 4. Demographic information for control, DLB, PD and PDD samples used in the study
Control (141) DLB  (72) PD (41) PDD (74)
Age of death 76.34 ± 7.93 (n=141) 75.14 ± 11.26 (n=72) 79.07 ± 7.10 (n=41) 77.72 ± 6.58 (n=74)
Males  (%) 56 (39.7) 36 (50.0) 26 (63.4) 38 (51.4)
PD duration (yrs) - 4.50 ± 5.34 (n=19) 11.63 ± 6.53 (n=41) 13.31 ± 5.94 (n=31)
PD before dementia (yrs) - 0.37 ± 4.46 (n=19) - 9.84 ± 5.31 (n=31)
Dementia duration (yrs) - 3.62  ±  2.52 (n=69) - 3.86 ± 3.66 (n=72)
MMSE before death - 18.39 ± 6.94 (n=54) - 17.73 ± 7.63 (n=59)
Brain pH 6.47  ±  0.28 (n=25) 6.48 ± 0.36(n=22) 6.63  ± 0.14 (n=38) 6.47 ± 0.32 (n=39)
PMD (hours) 36.15±  20.11 (n=26) 37.68 ± 19.27(n=22) 15.38 ± 6.55 (n=39) 29.44 ± 15.87 (n=39)
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Table 5.Demographic information for control, PD and PDD BA9 tissue samples used in the study
Control PD PDD
Age of death 80.52 ± 8.86 (n=33) 79.07 ± 7.10 (n=41) 80.15  ± 5.41 (n=39)
Males (%) 18 (54.5) 26 (63.4) 23 (59.0)
PD duration (yrs) - 11.63 ± 6.53 (n=41) 13.67 ± 5.97 (n=29)
PD before dementia (yrs) - - 10.07 ± 5.40 (n=29)
Dementia duration (yrs) - - 2.84 ± 2.60 (n=37)
MMSE - - 13.63  ±  7.77 (n=27)
Brain pH 6.47 ± 0.28 (n=24) 6.63  ± 0.14 (n=38) 6.45  ±  0.31 (n=37)
PMD (hours) 36.69 ± 19.99 (n=24) 15.39 ± 6.55 (n=39) 29.58  ±  16.06 (n=38)
CERAD (Aβ) score
Median (IQ range)
0.00(0) 1.00 (2) 1.00 (2)
Braak (tau) stage
Median (IQ range)
1.00 (1) 1.00 (0) 1.00 (1)
Lewy body (α-syn) score
Median (IQ range)
0.00 (0) 2.00 (0) 3.00 (1)
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2.4.1. TFAM SNP rs2306604 (A>G) association with PDD
Figure 2.1 shows examples of results obtained from TFAM SNP rs2306604 genotyping of
BA9 samples, using the two methods outlined in section 2.3.5.
TFAM SNP rs2306604 genotype and allele frequencies in the different diagnostic groups,
obtained using these methods, are summarised in Table 6.
Genotype frequencies were not different in control and DLB groups (χ2 = 1.273, p value =
0.5292), and similarly to the control group most samples were heterozygotes (A/G) (41.7%)
compared to the A/A and G/G (33.3 and 25.0 % respectively) in the DLB group. Similarly,
genotype frequencies were not significantly different in the PD group compared to controls
(χ2 = 4.882, p value = 0.0871). However, the PD cohort did present a majority of cases in
the A/A genotype (46.2%). This distribution was, however, not statistically different from
the control cohort.  In the PDD group, genotype frequency was significantly different from
the control group (χ2 = 9.080, p value = 0.0107).  47.9% of the samples were of A/A
genotype, suggesting that TFAM SNP rs2306604 (A>G) is associated with PDD in our cohort
study. Combining the PD and PDD groups together in one set further strengthens the
statistical significance of the genotype association compared to the control group.  In fact,
the genotype frequency is now significantly different from the control group with a p value
of 0.0052 and a χ2 value of 10.53. Genotype frequency distribution in the different
diagnosis groups is represented graphically in Figure 2.2A.
Combining the AG and GG genotypes together, allowed for the analysis of the frequency of
the AA allele compared to AG/GG. This, again, revealed no significant difference in the
frequency of the AA allele in DLB compared to control population (p = 0.4290, OR = 1.308).
The frequency of the AA allele was now significantly different in both the PD group (p =
0.0334, OR = 2.242) and in the PDD group (p= 0.0040, OR = 2.409) compared to controls.
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Grouping the PD and PDD groups in one set, again, further strengthened the statistical
difference in frequency of the AA allele compared to the control group (p = 0.0016, OR =
2.349). AA vs. AG/GG frequency distribution in the different diagnosis groups is
represented graphically in Figure 2.2B.
Figure 2.1 Genotyping of BA9 Control, PD, DLB and PDD samples
(A) Taqman SNP genotyping assay showing an increase in VIC-dye fluorescence indicating
homozygosity for allele A (X-axis, red), an increase in FAM-dye fluorescence indicating homozygosity
for allele B (Y-axis, blue), whilst an increase in fluorescence of both dyes indicates A/G heterozygosity
(green). The two black crosses indicate cases whose genotype was undetermined by the assay, whilst
the grey square indicates baseline fluorescence from the no template control (NTC). (B) TFAM 25kDa
transcript with a zoomed-in insert outlining the position of the primers used and the DdeI restriction
site. A 207 bp fragment is amplified (red) when G allele is present and fragment is subsequently cut
by DdeI. A 227 bp fragment (black) is amplified when A allele is present. (C) PD cases were genotyped
via PCR followed by restriction enzyme digestion with DdeI. Homozygous A/A cases gave a band at
approximately 227 bp, whilst homozygous G/G cases gave a band at approximately 207 bp.  Both
bands were observed when cases were heterozygous.
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Table 6 TFAM SNP rs2306604 (A>G) genotype distribution and allele frequency in Control,
DLB, PD and PDD
Control DLB PD PDD PDD/PD
n=141 n=72 n=39 n=73 n=112
AA (%) 39 (27.7) 24 (33.3) 18 (46.2) 35 (47.9) 53 (47.3)
AG (%) 70 (49.6) 30 (41.7) 15 (38.5) 24 (32.9) 39 (34.8)
GG (%) 32 (22.7) 18 (25.0) 6 (15.4) 14 (19.2) 20 (17.9)
χ2, d.f. 1.273, 2 4.882, 2 9.080, 2 10.53, 2
p-Value 0.5292 0.0871 0.0107 0.0052
Control DLB PD PDD PDD/PD
AA 39 (27.7) 24 (33.3) 18 (46.2) 35 (47.9) 53 (47.3)
AG/GG 102 (72.3) 48 (66.6) 21 (53.8) 38 (52.0) 59 (52.7)
p-Value 0.4290 0.0334 0.0040 0.0016










Figure 2.2 TFAM SNP rs2306604 A>G genotype distribution and allele frequency in control, DLB, PD
and PDD
(A) TFAM SNP rs2306604 A>G genotype distribution is significantly different in PDD cases compared
to control cases (χ2= 9.080, p = 0.0107). When PDD and PD cases are grouped together, the genotype
distribution is also significantly different compared to controls (χ2= 10.53, p = 0.0052). (B) The AA
allele compared to AG/GG cases grouped together is significantly more frequent in PD (p = 0.0334,
OR = 2.242) and in PDD (p = 0.0040, OR = 2.409) cases compared to controls. PDD and PD cases
grouped together also display a significant distribution of the AA allele compared to AG/GG (p =
0.0016, OR = 2.349).  *=p≤0.05, **=p≤0.01.
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2.4.2. TFAM SNP rs2306604 (A>G) is associated with males and not
females
Since the presence of TFAM SNP rs2306604 A>G was strongly associated with PDD
compared to controls, its association was also investigated in males and females
separately. Cases were stratified according to gender and this revealed a strong association
of the TFAM SNP rs2306604 A>G genotype in PDD males compared to control males, with
57.9% of the cases being homozygous for the A allele, compared to only 16.1% of the
controls (χ2 = 17.92, p value = 0.0001). Genotype frequencies were not different in control
and DLB males (χ2 = 2.821, p value = 0.2440), and as in the control group most samples
were heterozygotes (A/G) (47.2%) compared to the A/A and G/G homozygotes (30.6% and
22.2% respectively). Genotype frequency in PD males was also significantly different from
controls (χ2 = 5.906, p value = 0.0522), although not as strongly as for PDD males. Grouping
the PD and PDD groups into one set also gave a significantly different distribution in
genotype compared to controls (χ2= 15.95, p value = 0.0003) (Table 7).
Investigating differences in allele frequency by comparing  A/A homozygotes to A/G and
G/G pooled together, again, revealed no significant difference in the frequency of the AA
allele in DLB compared to control males (p = 0.1236, OR = 2.298). Allele frequencies in PD
males were again significantly differentially distributed compared to controls (p = 0.0252,
OR = 3.481), but this association was still weaker than that observed in PDD males. Indeed,
A allele frequency in PDD males was strongly significantly different from that in controls
(p = < 0.0001, OR = 7.181). Pooling PD and PDD males together into one set also revealed a
strong association of the A allele frequency in this set compared to control males (p =
<0.0001, OR = 5.391) (Table 7).
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Contrastingly, no significantly different genotype distribution was observed in females from
DLB, PD or PDD groups compared to controls (Table 8). This suggests that the presence of
TFAM rs2306604 A allele might be a risk factor for PD and PDD in males but not in females.
TFAM SNP rs2306604 A>G frequency distribution in the different diagnosis groups, when
stratified according to gender, is represented graphically in Figure 2.3.
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Table 7 TFAM SNP rs2306604 A>G genotype distribution in Control, DLB, PD and PDD
males.
Control DLB PD PDD PD/PDD
n=56 n=36 n=25 n=38 n=63
AA (%) 9 (16.1) 11 (30.6) 10 (40.0) 22 (57.9) 32 (50.8)
AG (%) 30 (53.6) 17 (47.2) 11 (44.0) 10 (26.3) 21 (33.3)
GG (%) 17 (30.4) 8 (22.2) 4 (16.0) 6 (15.8) 10 (15.9)
χ2, d.f. 2.821, 2 5.906, 2 17.92, 2 15.95, 2
p-Value 0.2440 0.0522 0.0001 0.0003
Control DLB PD PDD PD/PDD
AA (%) 9 (16.1) 11 (30.6) 10 (40.0) 22 (57.9) 32 (50.8)
AG/GG (%) 47 (83.9) 25 (69.4) 15 (60.0) 16 (42.10 31 (49.2)
p-Value 0.1236 0.0252 < 0.0001 < 0.0001










Table 8 TFAM SNP rs2306604 A>G genotype distribution in Control, DLB, PD and PDD
females.
Control DLB PD PDD PD/PDD
n=85 n=36 n=14 n=35 n=49
AA (%) 30 (35.3) 13 (36.1) 8 (57.1) 13 (37.1) 21 (42.9)
AG (%) 40 (47.1) 13 (36.1) 4 (28.6) 14 (40.0) 18 (36.7)
GG (%) 15 (17.6) 10 (27.8) 2 (14.3) 8 (22.9) 10 (20.4)
χ2, d.f. 1.953, 2 2.498, 2 0.6493, 2 1.360, 2
p-Value 0.3766 0.2867 0.7228 0.5067
Control DLB PD PDD PD/PDD
AA (%) 30 (35.3) 13 (36.1) 8 (57.1) 13 (37.1) 21 (42.9)
AG/GG (%) 55 (64.7) 23 (63.9) 6 (42.9) 22 (62.9) 28 (57.1)
p-Value 1.0000 0.1441 0.8376 0.4607










Figure 2.3 TFAM SNP rs2306604 A>G distribution in male and female Control, DLB, PD and PDD
samples.
(A) TFAM SNP rs2306604 (A>G) genotype distribution is significantly different in PDD males
compared to control males (χ2= 17.92, p=0.0001). When PDD and PD cases are grouped together, the
genotype distribution is also significantly different compared to controls (χ2= 15.95, p = 0.0003). (B)
TFAM SNP rs2306604 (A>G) genotype distribution is not significantly different in PDD females
compared to control females. (C) The AA allele compared to AG/GG cases grouped together is
significantly more frequent in PD (p = 0.0252, OR = 3.481) and in PDD (p = <0.0001, OR = 7.181)
males compared to control males. PDD and PD cases grouped together also display a significant
distribution of the AA allele compared to AG/GG (p = < 0.0001, OR = 5.391). (D) The distribution of
the AA allele compared to AG/GG cases grouped together is not significantly different in females of
the different diagnostic groups.   *= p ≤0.05, **= p ≤0.01, ***= p ≤0.001.
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2.5. Discussion
This chapter presents results from the first study investigating a genetic variant that might
potentially distinguish between PDD and DLB. TFAM SNP rs2306604 A>G was found to
confer a risk factor for PDD but not for DLB, suggesting that whilst the two forms of
dementia are indeed very similar in their symptomatic, neuropsychological and
neuropathological profiles, there might be different genetic factors that distinguish the two
(Gatt et al., 2013). Furthermore, the TFAM rs2306604 A/A genotype is significantly more
frequent in the PDD cohort of samples than in a non-demented PD cohort and that this
association is significantly stronger in males than in females.
2.5.1. Gender bias in AD and PD
TFAM SNP rs2306604 A>G has been shown to be associated with AD in multiple studies,
with the A allele identified as a risk factor for the disease, however the functional
consequences of this intronic variant remain unknown. Gender bias in association with this
SNP in AD has also been investigated, and whilst results reveal no significant association of
rs2306604 frequency with gender, the TFAM SNP rs1937 G>C was found to be significantly
more present in females compared to males (Günther et al., 2004; Belin et al., 2007;
Bertram et al., 2007; Laumet et al., 2010). Overall, Günther et al., reported that the
frequency of the haplotype Grs1937-Ars2306604 was significantly higher in AD females than AD
males (Günther et al., 2004). Similarly, the APOE ε4 allele confers greater risk for AD in
females than in males (Günther et al., 2004). There are no known reasons for this gender
bias in APOE genotype in AD, and it is unclear whether TFAM haplotype Grs1937-Ars2306604
might be contributing to this gender bias in AD risk. Overall, AD is also known to be more
common in women than in men, and again reasons for this gender link are unclear. Some
studies have suggested that in women, oestrogen might play a neuroprotective role.
Indeed, oestrogen carries antioxidant properties (Mooradian, 1993) and promotes growth
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of dendritic spines and synapses (Naftolin et al., 1993), as well as increasing cerebral blood
flow (Belfort et al., 1995). Therefore, high levels of oestrogen in women might be delaying
the risk of developing AD until after menopause when oestrogen levels have been
depleted. Theoretically, this would leave women at a greater risk at these later stages,
whilst men at risk of dementia would have possibly suffered earlier death due to
hypercholesterolemia, hypertension, or smoking (Andersen et al., 1999).
Contrastingly, PD is thought to be more common in men, with one meta-analysis
suggesting that men are at a 1.5 times greater risk of developing the disease than women
(Wooten et al., 2004). As in AD, no conclusion has been made as to any biological basis for
this gender-associated risk. Some studies suggest that differences in brain circuitry
between men and women might be playing a role in disease progression (Inestrosa et al.,
1998), whilst other hypotheses include that lifestyle choices made by men make them
more at risk of developing PD due to exposure to toxins and increased incidents of head
trauma (Tanner and Goldman, 1996). Alternatively, genetic linkage studies suggest that the
presence of a PD susceptibility gene on the X chromosome might explain the greater risk of
the disease in men (Pankratz et al., 2002). Studies have also suggested that the male
gender is more prevalent in PDD and DLB cases (Gillies and McArthur, 2010;
Fereshtehnejad et al., 2013). In the cohort used in this study, 59% of PDD cases and 63% of
PD total cases were male. In order to better understand whether gender plays a significant
role in TFAM SNP rs2306604 A>G association, statistical analysis on cases stratified by
gender was also carried out.
2.5.2. Gender bias in TFAM SNP rs2306604 A>G presence
Gender does not confer any association to the TFAM SNP rs2306604 A>G frequency in the
DLB cohort, as genotype distribution is similar in males and females in this group.
Contrastingly, gender stratification revealed a significant association of TFAM SNP
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rs2306604 A>G in PDD males compared to females. Indeed, genotype A/A frequency was
similar in PDD females compared to control females, suggesting that the SNP might confer
a stronger risk for PDD in males than in females.
The biological basis for this gender bias is unknown. The TFAM SNP might genetically
interact with an environmental risk factor to which men are more exposed to than women.
Alternatively, it might be due to an interaction of TFAM with a Y-chromosomal gene such as
SRY or ZFY, which have been identified as transcriptional regulators expressed in the
hypothalamus, frontal and temporal cortex of the male adult brain (Mayer et al., 1998).
Furthermore, whilst the data show no association of TFAM SNP rs2306604 A>G with PD
compared to control cases overall, stratification by gender revealed a higher frequency of
the A/A genotype in males compared to controls, and this difference was close to
approaching statistical significance. Indeed, when grouping A/G and G/G genotypes
together, the A allele is significantly more frequent in PD males compared to control males.
These data are in contrast with previous studies (Belin et al., 2007) which find no
association of TFAM SNP rs2306604 A>G with PD, even when stratifying the cases by
gender. These different results obtained might be attributed to the difference in cohort size
between the different studies. This study utilised only 41 PD samples in this study, which
when stratified by gender lead to a total of 26 males and 15 females, compared to a total
of 300 PD subjects in the Belin et al., study (Belin et al., 2007). Thus, the caveat of a small
sample number might have contributed to a bias in the result and further work is required
to conclude whether there truly is an association of TFAM SNP rs2306604 A>G with PD.
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2.5.3. TFAM SNP rs2306604 A>G presence might contribute to
cognitive decline in PD
The association of TFAM SNP rs2306604 A>G is certainly much stronger in PDD than PD,
suggesting that the SNP is associated with an increased risk of cognitive impairment in PD
rather than the risk of PD itself.
Recently, a study carried out by Bialecka et al., investigated an association of a
polymorphism in brain-derived neurotrophic factor (BDNF), a neurotrophin expressed in
the mammalian brain, known to regulate neuronal survival and cognition. The BDNF G196A
(Val 66 Met) polymorphism, resulting in a valine to methionine substitution at codon 66,
was not significantly associated with PDD and non-demented PD patients compared to
controls, however, patients expressing Met/Met alleles did perform better on a verbal
learning task than patients with Val/Val alleles (Bialecka et al., 2014). Furthermore, a
different group also found that PD patients carrying the BDNF 196A allele gave a better
performance at a planning task than carriers of the 196G allele (Foltynie et al., 2009).
Additionally, an Italian study carried out in 2009 had found a significant association of the
BDNF G196A (Val 66 Met) polymorphism in cognitively impaired PD compared (MMSE >24)
to non-demented PD cases (MMSE ≤ 24) (Guerini et al., 2009). The different cognitive
measures used might explain the discrepancy in results obtained between the Guerini
study and the Bialecka and Foltynie studies. Indeed, the latter two studies utilised more
comprehensive neuropsychological assessments for measuring cognition, and therefore the
results obtained cannot be directly compared. However, taken together, these data suggest
that there might be multiple genetic factors that offer a predisposition to cognitive decline
in PD. The data outlined above suggest that TFAM SNP rs2306604 A>G might offer such a
risk and might contribute to the development of PDD in PD patients.
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2.6. Conclusion
This study suggests that TFAM SNP rs2306604 A>G is observed in significantly higher
prevalence in PDD, especially in males, but is not associated with DLB. This work offers new
insight into a potential genetic variation distinguishing PDD from the highly similar form of
dementia, DLB.
However, the absence of this association in DLB cases, also suggests that this SNP might
play a role in determining the temporal onset of cognitive decline in PD. PDD and DLB are
mainly distinguished by the temporal onset of cognitive decline compared to decline in
motor ability, with DLB patients presenting symptoms of cognitive decline within the same
year in which they present motor symptoms. Therefore, one might speculate that this
finding suggests that the presence of TFAM SNP rs2306604 A>G might actually be exerting
a ‘neuroprotective’ role in that it is acting to delay the onset of dementia, following onset
of motor symptoms.
Cohort numbers in this study are relatively small, especially when groups are stratified by
gender or genotype. Furthermore, MMSE data for some PDD and PD patients was
unavailable, further limiting correlative analysis. Therefore, conclusions inferred from the
results can only be speculative and further research is required to better understand the
association of this SNP with different neurodegenerative diseases.
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3. Investigating changes in mitochondrial-associated proteins and
mitochondrial DNA levels in Parkinson’s disease and Parkinson’s
disease dementia compared to controls.
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3.1. Introduction
In the previous chapter of this thesis, TFAM SNP rs2306604 A>G was found to be associated
with PDD. Previous studies have shown that the presence of this SNP also leads to an
increased risk for AD. The presence of this SNP was also found to be more predominant in
PDD than in PD.  Taken together, these results brought us to speculate that the presence of
TFAM SNP rs2306604 A>G might lead to a greater risk of cognitive decline.
It is known that mitochondrial ETC complex I activity is decreased in the Snpc of PD
patients. However, mitochondrial function and activity in the frontal cortex in PD and in
PDD are not well investigated. Since changes associated with dementia are commonly
associated with frontal cortex function, it is of interest to investigate this brain region in
association with cognitive decline in PD leading to PDD.
Studies in post-mortem AD tissue have revealed reduced mitochondrial mass, reduced
cellular respiration, reduced expression of nuclear encoded respiratory genes, and reduced
expression of mitochondrial biogenesis genes, including TFAM, compared to controls
(Reddy et al., 2012; Sheng et al., 2012). An increased frequency of deleted mtDNA
molecules has also been reported in AD cortical tissue (Lin et al., 2002; Coskun et al., 2004).
Similarly, mitochondrial dysfunction is commonly implicated in PD (see section 1.12.2). As
mentioned in Chapter 1 (Section 1.7.2), a study in 2007 revealed that TFAM knockout in
mice DA neurons results in reduced mtDNA expression and respiratory chain dysfunction,
concomitantly with the development of intraneuronal inclusions, leading to parkinsonian
symptoms in adulthood (Ekstrand et al., 2007). This study therefore reaffirmed the role of
mitochondrial dysfunction and respiratory chain disruption in the development of PD
phenotypes.
Since cognitive decline in PD, in the form of PDD, exhibits neuropathological and
symptomatic features similar to AD, it was of interest to investigate whether mitochondrial
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dysfunction in the frontal cortex in PDD occurs as it does in AD. Moreover, it was of interest
to determine whether the presence of TFAM SNP rs2306604 A>G elicits any changes in
TFAM expression levels. Previous studies have also reported that the presence of this SNP
might affect splicing of the TFAM transcript (Tominaga et al., 1993; Poulton et al., 1994). I
was therefore interested in determining whether alternative TFAM spliceforms are
observed in this cohort and whether the presence of the SNP causes any functional
changes in terms of mtDNA levels and mitochondrial protein level in PDD compared to PD
and controls.
3.2. Chapter aims
Since TFAM SNP rs2306604 A>G was found to be associated with PDD but not DLB in
chapter 2, I aimed to investigate the functional consequences of the presence of this SNP in
such cases.  In particular, aims were:
 To investigate whether TFAM SNP rs2306604 A>G is associated with differences in
mtDNA copy number and altered expression of TFAM and other mitochondrial-
associated protein levels.
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3.3. Materials and Methods
3.3.1. Tissue homogenate preparation
For each tissue sample, the cortical grey matter was dissected from the white matter and
the meninges at 0oC. Approximately 100mg of cortical grey matter was homogenised in
1mL of ice-cold homogenisation buffer using an Ultra-Turrax tissue homogeniser (IKA
Werke, Germany). The homogenisation buffer contained 50mM Tris-HCl, 5mM EGTA,
10mM EDTA, (for chelation of magnesium and calcium ions), ‘Complete, mini, EDTA-free,
Protease inhibitor cocktail tablets’ from Roche Applied Science (1 per 10mL, for inhibition
of cysteine, serine, and metallo-proteases), and 20µg/mL PMSF, which was added
immediately prior to use. The crude homogenates were immediately frozen on dry ice and
stored at -80oC for later use.
3.3.2. Protein assay
The total protein concentration in the prepared crude homogenate was determined using
the Bradford protein assay method. Standards were prepared using bovine serum albumin
(BSA) diluted in homogenisation buffer in a series of dilutions, resulting in the following
concentrations: 0.5, 0.375, 0.250, 0.188, 0.125, 0.063, 0.031 and 0.0007 mg/mL. Each
homogenate sample was also diluted in a series of 1 in 4, 1 in 8, 1 in 16, 1 in 32, and 1 in
6dilutions in homogenisation buffer. 20µL of each standard or sample dilution were then
added to a 96-well plate in triplicate and 250µl of Coomassie reagent (Thermo Scientific,
USA) was added. The reaction was allowed to proceed for ten minutes and absorbance was
then read at 595nm using a FlexStation 3 (Molecular Devices Ltd, UK). The standard curve
and concentration of protein in the samples was analysed using Soft Max Pro Software
4.5.1 (Molecular Devices Ltd, UK).
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3.3.3. Semi-quantitative western blotting
Tissue samples for western blotting were prepared as previously described by Kirvell et al.
(Kirvell et al., 2006). Briefly, to prepare the crude homogenate for western blotting, 20µl of
5x Laemmli buffer for SDS-PAGE (10% SDS, 20% glycerol, 0.2M Tris-HCl pH 6.8, 0.05%
bromophenol blue), was added to 80µl of homogenate diluted in dH2O, for a final volume
of 100µl. All samples were prepared to a final concentration of 1µg/µl. 0.02M dithiothreitol
(DTT) was added to reduce protein disulfide bonds, and the samples were then heated to
95oC for 5 minutes. Once cooled, samples were stored at -20oC.
Western blot samples were run on a 10% SDS-polyacrylamide gel at approximately 70 volts
(V), for 30 minutes and then 100V for the rest of the run. On each gel 5µl of a pre-stained
protein ladder was run (EZ Run, PrestainedRec Protein ladder, Fischer) in the first lane.
20µl of a control sample, selected as an inter-blot control, was loaded in the second lane of
each gel. 20µl of each case sample, equivalent to 20µg of protein, were loaded in the
remaining eight lanes, when running a gel of ten lanes.
Once the samples had run to the bottom of the gel, the proteins were transferred onto
nitrocellulose hybond membranes (Amersham) for one hour at 25V. Non-specific binding
sites on the membranes were then blocked using a one hour incubation in a solution of
10% non-fat powdered milk in tris-buffered saline with 0.1% Tween20 (TBS-T). The
membranes were then incubated with the primary antibody (listed in Table 9) overnight at
4oC in 5% milk in TBS-T. The following day, excess antibody was removed with three 10
minute washes in TBS-T. Fluorescently labelled secondary antibodies (anti-mouse IR dye
700 (Rockland) and anti-rabbit IR dye 800 (LI-COR)) in 5% milk in TBS-T were added for one
hour at room temperature and blots were then scanned and analysed using an Odyssey
infrared scanner (LI-COR, Version 3.0).
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Table 9. Primary antibodies used in western blot (WB) analysis of BA9 homogenates
Odyssey infrared imaging systems application software version 3.0.25 was used to quantify
the intensity of the bands on the blots. Signal intensity of each individual band was
measured using the box tool on the Odyssey software (drawn while in ‘detailed view’
mode). The band intensity was then normalised to the intensity of the corresponding inter-
blot control band for each protein.  Furthermore, the intensity of each band was
normalised to the corresponding band of histone H3 or β-Actin, which served as loading
controls.
3.3.4. mtDNA deletion assay
A Long Range PCR dNTPack (Roche) was used to amplify a 10.4kb fragment spanning the
major arc of the mitochondrial genome (Bender et al., 2006). 20µl reactions were setup
consisting of 4µl 5x reaction buffer (Roche),1µl PCR nucleotide mix, 0.6µl each of forward
primer (nt5367-5386; ACCTCAATCACACTACTCCC) and reverse primer (nt129-110;
AGATACTGCGACATAGGGTG) (Sigma-Aldrich) at 10µM each,  0.6µl of DMSO, 0.28µl of
polymerase, 8.92µl of dH2O and 4µl of non-sonicated DNA at 10ng/µl. Amplifications were
Antibody WB dilution Species Company/Source Secondary antibody
(all at 1 in 5000
dilution)
Histone H3 1 in 1000 Ms Abcam ab24834 Ms 700
TFAM 1 in 5000 Rbt Wiesner Lab Rbt 800
ATP Synthase
(ATP5A)
1 in 5000 Ms Abcam ab14748 Ms700
β-Actin 1 in 4000 Rbt Cell Signalling 4967S Rbt 800
OXPHOS
cocktail
1 in 200 Ms Abcam ab110411 Ms 700
Porin 1 in 2000 Ms Abcam ab14734 Ms700
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carried out using a PTC-200 Thermal Cycler using the following conditions; 2 min at 92oC;
10 cycles of (10 sec at 92oC, 15 sec at 58oC and 10 min at 68oC), 20 cycles of (10 sec at 92oC,
15 sec at 58oC, 10 min at 68oC with an additional 20sec per cycle) and a final extension of 7
min at 68oC. Amplified products were then run on a 0.8% agarose gel containing ethidium
bromide and visualised using UV light.
3.3.5. Quantitative real-time PCR (qPCR) for measurement of mtDNA /
nuclear DNA ratio.
3.3.5.1. Standard curve preparation
A set of mitochondrial-specific, CACTTTCCACACAGACATCA (hMito forward) and
TGGTTAGGCTGGTGTTAGGG (hMito reverse) and nuclear-specific; GTTCCTGCTGGGTAGCTCT
(hB2M forward) and CCTCCATGATGCTGCTTACA (hB2M reverse) primers, (Malik et al.,
2011) were used to amplify mtDNA and nuclear DNA fragments within a control DNA
sample, using a GoTaq (Promega) PCR reaction. PCR products of the predicted band size
were then cut out using sterile scalpel blades under UV light. Once the pieces were
weighed, DNA was isolated and purified using the ‘Qiaquick’ spin column gel extraction kit
(Qiagen). A NanoDrop spectrophotometer was again used to calculate DNA concentration
in ng/µl. A stock solution of 1x109 copies of DNA per 2µl was prepared and a set of six
dilutions were then prepared to set up solutions of concentration 107 to 102 copies.
3.3.5.2. Sample preparation
DNA samples from the individual cases were diluted to 10ng/µl in a 50µl volume, and
sonicated for 10 minutes in a bath sonicator, as suggested in (Malik et al., 2011).
Ultimately, samples were diluted further to a concentration of 5ng/µl in water containing
tRNA (10µg/ml) in a total volume of 50µl.
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3.3.5.3. qPCR reaction and analysis
Real-time qPCR was carried out using a Sybrgreen reaction mix (qPCRSygreen mix Lo-ROX,
PCR Biosystems) in a LightCycler 480 Real-time PCR system (Roche). A 10µl total reaction
mixture containing 5µl qPCR Bio Sybrgreen master mix,0.4µl each of reverse and forward
primers (at 10µM) and 4.2ul of DNA (at 5ng/µl) was prepared for each sample, once using
the hMito primers and another using the hB2M primers. Reactions were run along with all
standard curve reactions and non-template controls. qPCR conditions used were; 95oC for
10 min followed by 40 cycles of (95oC for 15 sec, 57oC for 15 sec and 72oC for 15 sec)
followed by a melting cycle going up to 95oC. The LightCycler 480 Real-time PCR System
(Roche) was used to calculate mtDNA and nuclear DNA copy numbers by extrapolating
values using the standard curves obtained, using an absolute quantification method. Ratios
of mtDNA/ nDNA levels were calculated and transformed to log10 values for statistical
analysis.
3.3.6. Statistical analysis
Analysis to compare means in multiple groups was carried out by one-way analysis of
variance (ANOVA) followed by Bonferroni’s post-hoc multiple comparison test. If data did
not fit a normal distribution, a Kruskal-Wallis test followed by Dunn’s multiple comparison
test was carried out.
A two-way ANOVA followed by Tukey’s multiple comparison tests was used to compare
mtDNA levels in the different diagnostic groups and assess the influence of TFAM SNP
rs2306604 A>G on this mean.
A student un-paired t-test was used to compare means between two individual groups. If
data did not fit a normal distribution, a non-parametric Mann-Whitney test was carried
out.
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In all individual analyses, a null hypothesis was postulated which asserted that there is no
difference in mitochondrial protein levels, mtDNA levels or neuropathology scores amongst
the different diagnostic groups tested. In all cases, a result was considered statistically




3.4.1. Mitochondrial protein levels are not altered in control, PD and
PDD cases and are not associated with TFAM rs2306604 A>G
genotype.
Since TFAM SNP rs2306604 (A>G) was found to be associated with PD and PDD but was not
associated with DLB, further analysis was only carried out using controls, PD and PDD cases.
In order to assess whether TFAM protein levels were altered in the different diagnostic
groups, BA9 homogenates from control, PD and PDD cases were analysed by western blot
(Figure 3.1).  In order to investigate any changes in protein levels of respiratory chain
components, protein levels of ETC complex I subunit NDUFB8 (nuclear encoded), the
complex II 30kDa subunit (nuclear encoded), complex III subunit core 2 (nuclear encoded),
complex IV subunit II (mitochondrially encoded), and ATP synthase (complex V) subunit
alpha (nuclear encoded) were also quantified. β-actin and histone H3 levels were used as
total protein loading controls.
Overall, no difference was observed in the average protein levels in controls compared to
PD and PDD samples, suggesting that expression levels are unaltered in the different
diagnoses. However, comparing protein levels of the mitochondrial outer membrane
channel protein porin (VDAC1) amongst the different diagnostic groups revealed that, on
average, expression levels were statistically significantly higher in PD cases (an average of
10.5% increased expression) compared to controls (Kruskal-Wallis test, followed by Dunn’s
multiple comparisons test, p = 0.0087), suggesting that the average expression of VDAC1
is increased in PD (Figure 3.2).
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Furthermore, stratification of the diagnostic groups according to genotype also revealed
that there is no significant difference in expression levels for the proteins listed above, as
one-way ANOVA analysis revealed no association of genotype with protein levels within the
individual diagnostic groups (Figure 3.3).
3.4.2. Mitochondrial protein levels are not altered in control, PD and
PDD cases and are not associated with TFAM rs2306604 A>G genotype
in males.
Since TFAM SNP rs2306604 A>G was found to be more prevalent in PDD and PD males
compared to females, we also investigated whether a difference in protein levels would be
found in control, PD and PDD males and whether any difference would be associated with
the TFAM genotype in this gender group only.
This data shows that in males only, there is no difference in β-actin, TFAM and OXPHOS
complex protein levels between controls, PD and PDD samples.  Stratification of values by
gender and TFAM SNP rs2306604 A>G genotype, did reduce the numbers in the individual
data sets considerably, especially since G/G cases in the individual diagnostic groups were
very rare.  Therefore, stratifying the values by diagnosis, gender and TFAM genotype would
have not allowed a reliable statistical analysis. In order to overcome this limitation,
association of protein levels to genotype in males was tested by grouping the A/A, A/G and
G/G samples together, independent of diagnosis (Figure 3.4). This revealed that overall,
there was no difference in protein levels amongst A/A, A/G and G/G males in our whole
cohort.
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Figure 3.1 Representative western blot of control, PD and PDD BA9 homogenate samples
A representative western blot showing bands obtained using antibodies for histone H3
(used as loading control), subunits of Complex I, II, III, IV and V, TFAM, porin and β-actin.
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Figure 3.2 Protein levels in control, PD and PDD frontal cortex homogenates.
β actin, TFAM and ETC complex I-V subunit protein levels are unchanged in control (n=23), PD (n=40)
and PDD (n=33) frontal cortex homogenates, according to one-way ANOVA analysis. Porin (VDAC1)
expression levels are significantly increased in PD samples compared to controls.  All values are
normalised to levels of histone H3 and to an inter-blot control.  Lines on the scatter plots represent
mean with SEM. **= p≤0.01
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Figure 3.3 Protein levels in control, PD and PDD frontal cortex homogenates according to TFAM
SNP rs2306604 A>G genotype.
No difference in expression levels of β-actin, TFAM, porin (VDAC1) and ETC complex I-V subunit
proteins is observed when diagnostic groups are stratified according to TFAM SNP rs2306604 A>G
genotype. There is no statistical difference between control AA (n= 5), AG (n=12), GG (n=5), and PD
AA (n=18), AG (n=15), GG (n=6), and PDD AA (n=19), AG (n=11), GG (n=2) samples by one-way
ANOVA analysis.  Lines on the scatter plots represent mean with SEM.
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Figure 3.4 Protein levels in frontal cortex homogenates according to TFAM SNP rs2306604 A>G
genotype in males.
No difference in expression levels of β-actin, TFAM, porin (VDAC1) and ETC complex I-V subunit
proteins is observed between frontal cortex homogenate samples of TFAM SNP rs2306604 A>G
genotype AA (n=23), AG (n=23) or GG (n=8) in males, by one-way ANOVA analysis.  Values are not
divided by diagnostic group due to small n numbers.  Lines on the scatter plots represent mean with
SEM.
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3.4.3. TFAM rs2306604 A>G SNP is not associated with an alternative
splice form.
Studies have suggested that the presence of the intronic SNP rs2306604 in the TFAM
transcript might lead to the generation of an alternative splice form which produces a
truncated form of the protein.
Western blot analysis of control, PD and PDD samples did not reveal the presence of any
truncated forms of the TFAM protein and only bands corresponding to the 24 kDa mature
form of the protein were observed (Figure 3.5).
Figure 3.5 No alternative splice isoform of TFAM is observed in control, PD and PDD BA9
homogenates by western blot analysis.
A representative western blot shown that only TFAM bands corresponding to the mature 24 kDa
form of the protein were observed in control, PD and PDD BA9 brain homogenates.  No alternative
smaller splice form of the protein was observed.
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3.4.4. mtDNA levels are reduced in PDD
In order to investigate whether mtDNA levels differ in the different diagnostic groups, and
whether any correlation with the genotype presence is found, mtDNA copy number as a
ratio of nuclear DNA copy number was measured in control, PD and PDD BA9 samples.
A non-parametric one – way ANOVA (Kruskal-Wallis) analysis revealed that median mtDNA
levels were significantly reduced in PDD cases (p = 0.0304) with an average reduction of
18%. MtDNA levels were not reduced in PD cases compared to controls. When grouped
according to TFAM rs2306604 A>G genotype, a two-way ANOVA revealed a non-significant
interaction p value and no overall significant difference in mtDNA levels between the
different genotypes in the diagnostic groups. However, Bonferroni post-hoc tests did reveal
a significant difference in mtDNA levels between PD AG and PDD AG heterozygotes, with
the mtDNA levels being reduced in the PDD cases (Figure 3.6).
Since a significant association with TFAM rs2306604 A>G genotype was observed in PDD
and PD males, mtDNA levels in the different genotypes in the diagnostic groups was also
investigated exclusively in male cases. This revealed no difference between the diagnostic
groups upon performing a Kruskal-Wallis test (p = 0.0629), however a Mann-Whitney test
revealed a significant reduction in mtDNA levels in PDD male cases compared to controls
(p = 0.0391). A two-way ANOVA analysis revealed a non-significant interaction p value, and
no significant difference in mtDNA levels according to TFAM rs2306604 A>G genotype
(Figure 3.7). mtDNA levels in females did not change in the different diagnostic groups and
no association with TFAM SNP rs2306604 A>G was revealed (Figure 3.7).
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Figure 3.6 mtDNA/nDNA levels are significantly reduced in PDD cases.
(A) mtDNA/nDNA levels are significantly reduced in PDD cases, but not in PD cases, compared to
control (p = 0.0304, Kruskal-Wallis test followed by Dunn’s multiple comparisons test). (B)
mtDNA/nDNA levels are not significantly changed according to TFAM rs2306604 A>G genotype in the
different diagnostic groups (Two-way ANOVA followed by Tukey’s multiple comparisons test). (C)
mtDNA/nDNA levels are not significantly changed according to TFAM rs2306604 A>G genotype in the
different diagnostic groups, when grouping AG and GG together compared to AA (Two-way ANOVA
followed by Tukey’s multiple comparisons test). Lines on the scatter plots represent mean with SEM.
*= p≤0.05.
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Figure 3.7 mtDNA/nDNA levels in male and female Control, PD and PDD samples.
(A) mtDNA/nDNA levels are not significantly changed in Control, PD and PDD males (p = 0.0629,
Kruskal-Wallis test followed by Dunn’s multiple comparisons test). A non-parametric t-test reveals
that mtDNA/nDNA levels are reduced in PDD male cases compared to controls (p = 0.0391, Mann-
Whitney test). (B) mtDNA/nDNA levels are not significantly changed in female Control, PD and PDD
cases (One-way ANOVA followed by Dunn’s multiple comparisons test, p=0.4897). A non-parametric
t-test reveals that mtDNA/nDNA levels are not changed in PDD female cases compared to controls (p
= 0.1284, Mann-Whitney test). (C) mtDNA/nDNA levels are not significantly changed according to
TFAM rs2306604 A>G genotype in the different diagnostic groups in males (Two-way ANOVA
followed by Tukey’s multiple comparisons test).  (D) mtDNA/nDNA levels are not significantly
changed according to TFAM rs2306604 A>G genotype in the different diagnostic groups in females,
when grouping AG and GG together compared to AA (two-way ANOVA followed by Tukey’s multiple
comparisons test). Lines on the scatter plots represent mean with SEM.
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3.4.5. mtDNA deletions are not observed in control, PD and PDD
samples.
As described in Section 1.8, mtDNA mutations, including deletions in the genome, are
commonly found in neurodegenerative diseases (Kraytsberg et al., 2006; Krishnan et al.,
2007; Krishnan et al., 2008; Nicholas et al., 2009). In order to assess whether mtDNA
deletions are present in any of the PD, PDD and aged control cases used in this study, a
10.4 kb fragment of mtDNA was amplified, thereby allowing for the observation of all
possible deletions within the major arc of the mitochondrial genome.
Figure 3.8 shows a representative image of a gel, in which one strong intensity band is
observed for each sample, at the full length PCR product length of approximately 10 kb.
Additional low intensity bands can also be observed at shorter lengths in some cases
(Figure 3.8), however, as previously observed in literature, such ‘background’ bands could
represent deletions that are generated by the polymerase enzyme during the PCR reaction
(Khrapko et al., 1999).
The study by Khrapko et al., which measured the amount of mtDNA deletions in myocytes,
also compared mtDNA deletion analysis in tissue homogenates compared to single cells.
The authors suggest that in a homogenate, the number of cells containing a substantial
amount of mtDNA deletions will be few in comparison to the cells containing wild-type
mtDNA. Therefore any deletions will only be represented on the gels as low intensity
bands, and would be hard to distinguish from the ‘background’ bands explained above.
Therefore, it is hard to conclude whether any mtDNA deletions were truly present in these
homogenate samples, and analysis at the single—cell level would be required to fully
confirm or deny the presence of any mtDNA deletions.
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Figure 3.8 No mtDNA deletions are observed in control, PD and PDD BA9 homogenate samples
A representative 0.8% agarose gel showing bands obtained from DNA extracted from individual PDD
BA9 homogenates using a long-template PCR (lanes 1-4). This gel revealed only one major PCR
product for each sample corresponding to the full-length mtDNA major arc (approximately 10kb), as
suggested by the ladder shown in lane 5, implying the absence of any deleted mtDNA. Multiple low
intensity bands do appear in some cases (shown in *), however these are likely to correspond to
deletions being generated during the PCR reaction.
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3.5. Discussion
Chapter 2 concluded that the genetic variant TFAM SNP rs2306604 A>G confers a risk
factor for PDD, especially in males.  In this chapter I investigated whether the presence of
this SNP leads to functional consequences in terms of mitochondrial-associated protein
levels and mtDNA copy number. I find that mtDNA levels are significantly reduced in PDD
compared to control BA9 tissue. However, mitochondrial-associated protein levels were
unchanged in PDD and PD compared to controls.
3.5.1. TFAM and OXPHOS complex protein levels are unchanged in PD
and PDD samples compared to controls and are not associated with
TFAM SNP rs2306604 A>G genotype
In order to investigate whether TFAM SNP rs2306604 A>G is altering expression levels of
TFAM and other OXPHOS complex proteins, I carried out a western blot analysis on brain
homogenates of control, PD and PDD BA9 samples. Whilst western blot analysis can only be
semi-quantitative and there are a lot of factors within a western blot protocol that lead to
variable results, I argue that a high enough ‘n’ number of samples run, such as ones used in
this study, allows for a reliable statistical analysis in which one can test for normal
distribution and undergo suitable statistical tests to check for difference in expression
between the different diagnostic groups. The data presented in this chapter showed no
difference in protein levels of β-actin, TFAM and subunits of OXPHOS complexes I – V
between control, PD and PDD BA9 samples. However, a significant increase in porin
(VDAC1) protein levels was observed in PD cases compared to controls.
Recently an increase in VDAC1 protein levels has been reported in AD post-mortem brains
(Reddy, 2013), with the authors suggesting that increased VDAC1 levels might be
implicated in the progression of AD. The same authors determined that VDAC1 interacts
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with Aβ and phosphorylated tau, leading to reduced transport between the mitochondria
and the external environment in the cell. I therefore postulate that an increase in VDAC1
levels in PD might offer some interesting insight into the role of porins in
neurodegeneration, and that whilst VDAC1 levels were not significantly increased in PDD
cases compared to controls, further work is required to fully elucidate whether there is an
association of VDAC1 with PD disease progression as is postulated to be in AD.
Importantly, any alteration in protein levels was not significantly associated to TFAM SNP
rs2306604 A>G, as one-way ANOVA analysis in the individual diagnostic groups revealed no
significant difference in protein levels between A/A, A/G or G/G carriers.
The use of whole brain BA9 homogenates imposes a limit of detection in this study. IHC on
the individual case samples could potentially serve to expose any difference in expression
levels of the individual proteins in different cell types.
3.5.2. mtDNA levels are reduced in PDD but are not associated with
TFAM SNP rs2306604 A>G genotype
Increased oxidative damage in nuclear and mitochondrial DNA has been associated with
AD, PD (Sanders et al., 2014) and MCI (Wang et al., 2006), and elevated levels of mtDNA
mutations have been attributed to cognitive decline (Inczedy-Farkas et al., 2014).
Furthermore, frontal cortex mtDNA levels have been shown to be depleted in AD
(Rodriguez-Santiago et al., 2001) and a reduction of mitobiogenesis genes in the frontal
cortex in PD has also been reported (Thomas et al., 2012). The data presented in section
3.4.4 reveal no alteration in mtDNA copy number in the frontal cortex of PD cases
compared to controls. However, a significant reduction in mtDNA levels in PDD compared
to control is observed. Additionally, mtDNA levels appeared to be more reduced in PDD
males than in PDD females. However, this reduction in mtDNA levels was not attributable
to an association with TFAM SNP rs2306604 genotype, and was therefore only due to
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diagnosis. Moreover, no alteration in protein levels of TFAM, or mitochondrial encoded ETC
components (COXII), were observed by western blot analysis in PDD or PD cases compared
to controls. It has been reported that a 60-90% reduction in mtDNA levels is required for a
threshold level to be exceeded, and therefore for biochemical defects to become apparent
(Tuppen et al., 2010). Therefore, it is probable that the average 18% reduction in mtDNA
levels observed in the PDD cases compared to controls was not sufficient to induce
significant loss of mitochondrial proteins. However, since a significant reduction was only
observed in PDD and not in PD, the decline in mtDNA copy number might be related to a
decline in cognitive impairment. This suggests that an elevation of AD-related pathology in
the brain, as observed in PDD, might be the link to a reduced mtDNA level.
It is important to note that while a decrease in mtDNA levels was observed in the pre-
frontal cortex of PDD cases, no analysis was carried out on other brain regions. It would
therefore be imperative to compare mtDNA levels in other brain regions in both PD and
PDD samples, to investigate whether alterations in mtDNA levels in additional brain areas
might be contributing to cognitive decline in PD.
Since mtDNA damage in the SNpc has also been observed in PD, including an increase of
mtDNA deletions, we investigated whether we would observe increased mtDNA deletions
in the frontal cortex of PD and PDD patients. Amplification of a major arc of the
mitochondrial genome by long-template PCR revealed that all PCR products contained a
majority of the wild-type full length (10 kb) amplicons, without any obvious abundant
deletions giving rise to smaller PCR products. As argued in Section 3.4.5, this might be due
to the fact that DNA used in the PCR reaction was extracted from brain homogenate,
possibly containing cells of widely varying mtDNA mutation levels. In order to determine
whether our samples contain mtDNA deletions and whether frequency of such deletions
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differs between the diagnostic groups, the samples would have to be analysed at the single
cell level, using laser capture microdissection.
3.5.3. No alternative isoform of TFAM is observed in controls, PD and
PDD samples by western blot analysis
Western blot analysis also revealed that only the mature 24 kDa form of TFAM was
observed in our control, PD and PDD homogenate samples. A 1993 study by Tominaga et
al., examining the levels of steady state mRNA of TFAM in cultured HeLa cells, identified the
presence of a smaller isoform of the transcript (Tominaga et al., 1993). This isoform,
containing a 96 base deletion in exon 5 of the transcript, was present in most tissues and
constituted 30% of the total TFAM mRNA. Later studies identified this as an alternative
splice variant which generated a 22 kDa isoform (Poulton et al., 1994), 3 kDa smaller than
the wild-type 25 kDa polypeptide (Fisher and Clayton, 1988).
Furthemore, in silico studies have suggested that TFAM SNP rs2306604 (A>G) might
generate an alternatively spliced form of the protein for the G-allele (Günther et al., 2004;
Belin et al., 2007).  However, no alternative isoforms were predicted for the risk A allele.
This suggests that the A allele might be conferring an increased risk of neurodegeneration
via linkage disequilbrium with other causal variants and that such a disequilbrium could be
leading to mtDNA dysfunction, thereby inducing neuronal cell death. We observed no
smaller forms of the protein in our samples via western blot analysis; however, we cannot
exclude that alternative splice variants might simply not be visible using this technique.
Certainly, it is possible that the splice variant is expressed at levels that are below the
threshold required for visibility by western blot analysis. Additionally, the splice isoform
might undergo a rapid turnover rendering it difficult to detect at steady state levels.
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It is also important to note that as previously mentioned in section 1.7.2, TFAM is known to
be phosphorylated, possibly via different kinases, and that this phosphorylation might
trigger its degradation by Lon proteases (Lu et al., 2013). No differentially sized forms of
TFAM were detected in the samples analysed by western blot analysis, suggesting that the
presence of the TFAM SNP rs2306604 A>G plays no role in determining phosphorylation
state of the protein. However, the lack of observation of different phosphoforms could
again be due to the technique utilised, and therefore more in-depth investigation would be
required to make a conclusive statement regarding an association of TFAM SNP rs2306604
A>G with phosphorylation states.
3.6. Conclusion
The presence of the TFAM SNP rs2300604 A>G was not associated with mtDNA copy
number, protein levels of TFAM itself or other OXPHOS complex proteins or pathology
levels in the brain in PDD, PD or control BA9 cases. Therefore, the functional consequences
of this SNP presence remain unknown.
The association of this SNP to PDD, and AD, might be a result of linkage disequilbrium with
other gene variants, however, further investigation is required in order to reach such
conclusions. Moreover, any biochemical effects resulting from the SNP presence might be
limited to a subset of neurons, with the consequence that any functional change is diluted
out and becomes undetectable when analysing whole homogenate samples. Therefore,
isolation of specific neural subtypes using laser microdissection might circumvent this issue
and might lead to the discovery of a functional role of TFAM SNP rs2300604 A>G.
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As discussed in detail in Section 1.10, mtDNA mutations and mitochondrial dysfunction
have been studied in a variety of animal models, including Drosophila. The initial response
of the nervous system to mitochondrial dysfunction, however, is not well elucidated. This
chapter outlines the generation and use of Drosophila models to investigate this initial
response to neuronal mitochondrial dysfunction.
The Drosophila neuromuscular junction (NMJ) is a widely used model system for
investigating synaptic transmission, especially since this mechanism is highly conserved
between flies and mammals (Frank et al., 2013). Inducing mitochondrial dysfunction in the
motor neuron system of the fly allows us to investigate alterations in the neuron cell
bodies, along the axons, as well as at the NMJs, where neurotransmitter release occurs at
the synapses. Furthermore, since motor neurons are particularly energy demanding and
therefore dependent on mitochondrial activity, and since reduced mitochondrial activity at
the synapses is known to lead to neuronal dysfunction (Du et al., 2012), they are a
particularly suitable cell type for studying mitochondrial dysfunction.
Indeed, synaptic mitochondria are known to play a crucial role in maintaining neuronal and
synaptic activity, and defects in synaptic mitochondria are associated with reduced synaptic
function. Synaptic mitochondria are also known to be particularly susceptible to oxidative
damage and calcium damage during ageing. Therefore, synaptic mitochondrial damage has
been investigated in relation to neurodegenerative diseases, and several studies have
revealed that synaptic deficits are an early feature in AD and PD, with synaptic failure
thought to directly contribute to cognitive decline (Selkoe, 2002; Reddy and Beal, 2008).
As previously discussed, TFAM is a major regulator of mtDNA replication, mitochondrial
copy number and transcription (Section 1.7.2). Since mitochondrial function is crucial for
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efficient synaptic activity, altered levels of TFAM might contribute to mitochondrial
deficiency at the synapses.
Several studies have provided support for a potential therapeutic use of TFAM
overexpression, as elevated levels of TFAM have been shown to improve survival after
myocardial infarction and reduce age-related memory loss and mtDNA damage in microglia
in mice (Ikeuchi et al., 2005; Hayashi et al., 2008). However, overexpression of human
TFAM in mice has also been shown to result in enlarged nucleoid size in muscle and heart
tissue concomitant with an increased generation of mtDNA deletions. Furthermore, these
mice exhibited reduced levels of respiratory chain complex I and IV in skeletal muscle and
showed COX-deficient fibres in skeletal muscle and heart (Ylikallio et al., 2010).
Similarly to TFAM overexpression, expression of a mitochondrially-targeted restriction
enzyme, XhoI, also results in mitochondrial dysfunction. XhoI targets mtDNA at a single
restriction site located in the cytochrome c oxidase subunit I (CoI) locus in Drosophila,
resulting in the linearization of the circular mtDNA. Targeting XhoI to mitochondria has
been shown to cleave the majority of mtDNA molecules, and when expressed in a
ubiquitous manner using a tubulin (tub-Gal4) driver, leads to embryonic lethality.
Expressing mitoXhoI selectively in the eye, using an eyeless-Gal4 driver, resulted in the
complete loss or significant reduction of the eye (Xu et al., 2008).
In this chapter, I present data obtained using Drosophila models of neuronal mtDNA
dysfunction. I further investigate the mitochondrial retrograde response initiated upon
mitochondrial dysfunction using microarray analysis.
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4.2. Chapter aims
Overexpression of TFAM and expression of the restriction enzyme mitoXhoI have both
been shown to cause mitochondrial dysfunction in previous animal studies. Targeting their
expression specifically in the fly nervous system, would allow for the investigation of
mtDNA dysfunction at the cellular level in a tissue-specific manner.
Work previously carried out by Umut Cagin verified that overexpression of TFAM and
expression of mitoXhoI cause mitochondrial dysfunction in Drosophila motor neurons
(Cagin, 2013). In this thesis chapter I outline how these tools were used to further
investigate the initial response of neurons to mitochondrial dysfunction.
Therefore the general aims of this chapter include:
 To investigate the consequences of TFAM overexpression and mitoXhoI expression
on mtDNA levels and mitochondrial-associated proteins.
 To investigate synaptic mitochondrial phenotypes generated by these tools via
analysis of the NMJ.
 To investigate the oxidation/reduction status of the mitochondria and cytosol at
the NMJs in the mtDNA dysfunction models.
 To investigate alterations in gene expression in Drosophila models of neuronal
mitochondrial dysfunction by microarray analysis.
154
4.3. Materials and Methods
4.3.1. Fly food
R1 recipe: 64g Agar (Fischer), 160g ground yellow corn, 640g glucose (Sigma), 400g
Brewer’s yeast (MP Biomed Europe) in a total volume of 10L dH2O
R2 recipe: 64g Agar (Fischer), 160g ground yellow corn, 640g glucose (Sigma), 800g
Brewer’s yeast (MP Biomed Europe) in a total volume of 10L dH2O
The ingredients were mixed in a SystecMediaPrep media steriliser and cooled to a
temperature below 60oC.  18g methyl 4-hydroxybenzoate (Sigma), 30mL propionic acid
(Fischer Scientific) and 160mL ethanol were then added. Once well mixed, the food was
dispensed into vials and bottles (Regina Industries Ltd) which were stored in a cold room at
4oC.
4.3.2. Fly breeding
Virgin female flies were collected five days a week and were kept at 18oC in R1 food.
Experimental crosses using the Gal4/UAS system were set up on R2 food, and were kept at
25oC for three days. The adults were then removed and the embryos were allowed to
develop at 29oC. Dissections and behavioural analysis of wandering larvae were carried out
on the third day at 29oC, unless stated otherwise. In all cases, unless otherwise stated, the
control used in experiments was the Gal4 driver line specified in the experiment crossed to
the Drosophila background strain, w1118.
In Drosophila, the Gal4/UAS system is an efficient way of selectively expressing genes of
interest in specific tissues. Expression of the yeast transcriptional activator Gal4 is under
the control of a promoter. When activated, Gal4 directs the transcription of an upstream
activation sequence (UAS) which leads to the expression of the gene of interest.
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Importantly, Gal4 activation will not lead to expression of the target gene unless UAS is
present. Similarly, in the UAS-target gene line, the target gene is not expressed unless
activated by the Gal4. Therefore both lines are required and the target gene will only be
expressed in the tissue specified by the Gal4 system in the progeny (Brand and Perrimon,
1993).
Since ubiquitous overexpression of TFAM and expression of mitoXhoI cause early
developmental lethality, a temperature-sensitive Gal80ts system was used to express Tub-
Gal4. Gal80 is a Gal4 inhibitor and by using a temperature sensitive Gal80 (Gal80ts) one is
able to cause temporal regulation of the Gal4/UAS system in a temperature sensitive
manner. The Gal80ts allele suppresses Gal4 activity at temperatures of 18oC and then
allows Gal4 activity upon the temperature being elevated to 29oC, as the Gal80ts allele is
rendered inactive at this temperature (Figure 4.1) (Lee and Luo, 1999). This allowed for a
temporally controlled overexpression of TFAM and expression of mitoXhoI, in order to
obtain third instar larvae for qPCR and western blot analysis. Experimental crosses were set
up and embryos laid at 18oC for three days. The embryos were then left to incubate at 18oC
for an additional five days, and then put at 29oC before being homogenised at the
wandering third larval instar stage.
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Figure 4.1 Temporal control of the Gal4/UAS system
At low temperatures (19oC) Gal80ts suppresses Gal4 activity thereby inhibiting expression of the
transgene which is under control of the UAS. At higher temperatures (30oC) the Gal80ts is rendered





nSyb-Gal4 (Sousa-Nunes Lab) – post-mitoticneurons (synaptobrevin expressing)
Da-Gal4 (Perrin et al., 2003)– daughterless (ubiquitous expression)
OK371-Gal4 (Bloomington,26160) – glutamatergic neurons
Tub-Gal80ts (Bloomington, 7018) – Tubulin (temperature sensitive Gal4)




UAS-TFAM 3M (chromosome II, generated by Umut Cagin, Bateman Lab) – TFAM
overexpression
UAS-mitoGFP (Bloomington, 8442) – GFP mitochondrial marker
UAS-mitoXhoI (O’Farrell lab) – restriction enzyme targeting mtDNA:CoI
UAS-CD8GFP (Tear lab) – GFP expression in neuronal membranes
RNAi lines:
ATPSyn-Cf6 dsRNA (VDRC, CG4412 107826) – RNAi of ATP synthase Coupling factor 6
GFP fluorescent probes:
Mito-roGFP2-Grx1 (Albrecht et al., 2011) – measurement of glutathione redox potential in
the mitochondrial matrix
Mito-roGFP2-ORP1 (Albrecht et al., 2011) – measurement of hydrogen peroxide levels in
the mitochondrial matrix
Cyto-roGFP2-Grx1 (Albrecht et al., 2011) – measurement of glutathione redox potential in
the cytosol.
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4.3.4. Measurement of mtDNA levels by quantitative PCR (qPCR).
5 wandering third instar larvae were briefly washed in cold dH2O to remove excess food.
The larvae were then placed in an empty tube on ice and kept cold. 250µl of
homogenisation buffer (Tris-Cl 0.1M, pH 9.0, EDTA 0.1M, SDS 1%) were added, and the
larvae were homogenised using a small pestle. Once homogenised, the tubes were
immediately returned to ice and then incubated for 30 minutes at 70oC.  35µl of potassium
acetate were then added and the solution was shaken. The tubes were left on ice for 30
minutes and then spun for 15 minutes at 13000 rpm. The supernatant was then transferred
into a new tube and 1 volume of Phenol: Chloroform (1:1) was added. The tubes were
shaken thoroughly and spun at 13000 rpm for 5 minutes. The supernatant was again
transferred onto a new tube and the phenol: chloroform and centrifuge steps repeated.
The supernatant was then isolated and 150µl of isopropanol added. The solution was
shaken and spun for 5 minutes at 10000 rpm. The supernatant was then discarded and 1ml
of 70% ethanol added. Following a final 5 minute spin at 13000 rpm, the pellet was left to
dry at room temperature and then resuspended in 100µl of Tris-EDTA.
Real time qPCR was performed on a Corbett Rotor-Gene RG-3000 machine. LightCycler®
FastStart DNA MasterPLUS SYBR Green I (Roche) reaction mixture and gene specific primers
(mitochondrial: cytochrome c oxidase subunit I (mt:CoI) and nuclear: glyceraldehyde 3-
phosphate dehydrogenase (Gapdh1)) were used (Table 10). The PCR reaction consisted of
40 cycles with a 10s denaturing step at 95oC, followed by 15s of annealing at 60oC, an
extension step at 72oC for 20s and a final melting step with a temperature increase from
72oC to 95oC.
Standard curves for mt:CoI and Gapdh1 were generated using a series of 8 dilutions of
genomic DNA to ensure primer efficiency.  The relative mtDNA level for each sample was
calculated by measuring the ΔCT of Gapdh1 to CoI expression.
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Table 10. Primer sequences for measuring mtDNA levels in Drosophila
4.3.5. Western blot analysis
25 third instar larvae (per genotype) were homogenised in 150µl of 1x SDS PAGE loading
buffer (2% SDS, 10% glycerol, 50mM Tris-HCl pH 6.8, 0.1% bromophenol blue). 0.1% DTT
was then added to the supernatant and the samples were boiled at 95oC for 5 min and
stored at -20oC.
Western blot samples, at a known concentration of protein, were run on a 12% SDS-
polyacrylamide gel at approximately 70 volts (V), for 30 minutes and then 100V for the rest
of the run. On each gel, 5µl of a pre-stained protein ladder was run (EZ Run, PrestainedRec
Protein ladder, Fischer) in the first lane.
The proteins were transferred onto nitrocellulose hybond membranes (Amersham) for one
hour at 25V. The membranes were then incubated with the primary antibody overnight at
4oC in 5% milk in TBS-T. Primary antibodies used were rabbit anti-Drosophila TFAM (Abcam
ab47548, 1:500), mouse anti-ATP5A (Abcam ab14748, 1:5000), mouse anti-MTCOI (Abcam
ab14705, 1:1000) and rabbit anti-Actin (Cell Signalling, 1:4000). Western blots were
developed via chemiluminescence using an ECL Prime western detection reagent
(Amersham). Band intensities, corresponding to protein levels, were quantified using Image
J 1.45s software. The intensity of each band was normalised to the corresponding level of
actin.
Gene Primers Sequence
Mt: CoI Forward primer 5’-GAGCTGGAACAGGATGAACTG-3`
Reverse primer 5’-TTGAAGAAATCCCTGCTAAATGT-3`
Gapdh1 Forward primer 5`-GACGAAATCAAGGCTAAGGTCG-3`
Reverse primer 5`-AATGGGTGTCGCTGAAGAAGTC-3`
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4.3.6. Larval flat preps
Wandering third instar larvae were briefly placed in ice-cold PBS (Oxoid, Thermo Scientific)
to rinse away food and to reduce muscle contractions. The larvae were then transferred to
a drop of PBS on a Sylgard dish and pinned down dorsal side up using micro-pins
(Entomoravia) placed on the anterior and posterior tips of the larva. Iridectomy scissors
(Fine Science Tools) were then used to cut the larval body wall from the posterior to the
anterior end, and intestines, fat bodies and the tracheal system were carefully removed
using a pair of forceps. The larvae were then pinned flat using additional micro-pins,
maintaining the nervous and muscle system intact. The flat preps were then fixed in 4%
formaldehyde (FA) /PBS for 30-45 minutes and the pins were removed. The preps were
then transferred into a 1.5ml microcentrifuge tube containing PBST (PBS, 0.1% Triton X
100) and washed three times at ten minute intervals. The tissue was then blocked in 10%
NGS for 30 minutes. Anti-horseradish peroxidase (goat anti-HRP-Cy3, Stratech), used as a
marker for neuronal membranes (Jan and Jan, 1982), was then added at a concentration of
1 in 250µl and the preps were left to incubate overnight at 4oC on a shaking platform. The
larval preps were then washed again three times in PBST. Once mounted in vectashield
(Vector labs), the slides were stored at 4oC in the dark. The NMJ synapses on muscle group
4 in segment A3 of the larva were imaged using a Zeiss LSM710 confocal microscope.
4.3.7. Microscopy and Image Processing
All slides were imaged using a Zeiss LSM710 confocal microscope using ZEN Software
(2010, Version 6.0).  Images were taken at a resolution of 1024 x 1024 pixels and 4 times
averaging, with a 7x speed.  Lenses used were 10x with a numerical aperture (NA) of 0.30,
20x with a NA of 0.50 and 40x, NA of 1.30 (oil immersion).
Images were processed and analysed using the Volocity Software (v5.5, Perkin Elmer)
program. An image projection scanning the entire NMJ was used for analysis and a
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specified measurement protocol in which objects greater than 0.02 µm3 were selected.
Additionally, an average size guide of 0.05 µm3 was set for separating touching objects. A
region of interest was selected, outlining the NMJ structure, and the number of
mitochondria and their respective volume were measured. Intensity threshold levels were
adjusted independently for each experiment.
4.3.8. Larval locomotion assay
A 1.5% agarose (Fischer Scientific) in PBS solution was poured into 15 cm petri dishes and
allowed to cool and solidify at room temperature. Larval locomotion assays were carried
out in a dark room under safe light. Wandering third instar larvae were picked up using a
moist paint brush and briefly washed in water. The larvae were then transferred to an
agarose plate for a 30 second acclimatisation period. Finally, the larvae were placed on a
15cm petri dish for 2 minutes, and their trail was followed and marked using a marker pen.
The petri dishes were then scanned and the trail analysed as distance travelled using Image
J 1.45s software.
4.3.9. NMJ dissections for redox level measurement
This dissection protocol was adapted from the method outlined by Albrecht et al. (Albrecht
et al., 2011). Wandering third instar larvae were briefly placed in cold dH2O to wash away
excess food. In order to obtain preps of fully reduced larvae, dissections as in 4.3.6 were
carried out in 20mM thiol reducing agent DTT and then left to incubate for 10 minutes. The
DTT was then removed and replaced with 20mM thiol blocker N-ethylmaleimide (NEM) for
an additional 10 minutes.  After one rinse with PBS, the preps were fixed in 4% FA in PBS
for 15 minutes.  Once fixed, the preps were again rinsed in PBS and washed three times in
PBST for 10 minute intervals. The preps were then incubated for 40 minutes with anti-HRP-
Cy3 (Stratech), PBST and 10% NGS, followed by three 10 minute interval washes in PBST
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and a final wash in PBS.  The preps were then mounted on slides in vectashield. The same
procedure was repeated for preps of fully oxidised larvae, utilising 2mM thiol oxidising
agent diamide (DA) instead of DTT. Control and test larvae were not treated with DA or
DTT but were directly dissected in 20mM NEM and left for 10 minutes. The rest of the
procedure was the same as outlined above. Reduced, oxidised, control and test larvae were
imaged on the confocal microscope on the same day as dissection and mounting.
4.3.10. Microarray experiments and analysis
The central nervous system (CNS) from 15 wandering third instar control (nSyb-
Gal4>w1118), TFAM overexpressing (nSyb-Gal4>UAS-TFAM 3M) or ATPSyn-Cf6 dsRNA
expressing (nSyb-Gal4>ATPSyn-Cf6 dsRNA) larvae were dissected in PBS. The brains were
then transferred into 100µl of lysis buffer from the Absolutely RNA Microprep kit
(Stratagene) and vortexed for 5 seconds. Total RNA was then prepared following the kit
instructions. Triplicate RNA samples were prepared for each genotype and stored at -80oC.
RNA integrity was measured using an Agilent 2100 Bioanalyzer instrument (version 2.6,
Agilent Technologies, Inc.), and cDNA was prepared from 500ng of total RNA using the
Ambion WT Expression kit.
An Affymetrix Terminal Labelling kit on Drosophila Gene 1.0 ST Arrays (Affymetrix) was
used to perform the probe hybridisations. Imaging of the arrays was performed using the
Affymetrix GCS3000 microarray system. The data was processed using a Robust Multichip
Average (RMA) algorithm (Bolstad et al., 2003) and analysed using the Omics Explorer
package (Qlucore) using a false discovery rate (FDR) of 0.2%.
Gene ontology (GO) analysis was carried out using Database for Annotation, Visualization
and Integrated Discovery (DAVID) v6.7 (Huang da et al., 2009). Results obtained via
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functional annotation clustering were visualised as a chart and graphically represented as a
histogram using Microsoft Excel (2007 version).
The data obtained have been uploaded on NCBI's Gene Expression Omnibus and are
accessible via GEO Series accession number GSE53509.
4.3.11. Statistical analysis
Statistical analysis of data and generation of graphs were performed using GraphPad Prism
version 5.0 (GraphPad Software Inc).
Comparison of data between two individual groups was carried out using a two-tailed
unpaired t-test, when variances in the groups passed the equality test. When variances
were considered unequal, a t-test with Welch’s correction for unequal variances was
carried out. When the data in one or both of the individual groups compared did not fit a
normal distribution, a non-parametric Mann-Whitney test was carried out.
Analysis to compare means in multiple groups was carried out by one-way analysis of
variance (ANOVA) followed by Tukey’s post-hoc multiple comparison test. If data did not fit
a normal distribution, a Kruskal-Wallis test followed by Dunn’s multiple comparison test
was carried out.
In all experimental analysis, data was considered significantly different when the p value
was lower or equal to 0.05 (p ≤ 0.05).
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4.4. Results
4.4.1. Ubiquitous overexpression of TFAM and expression of mitoXhoI
result in mtDNA dysfunction
Previous studies have suggested that overexpression of TFAM and expression of the
mitochondrially-targeted restriction enzyme, mitoXhoI could be used as efficient tools to
induce mitochondrial dysfunction (Xu et al., 2008; Ylikallio et al., 2010). Work by Umut
Cagin, outlined in his PhD dissertation (Cagin, 2013) suggested that the use of these tools
causes synaptic and behavioural phenotypes which are consistent with mtDNA dysfunction
in Drosophila.
To further characterise the effects of TFAM overexpression and mitoXhoI expression as
tools of mtDNA dysfunction, they were expressed ubiquitously under the control of a
daughterless (Da-Gal4) driver. This resulted in lethality in early development stages in both
cases. TFAM overexpression resulted in lethality at the first instar larval stage, whilst
mitoXhoI expression caused lethality at the embryonic or early first instar larval stage
(Table 11).
Using the Gal80ts system, TFAM was ubiquitously overexpressed for three days following
the start of the second larval instar stage. This did not result in a significant alteration in
mtDNA levels when compared to controls (Figure 4.2 A). However, western blot analysis
revealed that increased protein levels of TFAM (Figure 4.2 B,C) were accompanied by a
significant reduction in protein levels of the mitochondrially encoded CoxI (Figure 4.2 B,D).
Contrastingly, there was no change observed in protein levels of the nuclear encoded ATP
synthase α subunit (Figure 4.2 B,E).  This therefore suggests that overexpression of TFAM
results in unaltered mtDNA levels but reduced mitochondrial gene expression.
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Similarly, since UAS-mitoXhoI caused early developmental lethality under the control of Da-
Gal4, a temperature-sensitive Tub-Gal80 (Gal80ts) construct was used to induce Gal4
activity in a temporally controlled manner. Flies expressing mitoXhoI ubiquitously exhibited
reduced levels of mtDNA (Figure 4.3 A,B).  However, mtDNA levels were only found to be
statistically significantly reduced when utilising primers that spanned the restriction site
within the coxI gene in the mitochondrial genome (Figure 4.3 A,C). This suggests that while
the XhoI enzyme efficiently linearises the mtDNA, it does not significantly deplete mtDNA
levels compared to control.
166
Figure 4.2 MtDNA levels and mitochondrial-encoded protein levels in larvae overexpressing TFAM.
(A) mtDNA (coxI) /nDNA (Gapdh1) levels are not significantly different from control in flies
ubiquitously overexpressing TFAM using Tub-Gal80ts; Tub-Gal4. Control n=8, TFAM overexpression
n=8. The horizontal line in box and whisker plots represents the median whilst whiskers represent
the 5th and 95th percentile. (B) Western blot analysis of third instar larvae from control (lanes 1-3)
and TFAM overxpressing (lanes 4-6) flies. Protein levels were normalised to Actin expression levels.
(C) Quantification of protein levels of TFAM. (D) Quantification of protein levels of CoxI. (E)
Quantification of protein levels of ATP synthase α. Control n=3, TFAM overexpression n=3. Lines on
the bar graphs represent mean with SEM. *=p=≤0.05. In all cases, control represents Tub-Gal80ts;
Tub-Gal4>wIII8.
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Figure 4.3 MtDNA levels in larvae expressingmitoXhoI.
(A)The Drosophila melanogaster mitochondrial genome. Protein coding genes are represented in
grey, the AT rich repeat region is shown in blue and the rRNAs and tRNAs are represented in green
and white respectively. (B) Quantification of mtDNA/nDNA levels in flies ubiquitously expressing
mitoXhoI using Tub-Gal80ts; Tub-Gal4, using coxI primers that span the amplicon indicated by the
black line in (A). (C) Quantification of mtDNA/nDNA levels in flies ubiquitously expressing mitoXhoI
using Tub-Gal80ts; Tub-Gal4, using coxI primers that span the amplicon indicated by the red line in
(A) which also spans the XhoI site in coxI, Control n=7, mitoXhoI n=5. The horizontal line in box and
whisker plots represents the median whilst whiskers represent the 5th and 95th percentile. In all
cases, control represents Tub-Gal80ts; Tub-Gal4>wIII8.
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4.4.2. Overexpression of TFAM and expression of mitoXhoI in the fly
motor neuron system results in loss of synaptic mitochondria
Once the tools for inducing mtDNA dysfunction were established, the motor neuron driver
OK371-Gal4 was used to drive their expression specifically in this neural population.
Overexpression of TFAM in motor neurons resulted in late pupal lethality at 29oC. Most
progeny was also late pupal lethal at 25oC, with few eclosed adults. Expression of mitoXhoI
in motor neurons resulted in late pupal lethality when the experiments were performed at
25oC, and earlier pupal lethality when performed at 29oC (Table 11).
In order to assess whether mitochondrial dysfunction results in synaptic abnormalities, the
NMJs in muscle 4 of segment A3 were investigated. The number of boutons, which are sites
of neurotransmitter release, is an indicator of NMJ development and size. This was
unchanged in flies overexpressing TFAM and those expressingmitoXhoI (Figure 4.4).
To investigate whether there was any change in mitochondrial number and volume at the
NMJ, mitoGFP was used to quantify these parameters. Both mitochondrial number and
volume were significantly reduced in NMJs of flies overexpressing TFAM compared to
controls (Figure 4.4). Expression of mitoXhoI in the Drosophila motor neuron system also
results in a reduced number of significantly smaller mitochondria at the synapses (Figure
4.4)
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Table 11. Viability of Drosophila overexpressing TFAM or expressingmitoXhoI under the
control of ubiquitous driver Da-Gal4 and motor neuron driver OK371-Gal4.
TFAM overexpression MitoXhoI expression
Da-Gal4 (ubiquitous
expression)




Late pupal lethal / viable





Late pupal lethal Pupal lethal
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Figure 4.4 Synaptic mitochondria in flies overexpressing TFAM andmitoXhoI.
NMJs of muscle 4 in segment A3 in control (A), TFAM overexpressing (B), and mitoXhoI
expressing (C) third instar larvae. MitoGFP was driven in motor neurons via expression of
the glutamatergic driver OK371-Gal4 to visualise mitochondria, whilst anti-HRP was used to
visualise neuronal membranes. Quantification of bouton number (D), mitochondrial
number (E) and mitochondrial volume (F) in larvae overepxressing TFAM or mitoXhoI
compared to control. Bouton number, mitochondrial number and volume were quantified
in 10-12 muscle 4 NMJs for each genotype. Data are represented as mean +/- SEM,
***=p=≤0.001. In all cases, control represents OK371-Gal4>wIII8.
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4.4.3. Redox homeostasis in flies overexpressing TFAM and expressing
mitoXhoI
As previously discussed in Section 1.5, oxidative stress and antioxidant levels are widely
suspected to be involved in disease progression and are also believed to be involved in the
process of ageing. Despite these theories, however, redox changes in vivo are not very well
studied and the mechanism underlying the involvement of oxidants in physiological
changes is still poorly understood.
Recently, Albrecht et al., developed a method allowing quantitative in vivo mapping of
oxidative changes in a tissue-specific, pH-independent manner in Drosophila (Albrecht et
al., 2011). The method utilises redox sensitive GFPs (roGFPs) (Dooley et al., 2004; Hanson et
al., 2004), fused to glutaredoxin (GRX); a glutathione co-factor in the glutathione system.
RoGFPs contain a dithiol/disulphide switch which responds to changes in redox potential
giving a measurable fluorescent change. The fusion with GRX allows for a sensitive
response to glutathione redox changes thereby allowing for a readable glutathione redox
potential (EGSH). Furthermore, since the GRX and roGFPs are engineered as exogenous
constructs, the EGSH measurement is independent of endogenous GRX.
The use ofmito-roGFP2-GRX1 constructs under the control of the OK371-Gal4 driver allows
for the measurement of EGSH redox potential specifically in the mitochondrial matrix of
motor neurons.  Exposure of the brain tissue to exogenous reductant (DTT) or oxidant (DA)
allowed for the measurement of a full redox potential range between fully reduced and
fully oxidised cases.
The redox state in control larvae was close to the reduced end of the measuring range,
suggesting that in a wild-type situation, glutathione is in a mostly reduced state. The redox
potential was even further reduced in flies overexpressing TFAM and in flies expressing
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mitoXhoI. This suggests that upon mitochondrial dysfunction, the EGSH redox potential in
the mitochondrial matrix is significantly reduced compared to control (Figure 4.5).
Similarly, a cyto-roGFP2-GRX1 construct allowed for the measurement of EGSH redox
potential specifically in the cytosol of the NMJs. Unlike the mitochondrial-targeted
construct, the cytosolic probe showed no difference in redox potential between controls
and flies overexpressing TFAM or mitoXhoI (Figure 4.6). While this result might suggest that
cytosolic EGSH redox potential is unchanged under these conditions of mitochondrial
dysfunction, it is important to note that the 405/488m ratio in controls was not significantly
different than in the maximally reduced controls (Red (DTT)). This suggests that the redox
potential in the control NMJ is already at the limit of reduced potential detection.
Therefore, if the redox potential is further reduced in flies overexpressing TFAM or
expressingmitoXhoI, the change could remain undetected using this technique.
An alternative roGFP fused to the microbial H2O2 sensor oxidant receptor peroxidise 1
(ORP1) can be used to measure redox levels of the major oxidant species involved in redox
regulation, H2O2 (Albrecht et al., 2011). Expression of a mito-roGFP2-ORP1 construct in the
motor neurons using an OK371-Gal4 driver revealed that there was no change in the
measurement of H2O2 levels in the mitochondrial matrix of flies expressing mitoXhoI
compared to controls. However, similar to what was observed for cyto-roGFP2-GRX1
measurement, the level in controls was similar to that in the maximally reduced larvae,
suggesting that the H2O2 levels in the control mitochondria at the NMJ is also at the limit of
reduced potential detection (Figure 4.7). Therefore, it could also be that further alterations
in H2O2 levels in larvae expressing mitoXhoI are outside the measurable range and
therefore undetectable using this technique.
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Figure 4.5 Glutathione redox potential in the mitochondrial matrix in the motor neurons of mito-
roGFP2-GRX1 flies.
Images and respective quantifications of 405/488 nm ratio in NMJs of muscle 4 in segment A3 in
control (A), mitoXhoI expressing (B, C) (DTT n=9, DA n=11, Control n=13, mitoXhoI n=21), and TFAM
overexpressing (D, E) (DTT n= 14, DA n=8, Control n=15, TFAM overexpression n=12) third instar
larvae. Reduced (red) images represent control larvae treated with the reductant DTT, which exhibit
a low 405/488 nm ratio. Oxidised (Oxid) images represent control larvae treated with the oxidant
DA, which exhibit a high 405/488 nm ratio... Data are represented as mean +/- SEM, *=p=≤0.05,
**=p≤0.01. In all cases, control represents OK371-Gal4 >mito-roGFP2-GRX1.
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Figure 4.6 Glutathione redox potential in the cytosol in the motor neurons of cyto-roGFP2-GRX1
flies
Images and respective quantifications of 405/488 nm ratio in NMJs of muscle 4 in segment A3 in
control (A), mitoXhoI expressing (B, C) (DTT n=8, DA n=8, Control n=20, mitoXhoI n=12), and TFAM
overexpressing (D, E) (DTT n=10, DA n=3, Control n=17, TFAM overexpression n=19) third instar
larvae. Reduced (red) images represent control larvae treated with the reductant DTT, which exhibit
a low 405/488 nm ratio. Oxidised (Oxid) images represent control larvae treated with the oxidant
DA, which exhibit a high 405/488 nm ratio. Data are represented as mean +/- SEM. In all cases,
control represents OK371-Gal4 >cyto-roGFP2-GRX1.
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Figure 4.7 Hydrogen peroxide levels in the mitochondrial matrix in the motor neurons of mito-
roGFP2-ORP1 flies
Images and respective quantifications of 405/488 nm ratio in NMJs of muscle 4 in segment A3 in
control (A) and mitoXhoI (B,C) (DTT n=10, DA n=8, Control n=12, mitoXhoI n=14) expressing third
instar larvae. Reduced (red) images represent control larvae treated with the reductant DTT, which
exhibit a low 405/488 nm ratio. Oxidised (Oxid) images represent control larvae treated with the
oxidant DA, which exhibit a high 405/488 nm ratio. Data are represented as mean +/- SEM. Control
represents OK371-Gal4 >mito-roGFP2-ORP1.
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4.4.4. Characterisation of the mitochondrial retrograde response in
the Drosophila CNS.
In order to better understand the molecular mechanisms underlying mitochondrial
dysfunction, a microarray analysis was carried out to investigate altered gene expression in
the late larval CNS, upon induction of mitochondrial dysfunction. The genechip Drosophila
genome 2.0 Array from Affymetrix contains 18,880 probe sets and allows investigation of
the expression profiles of more than 18,500 Drosophila transcripts (Affymetrix).
The nSyb-Gal4 driver, driving expression in all post-mitotic neurons, was used to induce
pan-neuronal mitochondrial dysfunction. Expression of mitoXhoI using nSyb-Gal4 resulted
in mid-larval lethality and this tool was, therefore, not used for this study. Expression of
dsRNA against ATP synthase Coupling factor 6 (ATPSyn-Cf6 dsRNA) was therefore used as
an alternative method of inducing mitochondrial dysfunction. The F6 subunit of the
complex is found in the F0 unit, which is the proton channel component of ATP synthase,
and is required for the interaction of the F0 subunit with the F1 subunit. Larvae expressing
ATPSyn-Cf6 dsRNA display similar synaptic and behavioural phenotypes to mitoXhoI and
TFAM overexpressing flies (Cagin et al., submitted). Therefore, larvae overexpressing TFAM
and larvae expressing ATPSyn-Cf6 dsRNA were chosen as candidates for the microarray
study.
Overexpression of TFAM and knockdown of ATPSyn-Cf6 in post-mitotic differentiated
neurons resulted in late pupal lethality in both cases. Behavioural analysis of larvae from
nSybGal> TFAMo/e and nsybGal4> ATPSyn-Cf6 dsRNA showed that larval locomotion was
significantly reduced in both cases when compared to controls. Larval locomotion in larvae
expressing ATPSyn-Cf6 dsRNA was even more significantly reduced than in larvae
overexpressing TFAM (Figure 4.8).
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RNA from larval CNS tissue was used for microarray analysis. Overall, data analysis revealed
that gene regulation following mitochondrial dysfunction was highly correlated in larvae
overexpressing TFAM and those expressing ATPSyn-Cf6 dsRNA (r = 0.72, p = ≤0.0001, Figure
4.9), suggesting that genes responded in a similar manner to the two methods of
mitochondrial dysfunction. Using a false discovery rate of 0.2%, microarray analysis
revealed that 340 probes, corresponding to 293 genes were differentially regulated in
TFAM overexpressing larvae (Appendix 2.1), whilst 424 probes, corresponding to 371 genes
were differentially regulated in larvae expressing ATPSyn-Cf6 dsRNA (Appendix 2.2). 142 of
the genes were commonly differentially regulated in both cases (Appendix 2.3) (Figure 4.9).
A correlation analysis on these 142 genes, again revealed a highly significant positive
correlation (r = 0.93, p = ≤0.0001, Figure 4.9)
Heat map E in Figure 4.9 shows the 20 genes that were most upregulated in TFAM o/e flies
compared to ATPSyn-Cf6 dsRNA flies, whilst heat map F shows the 20 genes that were most
upregulated in ATPSyn-Cf6 dsRNA flies compared to TFAM overexpressing flies. Heatmap G
shows 20 genes that were commonly differentially regulated in TFAM overexpressing
larvae and larvae expressing ATPSyn-Cf6 dsRNA compared to controls.
Among the common differentially regulated genes in the TFAM o/e and ATPSyn-Cf6 dsRNA
expressing larvae, were the ones listed in Table 12.
Figure 4.10 depicts histograms representing gene ontology analysis carried out on genes
differentially regulated in larvae expressing ATPSyn-Cf6 dsRNA (Figure 4.10A), larvae
overexpressing TFAM (Figure 4.10B), and genes which were commonly regulated in the two
cases (Figure 4.10C). Detailed charts listing the names of the genes annotated to each
cluster and relative enrichment scores can be found in appendices 2.4, 2.5 and 2.6.
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Figure 4.8 Larval locomotion in larvae overexpressing TFAM and ATPSyn-Cf6 dsRNA.
Larval locomotion is significantly reduced in larvae overexpressing TFAM and in larvae expressing
ATPSyn-Cf6 dsRNA (One-way ANOVA followed by Tukey’s multiple comparison test) n=10 for Control,
TFAM o/e and ATPSyn-Cf6 dsRNA. The horizontal line in box and whisker plots represents the
median whilst whiskers represent the 5th and 95th percentile.  *=p≤0.05, **=p≤0.01, ***=p≤0.001.
Control represents nSybGal4>WIII8.
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(Figure legend on next page)
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Figure 4.9 Microarray analysis reveals mitochondrial retrograde response upon TFAM
overexpression or ATPSyn-Cf6 knockdown.
(A,B) Volcano plots of gene expression levels in flies expressing TFAM o/e (A) or ATPSyn-Cf6 dsRNA
(B). Genes whose expression was significantly increased ≥1.2 fold with a p value ≤0.01 are shown in
red. (C) Venn diagram depicting the number of genes whose expression was significantly changed
with a p value ≤0.01 in larval CNS of flies overexpressing TFAM (TFAM o/e) (n = 151), ATPSyn-Cf6
dsRNA (n=229) and in both conditions (n=142). (D) Correlation plot of all ATPSyn-Cf6 dsRNA vs. TFAM
o/e gene expression levels. Blue scatter dots represent genes which display positive correlation
between the two conditions. Red scatter dots represent genes which are inversely correlated and
are therefore upregulated in one condition whilst being downregulated in another. (E) Correlation
plot of genes which were statistically commonly regulated upon ATPSyn-Cf6 dsRNA and TFAM o/e.
(F,G) Heat maps showing expression levels of 20 genes whose expression was significantly
upregulated in TFAM o/e flies (F) and in ATPSyn-Cf6 dsRNA flies (G). (H) Heat map showing
expression level of 20 genes whose expression was similarly regulated in ATPSyn-Cf6 dsRNA and
TFAM o/e flies.
Table 12. Selected common differentially regulated genes in the TFAM o/e and ATPSyn-
Cf6 dsRNA expressing larvae
TFAM o/e
fold change
Gene Function ATPSyn-Cf6 dsRNA
fold change
3.584 Impl3 Ecdysone-inducible gene L3 – L-lactate
dehydrogenase activity
7.971
1.486 Tret1-1 Trehalose transporter 2.813
3.235 Thor 4E-BP –eukaryotic initiation factor 4E
binding
5.832
0.607 Ilp1 Insulin-like peptide – Insulin Receptor
Signalling pathway
0.711
Impl3 encodes lactate dehydrogenase, which converts pyruvate, the final product of
glycolysis, to lactate when oxygen is limiting. Trehalose is the primary circulating sugar in
insects and is taken up into the various cellular systems via the facilitated trehalose
transporter, Tret1-1. Both Impl3 and Tret1-1 were upregulated in larvae overexpressing
TFAM and expressing ATPSyn-Cf6 dsRNA suggesting a common upregulation of glycolysis
induced upon mitochondrial dysfunction.
Thor, encoding for eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) was
also highly upregulated in both conditions, whilst Drosophila insulin-like peptide 1 (Ilp1)
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was significantly downregulated in both larvae overexpressing TFAM and those expressing
ATPSyn-Cf6 dsRNA. Ilp3 was additionally significantly downregulated in the latter group.
Together, these findings suggest a downregulation of the mTOR pathway in response to
mitochondrial dysfunction. These genes were consequently selected as indicative of a
mitochondrial retrograde signalling mechanism. Validation of the differential regulation of
these genes and further investigation into their role in mitochondrial retrograde signalling
is further described in Chapter 5.
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Figure 4.10 Gene ontology (GO) analysis, based on functional annotation clustering, of genes
differentially or commonly regulated in larvae expressing ATPSyn-Cf6 dsRNA or overexpressing
TFAM.
Histograms representing functional annotation clusters resulting from GO analysis of genes
significantly differentially regulated in larvae expressing ATPSyn-Cf6 dsRNA (A) or over-expressing
TFAM (B). Only clusters which included a count of gene number ≥ 10 are represented in charts A and
B. (C) A histogram representing functional annotation clusters from GO analysis of genes that were
commonly regulated upon expression of ATPSyn-Cf6 dsRNA or TFAM overexpression. The x-axis
represents the number of genes represented in each cluster. The y-axis represents the functional
annotations which were found to be enriched by GO analysis using DAVID v6.7.
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4.5. Discussion
Overexpression of TFAM and expression of the mitochondrially-targeted restriction enzyme
mitoXhoI proved to be efficient tools for inducing mitochondrial dysfunction in Drosophila.
In this study, these tools were used to induce mitochondrial dysfunction specifically in the
nervous system of the fly, thus creating a novel neuronal model of mitochondrial
dysfunction. As in previous studies, overexpression of TFAM resulted in a reduction of
mitochondrial gene expression whilst expression of mitoXhoI resulted in linearization of
mtDNA. In a Drosophilamotor neuron model, mtDNA dysfunction caused a reduction in the
number of synaptic mitochondria and a reduction in the glutathione redox potential within
the mitochondrial matrix.
4.5.1. Overexpression of TFAM and expression of mitoXhoI result in
mtDNA dysfunction
Previous studies have shown that the effects of overexpression of TFAM can be different
depending on cell type, model organism and most importantly the ratio of the protein to
mtDNA (Falkenberg et al., 2002; Ekstrand et al., 2004; Maniura-Weber et al., 2004;
Pohjoismaki et al., 2006; Ylikallio et al., 2010). The results outlined in this study show that
in Drosophila, when TFAM is in excess, mtDNA copy number is similar to control, however
gene expression of mtDNA is compromised. Indeed, complex IV COX I protein levels were
significantly reduced in wandering larvae overexpressing TFAM.
It is important to note that whilst TFAM overexpression did clearly result in mtDNA
dysfunction, the methodologies used cannot allow us to conclude that the phenotypes
observed are due to overexpression of TFAM itself rather than any other mitochondrial
protein. Whilst studies in literature do emphasise that TFAM levels are crucial in
determining mitochondrial function, it is also true that overexpression of several
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mitochondrially- targeted proteins could affect mitochondrial function and result in
disruption of the ETC. Several experiments outlined in this chapter would have therefore
benefitted from the use of a mitochondrial-targeted control, such as over-expression of an
inert mitochondrial target (for example, mito-GFP) which could have helped to validate the
choice of TFAM overexpression as a tool of mitochondrial dysfunction.
Expression of mitoXhoI did not cause a statistically significant reduction in mtDNA levels,
however it did cause a linearization of mtDNA. MtDNA is transcribed as two polycistronic
mRNAs. Therefore, transcription of the majority of the mtDNA encoded genes is probably
inhibited as XhoI cuts the strands at the coxI restriction site.
Overexpression of TFAM and expression of mitoXhoI specifically in the motor neurons of
the fly resulted in a reduction in the number of mitochondria at the synapses at the third
instar larval stage. Mitochondria at the synapses were quantified using a mitochondrial-
targeted mitoGFP construct. Ideally, mitochondrial numbers would have been counted
using an endogenous marker such as porin, however this was not possible as the porin
antibody available was not efficient for use in immunohistochemistry, at least not to an
extent that allowed for reliable quantification.
Overexpression of TFAM in the motor neurons also led to late pupal lethality in most cases,
and the few adults which eclosed out of their pupal cases only survived for the first week.
Flies overexpressing mitoXhoI in motor neurons did not survive past the late pupal stage,
suggesting that mitochondrial dysfunction in these flies had an even more severe impact.
It could be that the phenotypes observed are directly due to the loss of synaptic
mitochondria. Indeed, flies expressing a mutant form of the mitochondrial fission gene
drp1, have also been shown to exhibit a loss of synaptic mitochondria at the larval NMJ,
similar to what is observed in these models. Furthermore they also exhibit locomotor
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defects at the adult stage (Verstreken et al., 2005). These mutant flies have reduced levels
of ATP which is required for reserve pool tethering and release. Therefore, they exhibit a
reduction in synaptic reserve pool vesicle mobilisation, which could be causing the synaptic
and locomotor phenotypes. Further investigation is required to study whether a similar
mechanism is occurring in the TFAM overexpressing andmitoXhoI expressing flies.
Neurotransmitter release at the synapses occurs at active zones found within individual
boutons at the NMJ. In flies overexpressing TFAM or mitoXhoI, bouton number was not
significantly altered. This suggests that the synaptic and behavioural phenotypes observed
are due to a bioenergetic deficit resulting from a reduced number of mitochondria, rather
than due to dysfunctional development of the NMJ as a structure.
As previously argued in section 1.12, studies on AD and PD models and post-mortem tissue
have implicated a loss of synaptic activity and structure in the disease process. Therefore,
overall our results support the theory that neuronal mitochondrial dysfunction might
contribute significantly to these neuropathologies.
4.5.2. Redox state changes in flies overexpressing TFAM and
expressing mitoXhoI.
Since overexpression of TFAM and expression of mitoXhoI caused mitochondrial
dysfunction at the synapses, it was of interest to investigate any redox changes in these
mitochondria and surrounding cytosol. It is generally thought that dysfunctional
mitochondria and oxidative stress are an inter-linked phenomenon and alterations in
cellular redox state, towards a more pro-oxidative state, are regularly associated with
ageing and neurodegeneration.
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The results obtained in this study, however, suggest that when investigating redox changes
specifically in the Drosophila motor neuron system, no pro-oxidative change is observed
upon mitochondrial dysfunction.
Similar to observations reported by Albrecht et al., cytosolic glutathione redox potential in
wild-type flies was more towards the reduced state in the motor neuron NMJs (Albrecht et
al., 2011). Furthermore, cytosolic EGSH was not significantly different in larvae
overexpressing TFAM and expressing mitoXhoI. Therefore, these results support the
findings of Albrecht et al., which suggest that cytosolic EGSH is close to the lower end of the
roGFP2 measuring range all throughout the organism, and that this lack of variation is
suggestive of a stable and robust steady-state glutathione redox potential, which prevents
the excessive oxidation of thiols on cytosolic proteins. However, as argued in section 4.4.3,
it is possible that a further reduction in cytosolic glutathione redox potential in larvae
overexpressing TFAM or expressing mitoXhoI, would have been undetected due to
limitations of the technique used. In conclusion, the parameters set by this experiment
might not be adequate for the efficient measurement of cytosolic glutathione redox
potential in NMJs of larvae with mitochondrial dysfunction. An additional caveat to this
experiment is that the use of such probes could potentially alter the mitochondrial
membrane potential leading to reduced mitochondrial import. This could have been tested
by using porin as a marker for mitochondrial number as well as integrity of the organelle.
However, as previously stated (section 4.5.1) the porin antibody available was not found to
be efficient in use for IHC.
Previous studies in Drosophila have also shown that during ageing, glutathione is present at
a more oxidised state and hydrogen peroxide levels are increased in the whole organism
(Rebrin et al., 2004; Cocheme et al., 2011). Albrecht et al., however, find that the observed
steady-state cytosolic glutathione redox potential is also maintained in aged Drosophila,
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suggesting that in this experimental setup, ageing does not directly correlate with a pro-
oxidative state. Similarly, the data presented in this study indicate that cytosolic
glutathione redox potential is also maintained in a steady reduced state in conditions of
mitochondrial dysfunction.
Albrecht et al., also argue that mitochondrial EGSH is much more variable in different tissue
types (Albrecht et al., 2011). Similarly, data presented here suggests that the mitochondrial
EGSH in motor neurons was even more reduced in flies overexpressing TFAM and in flies
expressing mitoXhoI than in controls. Therefore, mitochondrial dysfunction in motor
neurons does not cause excessive oxidation within mitochondria, but conversely results in
a more reduced state within the organelle. This might be due to the reduced number of
functional mitochondria at the NMJ. Since the method used for inducing mitochondrial
dysfunction results in a reduced expression of mitochondrial-encoded genes, as seen by the
reduced levels of COXI, it is possible that the respiratory chain in these mitochondria is not
as efficient and therefore generates less oxidative stress than in wild-type mitochondria.
Furthermore, studies have shown that knockdown of different complexes of the OXPHOS
chain cause differential regulation of ROS levels. In 2008, Owusu-Ansah et al., showed that,
in Drosophila, downregulation of the complex I gene Pdsw results in cell-cycle arrest at the
G1 phase and a five-fold increase in ROS. Conversely, knockdown of the CoVa gene in
complex IV resulted in a 20% decrease in ROS, whilst still blocking the cell cycle at G1 phase
(Owusu-Ansah et al., 2008). Similarly, deletion of another gene required for complex IV
assembly, COX10, in a mouse model of AD also resulted in a reduction in oxidative stress
(Fukui et al., 2007), whilst an AD-mitoPstI mouse model exhibit no alteration in
mitochondrial hydrogen peroxide production, suggesting that mitochondrial dysfunction
did not trigger an upregulation of ROS. This further suggests that ROS regulation upon
mitochondrial dysfunction is a complex process, and further work is required to elucidate
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the role of ROS in the mitochondrial retrograde response. Investigating the mitochondrial
and cytosolic redox states in larvae expressing ATPSyn-Cf6 dsRNA might offer some insight
into whether mitochondrial dysfunction induced upon downregulation of a Complex V
gene, causes a differential regulation of ROS compared to overexpression of TFAM or
expression ofmitoXhoI.
4.5.3. Mitochondrial dysfunction leads to a transcriptional retrograde
response.
A microarray analysis revealed that in the third larval stage, neuronal mitochondrial
dysfunction leads to alterations in the nuclear transcriptome which clearly underline a
mitochondrial retrograde response.
Indeed, both overexpression of TFAM and expression of ATPSyn-Cf6 dsRNA, led to an
increased expression of lactate dehydrogenase (Impl3) and trehalose transporter (Tret1-1)
in post-mitotic neurons. Upregulation of Impl3 and Tret1-1 suggest a compensatory
mechanism to upregulate glycolysis upon mitochondrial dysfunction, as an alternative to
oxidative phosphorylation. Inhibition of OXPHOS is known to trigger a metabolic switch
towards an upregulated rate of glycolysis (Freije et al., 2012). Downregulation of the gene
encoding subunit Va of the OXPHOS complex IV (CoVa) in Drosophila S2 cells, has also been
shown to induce increased glycolysis, with an upregulated expression of Impl3 and Tret1-1.
Glycolytic capacity of the cells was also overall increased upon CoVa knockdown (Freije et
al., 2012). Additionally, studies of the mitochondrial retrograde signalling pathway in
mammalian cancer cell lines have also revealed a metabolic shift towards glycolysis as well
as upregulation of genes involved in mitochondrial biogenesis, cell adhesion, cytoskeletal
markers, invasiveness, metabolism, transcription factors and alternative splicing (Guha et
al., 2010; Guha and Avadhani, 2013) .
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Such a metabolic shift towards glycolysis has already been shown to act in response to
mitochondrial dysfunction in human in vitro studies, and lactic acidemia, an excess of lactic
acid in the blood, is also known to occur in patients with mitochondrial diseases (Robinson,
2006; Distelmaier et al., 2015).
The microarray analysis also revealed an upregulation of the transcription factor sima, as
well as a down-regulation of Drosophila insulin-like peptide Ilp1 and Ilp3, and an
upregulation of Thor, Drosophila 4E-BP. This is suggestive of a mitochondrial retrograde
signal which is acting towards a downregulation of the mTOR (mechanistic target of
rapamycin) pathway.
The mTOR pathway, the main component of which is the mTOR serine/threonine protein
kinase, regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis,
and transcription. Furthermore, it also regulates mitochondrial biogenesis and the
translation of nuclear-encoded mitochondrial proteins via its inhibitory effects on the
downstream translation suppressor, eukaryotic translation initiation factor 4E-BP1 (Zoncu
et al., 2011).
Flies overexpressing TFAM and flies expressing ATPSyn-Cf6 dsRNA demonstrate a down-
regulated expression of Ilp1 and Ilp3, ligands known to activate the mTOR pathway, as well
as an upregulated expression of the translation suppressor Thor. Therefore, this might
suggest that as an initial neuronal response, mitochondrial dysfunction exerts an inhibitory
effect on the process of mitochondrial biogenesis and protein translation. This might be a
neuroprotective response aiming to protect the nervous system from too much energy
expenditure during such stressful conditions.
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4.6. Conclusion
Overexpression of TFAM and expression of the restriction enzyme mitoXhoI specifically in
the motor neurons in Drosophila results in mitochondrial dysfunction which elicits a
synaptic phenotype at the NMJ.
A microarray analysis revealed that the induction of mitochondrial dysfunction specifically
in the Drosophila post-mitotic nervous system, results in a mitochondrial retrograde
response which encompasses an upregulation of sima, the Drosophila homologue of HIF1α,
a downregulation of the mTOR pathway and an upregulation of the translational inhibitor
4E-BP.
In order to better understand this mechanism, these microarray results were validated and
this retrograde response was further investigated in in vivo models of Drosophila
mitochondrial dysfunction. This data is presented in Chapter 5.
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As argued in Chapter 1, section 1.11, mitochondrial retrograde signalling is a phenomenon,
mostly well known in yeast, in which mitochondria communicate back to the nucleus
exerting an effect on nuclear gene expression.
This arrangement appears to be conserved throughout animal species; however the exact
mechanism and signal transducers involved might differ. Recent studies have highlighted
the presence of such a system in mammals, with several studies suggesting that an
adaptive compensatory mechanism acts in response to mitochondrial malfunction. Such
compensatory mechanisms observed include an increase in the expression of ETC complex
subunits, increase in mtDNA biogenesis, alterations in nuclear DNA methylation and
alterations in oxidative stress (Cannon et al., 2011; Bellizzi et al., 2012; Kao et al., 2012; Ling
et al., 2012).
An overall incapability of maintaining these compensatory mechanisms might therefore
result in the loss of cellular homeostasis and organism health. Alternatively, a long-term
upkeep of such compensatory response might be toxic to the cellular environment and
could therefore result in disease onset. Indeed, disruption of the mitochondrial retrograde
response and compensatory mechanisms may contribute to several diseases including
forms of cancer, type II diabetes and neurodegenerative disease such as AD and PD (Horan
and Cooper, 2014).
In Chapter 4, I demonstrated that utilising TFAM overexpression as well as knockdown of
the ETC complex V subunit ATPSyn-Cf6 as tools of mitochondrial dysfunction in Drosophila
post-mitotic neurons triggered a mitochondrial retrograde response causing differential
expression of around 300 genes in both of the mitochondrial dysfunction models.
Moreover, microarray analysis also revealed 142 of these genes were commonly
differentially regulated suggesting that differential expression of some genes is a response
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to general mitochondrial dysfunction, whilst other genes are regulated in response to a
specific perturbation in mitochondrial function.
This chapter focuses on the genes whose expression is commonly regulated by
mitochondrial dysfunction induced by overexpression of TFAM or knockdown of ATPSyn-
Cf6. The regulation of these genes could offer insight into a retrograde mechanism which
acts in response to mitochondrial dysfunction.
5.2. Chapter aims
Overexpression of TFAM and knockdown of ATPSyn-Cf6 result in mitochondrial dysfunction
which elicits a mitochondrial retrograde response, altering the expression of the nuclear
transcriptome. Data presented in this chapter aim to validate the results obtained in a
microarray carried out on Drosophila models of neuronal mitochondrial dysfunction.
Furthermore, this in vivo setup was used to better understand the interaction of these
differentially expressed genes to develop a working mechanism of mitochondrial
retrograde signalling.
Therefore the general aims of this chapter include:
 To validate microarray results in vivo, in the Drosophila nervous system using
bacterial lacZ reporters.
 To better elucidate the retrograde mechanism acting in response to mitochondrial
dysfunction.
 To identify ways in which modulation of this retrograde response can be used to
rescue behavioural and synaptic phenotypes in Drosophilamodels of mitochondrial
dysfunction.
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5.3. Materials and Methods
5.3.1. Fly stocks




nSyb-Gal4 (Pospisilik et al., 2010) – post-mitotic neurons (synaptobrevin expressing)
OK371-Gal 4 (Bloomington,26160) – glutamatergic neurons




UAS-TFAM 3M (chromosome II, generated by Umut Cagin, Bateman Lab) – TFAM
overexpression
UAS-TFAM 10M (chromosome III, generated by Umut Cagin, Bateman Lab) – TFAM
overexpression
UAS- mitoXhoI (Xu et al., 2008) – restriction enzyme targetingmtDNA:CoI
UAS-CD8GFP (Tear lab) – GFP expression in neuronal membranes
UAS-sima (Bloomington, 9582) – sima overexpression
RNAi lines:
Sima HMS00832(Bloomington, 33894) – sima RNAi
Sima HMS00833(Bloomington, 33895) – sima RNAi
LacZ reporter lines:
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Thor-lacZ (Bloomington, 9558) – reporting expression of Thor
Ilp3-lacZ (Ikeya et al., 2002) – reporting expression of Ilp3
5.3.2. Larval CNS dissections
Wandering third instar larvae were briefly placed in ice-cold PBS (Oxoid, Thermo Scientific)
to rinse away food. The larvae were then dissected with fine forceps (Agar Scientific) under
a dissection microscope. The dissected brains were placed in a 1.5ml microcentrifuge tube
containing 4% formaldehyde (Thermo Scientific) / PBS and left to fix for 30-45 minutes
while on a shaking platform (Rotarod). Once fixed, the brains were washed for ten minutes
three times in PBST (PBS, 0.1% Triton X 100). The brains were then blocked in 10% normal
goat serum (NGS, Sigma-Aldrich) for 30 minutes. Once blocked, primary antibodies in 10%
NGS/PBST were added to the brains (anti-beta-galactosidase (β-Gal), 1 in 1000, Abcam,
9361) and left to incubate overnight on a shaking platform at 4oC. The tissue was then
washed three times in PBST at ten minute intervals on a shaking platform at room
temperature. Secondary antibodies (Goat anti-Chk AlexaFlour 555 (A21437), Life
Technologies, 1 in 1000) were then added at the appropriate dilution and left to incubate
for 1.5 hours whilst wrapped in aluminium foil so as to protect the fluorescent signal. The
brains were again washed three times in PBST at ten minute intervals, prior to mounting
onto slides.  The brains were then fully dissected on the slide in PBS. Excess PBS was then
removed and 15ul of Vectashield mounting media (Vector Laboratories) were added. Cover
slips were then carefully placed to cover the tissues and the slides were stored at 4oC until
imaging. All tissue was imaged using a Zeiss LSM710 confocal microscope.
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5.3.3. Microscopy and image processing
CNS tissue was dissected and imaged on a Zeiss LSM710 confocal microscope.
Quantifications were carried out on maximum intensity projections which encompassed
the whole region of interest.
Thor-lacZ expression in motor neuron cell bodies of VNC was measured as intensity of β-
Gal using the point tool on Image J. The intensity was measured in approximately 24 motor
neuron cell bodies and the average expression in each VNC was then calculated. Thor-lacZ
expression in each experimental VNC was then normalised to expression levels in controls.
Ilp3-lacZ expression in CNS neurosecretory cells in the optic lobes was measured as
intensity using the point tool on Image J. The intensity was measured in all 14 cells per
brain (7 insulin secreting cells per hemisphere). Average expression in each CNS was then
calculated and normalised to expression levels in controls.
5.3.4. Climbing (Negative geotaxis) assay
Climbing assays were carried out on males only. Males were collected, using CO2 gassing,
upon eclosion and kept separately from females in a vial with fresh food. The males were
left at 25oC for 24 hours, a time interval deemed sufficient to regain mobility and a normal
metabolic profile following CO2 anaesthesia (Colinet and Renault, 2012). The assay was
then carried out on one-day old males between the hours of 8 am and 10 am in the
morning, so as to record climbing ability at a standard time and circumvent variability due
to the fly circadian clock.
An individual male fly was aspirated, via a mouth aspirator, into a 5mL Falcon pipette with
a cut-off tip. The pipette was then tapped on the bench so that the fly fell to the bottom of
the graduated pipette. The timer was started as soon as the fly starting climbing the pipette
wall. The time was stopped after 10 seconds and the distance climbed was recorded. Trials
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in which the flies paused or walked down the pipette were ignored. The climbing distance
of each individual male was recorded 3 times and 10-14 flies were tested per genotype.
5.3.5. Wing inflation assay
D42-Gal4 driver was used to drive overexpression of TFAM (TFAM o/e), knockdown of sima
(sima HMS00832), or sima RNAi in flies overexpressing TFAM (sima HMS00832;TFAM o/e). The
progeny of each cross was left to develop at 25oC. The wing phenotype of the adults was
checked 24 hours after eclosion. The phenotype of the wings of both male and female flies
was classified as inflated (normal), half-way inflated or folded. The data from two separate
trials was pooled and the frequency calculated as a percentage.
5.4. Results
5.4.1. Thor expression is upregulated in in vivo Drosophila models of
mitochondrial dysfunction
Microarray analysis on CNS tissue from third instar larvae overexpressing TFAM or knocked
down ATPSyn-Cf6 revealed an upregulation of Thor, encoding the cap-dependent
translation inhibitor and mTOR downstream target 4E-BP1.
I wanted to validate whether such an upregulation is also observed in vivo, following
mitochondrial dysfunction. Immunofluorescence using a 4E-BP antibody proved difficult as
no clear signal, which would allow for efficient quantification, was observed. In Drosophila,
gene expression can also be measured in vivo by monitoring the expression of the gene of
interest that is under the control of a reporter gene such as bacterial lacZ. LacZ encodes
beta-galactosidase (β-gal) and an anti- β-gal antibody was therefore used to measure levels
of the gene product by immunofluorescence. Therefore, overexpression of TFAM or
expression of mitoXhoI, were driven specifically in the motor neurons, and lacZ reporters
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were used to measure the endogenous expression of genes of interest. This allowed for the
validation of microarray results obtained in vivo.
Control flies exhibited a low level expression of Thor in motor neuron cell bodies in the
ventral nerve cord (VNC). However, this expression was strongly upregulated in both flies
overexpressing TFAM (p = ≤0.001, Figure 5.1) and those expressing mitoXhoI (p = ≤0.001,
Figure 5.2). These results therefore validate the data obtained in the microarray and
confirm that Thor expression is upregulated upon Drosophila mitochondrial dysfunction.
Furthermore, the fact that its upregulation is also observed in flies expressing mitoXhoI
suggests that this response is conserved in other cases of mitochondrial dysfunction.
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Figure 5.1 Thor expression is upregulated in flies overexpressing TFAM
Expression of Thor-lacZ, measured by β-Gal immunostaining, in motor neurons in VNC of
control larvae (A-A’) and in larvae overexpressing TFAM (B-B’) using OK371-Gal4, CD8-GFP.
Quantification of Thor expression levels normalised to control is shown in (C) (Unpaired t-
test). Control n=21, TFAM overexpression n=16.  ***= p = ≤0.001.  The horizontal line in box
and whisker plots represents the median whilst whiskers represent the 5th and 95th
percentile. Control represents OK371-Gal4, CD8-GFP>WIII8.
Figure 5.2 Thor expression is upregulated in flies expressing mitoXhoI
Expression of Thor-lacZ, measured by β-Gal immunostaining, in motor neurons in VNC of
control larvae (A-A’) and in larvae expressing mitoXhoI (B-B’) using OK371-Gal4, CD8-GFP.
Quantification of Thor expression levels normalised to control is shown in (C) (Unpaired t-
test). Control n=18, mitoXhoI n=18.  ***=p=≤0.001.  The horizontal line in box and whisker
plots represents the median whilst whiskers represent the 5th and 95th percentile. Control
represents OK371-Gal4, CD8-GFP>WIII8.
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5.4.2. Ilp3 expression is downregulated in in vivo Drosophila models
of mitochondrial dysfunction
Microarray analysis on third instar larvae overexpressing TFAM or expressing ATPSyn-Cf6
dsRNA also revealed a downregulated expression of two Drosophila Ilps; Ilp1 (fold change =
0.607 in TFAM o/e and 0.711 in ATPSyn-Cf6 dsRNA) and Ilp3 (fold change = 0.681 in TFAM
o/e and 0.499 in ATPSyn-Cf6 dsRNA).
In order to validate these results in vivo, Ilp3 expression was measured in control larvae as
well as larvae overexpressing TFAM and expressing mitoXhoI under the control of an nSyb-
Gal4 driver. Ilp3 was found to be expressed in median neurosecretory cells and Ilp3-lacZ
levels were found to be significantly decreased in TFAM overexpressing (p=0.0012) and
mitoXhoI expressing larvae (p=<0.0001) compared to controls (Figure 5.3).
These results validate the data obtained by the microarray and also suggest that general
modes of mitochondrial dysfunction might trigger a downregulation of Ilp3 expression.
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Figure 5.3 Ilp3 expression is downregulated in flies overexpressing TFAM and flies expressing
mitoXhoI.
Expression of Ilp3-lacZ, measured by β-Gal immunostaining, in neurosecretory cells in CNS of control
larvae (A, D) and in larvae overexpressing TFAM (B) or expressing mitoXhoI (E), using nSyb-Gal4.
Quantification of Ilp3 expression levels in flies overexpressing TFAM normalised to control is shown
in (C) (Unpaired t-test). Control n=15, TFAM o/e n=20. **=p≤0.01. Quantification of Ilp3 expression
levels in flies expressing mitoXhoI normalised to control is shown in (F) (Unpaired t-test). Control
n=15, mitoXhoI n=15.  ***=p=≤0.001. The horizontal line in box and whisker plots represents the
median whilst whiskers represent the 5th and 95th percentile. In all cases, control represents nSyb-
Gal4>WIII8.
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5.4.3. Ilp3 expression is downregulated upon overexpression of sima.
Multiple genes which were found to be differentially regulated in the microarray analysis
are known targets of the transcription factor hypoxia inducible factor (HIF). HIF is a primary
sensor of cellular oxygen levels and regulates cellular responses to hypoxia, including an
upregulation of glycolytic processes (Majmundar et al., 2010). Impl3, a known HIFα target
which encodes LDH in Drosophila (Firth et al., 1995; Lavista-Llanos et al., 2002), was
upregulated in both TFAM overexpressing and ATPSyn-Cf6 dsRNA flies (Table 12).
Similar (sima) is the Drosophila orthologue of HIFα. I hypothesised that sima is playing a
role in the differential regulation of several genes in response to mitochondrial dysfunction.
Therefore, in order to assess whether sima is acting to induce the downregulation of Ilp3
upon mitochondrial dysfunction, nSyb-Gal4 was also used to monitor Ilp3-lacZ expression
in flies overexpressing sima.
This revealed that Ilp3 expression is also significantly downregulated in flies overexpressing
sima, (p = 0.0003, Figure 5.4) suggesting that the upregulation of sima upon mitochondrial
dysfunction is the trigger for a downregulated Ilp3 expression response.
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Figure 5.4 Ilp3 expression is downregulated upon overexpression of sima
Expression of Ilp3-lacZ, measured by β-Gal immunostaining, in neurosecretory cells in CNS of control
larvae (A) and in larvae overexpressing sima (B) using nSyb-Gal4. Quantification of Ilp3 expression
levels in flies overexpressing sima normalised to control is shown in (C) (Unpaired t-test). Control
n=18, sima o/e n=22.  ***=p=≤0.001. The horizontal line in box and whisker plots represents the
median whilst whiskers represent the 5th and 95th percentile. Control represents nSyb-Gal4>WIII8.
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5.4.4. Thor expression is upregulated upon overexpression of sima.
Since sima is a transcription factor, and since Thor was also upregulated in response to
TFAM overexpression and ATPSyn-Cf6 RNAi, it was of interest to investigate whether sima
might be the factor responsible for the upregulation of Thor in such conditions.
Thor expression was found to be highly significantly upregulated upon overexpression of
sima in Drosophila motor neurons (p = ≤0.001, Figure 5.5) suggesting that Sima acts to
upregulate the expression of Thor upon mitochondrial dysfunction.
Figure 5.5 Thor expression is upregulated in flies overexpressing sima
Expression of Thor-lacZ, measured by β-Gal immunostaining, in motor neurons in VNC of control
larvae (A-A’) and in larvae overexpressing sima (B-B’) using OK371-Gal4, CD8-GFP. Quantification of
Thor expression levels normalised to control is shown in (C) (Unpaired t-test). Control n=4, sima o/e
n=4.  ***=p=≤0.001. The horizontal line in box and whisker plots represents the median whilst
whiskers represent the 5th and 95th percentile. Control represents OK371-Gal4, CD8-GFP >WIII8.
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5.4.5. Knockdown of sima restores Thor expression to control levels in
flies overexpressing TFAM.
Since data described above suggested that sima might be the transcription factor involved
in upregulating Thor expression upon mitochondrial dysfunction, this hypothesis was also
tested in vivo by investigating how Thor expression is altered upon mitochondrial
dysfunction in Drosophila CNS in which sima is knocked down.
Downregulation of sima in sima RNAi flies appeared to have no effect on Thor expression,
as these flies exhibited similar levels of Thor expression as in controls, in VNC motor neuron
cell bodies. As previously stated, Thor expression was significantly upregulated in flies
overexpressing TFAM. However, when OK371-Gal4 was used to drive Thor-lacZ in flies
overexpressing TFAM and sima knock-down (OK371-Gal4,Thor-lacZ > Sima RNAi; UAS-
TFAM), these flies exhibited similar Thor expression levels to control flies, and to flies
expressing sima RNAi (p=≤0.001, Figure 5.6). Furthermore, Thor expression was
significantly reduced when compared to flies overexpressing TFAM (p=≤0.001, Figure 5.6).
This suggests that sima is necessary in order for Thor expression to be upregulated upon
mitochondrial dysfunction induced by TFAM overexpression.
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(Figure legend on next page)
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Figure 5.6 sima RNAi inhibits upregulation of Thor in TFAM overexpressing flies.
Expression of Thor-lacZ levels, measured by β-Gal immunostaining, in motor neurons in VNC of
control larvae (A-A’), in larvae expressing sima RNAi (B-B’), in larvae overexpressing TFAM (C-C’) and
in larvae expressing sima RNAi; TFAMo/e (D-D’) using OK371-Gal4, CD8-GFP. Quantification of Thor
expression levels normalised to control is shown in (E) (One-way ANOVA followed by Tukey’s
multiple comparison test). Control n=10, sima RNAi n=10, TFAM o/e n = 12, sima RNAi; TFAM o/e
n=13. ***= p =≤0.001.  The horizontal line in box and whisker plots represents the median whilst
whiskers represent the 5th and 95th percentile. Control represents OK371-Gal4, CD8-GFP >WIII8.
5.4.6. Knockdown of sima has no effect on Ilp3 expression flies
overexpressing TFAM.
Overexpression of sima in larval CNS tissue was found to result in a reduced expression of
Ilp3 in neurosecretory cells, suggesting that upregulated levels of sima induced upon
mitochondrial dysfunction could be responsible for the downregulated Ilp3 levels observed.
In order to further investigate the role of sima in the regulation of Ilp3 expression, the
nSyb-Gal4 driver was used to drive TFAM overexpression and sima knockdown in post-
mitotic neurons. The levels of the secreted peptide were then measured in the larval CNS
of larvae.
Ilp3 levels in flies expressing sima knockdown were found to be similar to controls.
Furthermore, the knockdown of sima bore no effect on the levels of Ilp3 expression in
larvae overexpressing TFAM, as Ilp3 expression was still significantly decreased when
compared to control (Figure 5.7).
This suggests that knockdown of sima alone is not sufficient to restore Ilp3 expression to
control levels in larvae with mitochondrial dysfunction.
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Figure 5.7 sima RNAi does not restore Ilp3 expression levels in flies overexpressing TFAM.
Expression of Ilp3-lacZ, measured by β-Gal immunostaining, in neurosecretory cells in CNS of control
larvae (A-A’), in larvae overexpressing TFAM (B-B’), in larvae expressing sima RNAi (C-C’), and in
larvae expressing sima RNAi; TFAMo/e (D-D’) using nSyb-Gal4. Quantification of Ilp3 expression
levels normalised to control is shown in (E) (One-way ANOVA followed by Tukey’s multiple
comparison test). Control n=37, TFAM o/e n = 32, sima RNAi n=27, sima RNAi; TFAM o/e n=29. *= p
≤0.05, **= p ≤0.01. The horizontal line in box and whisker plots represents the median whilst
whiskers represent the 5th and 95th percentile. Control represents nSyb-Gal4 >WIII8.
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5.4.7. Knockdown of sima partially rescues climbing and wing inflation
ability of flies overexpressing TFAM.
In Section 5.4.5, mitochondrial dysfunction in Drosophila was found to elicit an upregulated
expression of the cap-dependent translation inhibitor Thor, and the nuclear transcription
factor sima was required for this upregulation to occur. In order to assess whether sima is
also required for behavioural phenotypes exhibited upon mitochondrial dysfunction, the
climbing ability of flies overexpressing TFAM in a sima RNAi background was assessed.
Flies overexpressing TFAM in motor neurons, under the control of a D42-Gal4 driver,
exhibit a significantly reduced climbing ability (Figure 5.8A). Flies expressing sima RNAi,
exhibited no climbing phenotype and indeed climbed to similar distances as in control flies.
Interestingly, flies overexpressing TFAM and downregulated sima (sima832;TFAM o/e)
exhibited a significantly improved climbing ability when compared to TFAM overexpressing
flies. This suggests that functional sima is required for climbing ability to be compromised
in flies overexpressing TFAM, and furthermore this also suggests that knockdown of sima
partially rescues the locomotor defect observed upon mitochondrial dysfunction.
The D42-Gal4 driver used to assess climbing ability is also expressed in bursicon-secreting
neurons: crustacean cardioactive peptide (CCAP) neurons. The neuropeptide bursicon plays
an important role in wing maturation during the last stages of metamorphosis. CCAP
neurons activate the release of bursicon into the hemolymph during ecdysis, resulting in
wing inflation and hardening of the wing cuticle. Inability to release bursicon due to
inhibition of CCAP neuronal activity results in blocked wing inflation leading to adult wings
which remain folded (Luan et al., 2006; Vanden Broeck et al., 2013).
Overexpression of TFAM under the control of the D42-Gal4 driver resulted in a 54%
reduction of inflated wings, with 15% having a partial inflation defect (Figure 5.8B,D) and
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39% of wings being fully-folded (Figure 5.8B,E). Knockdown of sima in a TFAM
overexpression background, however, significantly restored wing inflation ability with 93%
of wings being inflated (Figure 5.8 B,C), 3% half-way inflated (Figure 5.8 B,D) and only 4%
which remained folded (Figure 5.8 B,E). This suggests that mitochondrial dysfunction
results in partial inhibition of CCAP neuronal activity which is restored upon knockdown of
sima.
Figure 5.8 sima RNAi restores climbing and wing inflation ability in flies overexpressing TFAM.
(A) Climbing ability in flies expressing sima RNAi, TFAM o/e, and sima RNAi; TFAM o/e compared to
control. n=13 for all. *=p=≤0.05, ***=p=≤0.001. The horizontal line in box and whisker plots
represents the median whilst whiskers represent the 5th and 95th percentile. (B) Graphical
representation of the proportion of flies with the different wing inflation phenotypes in control flies,
flies expressing sima RNAi, flies overexpressing TFAM and flies expressing sima RNAi whilst
overexpressing TFAM. (C-E) Representative images of flies with inflated wings (C), wings inflated half-
way (D) and folded wings (E). In all cases control represents D42-Gal4>WIII8.
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5.5. Discussion
In the final section of chapter 4, a microarray gene expression analysis showed that
mitochondrial dysfunction elicits a mitochondrial retrograde response in the Drosophila
larval nervous system. Amongst the genes differentially regulated upon mitochondrial
dysfunction were ones pertaining to the mTOR pathway. The expression of two Drosophila
insulin-like peptides, Ilp1 and Ilp3, was downregulated whilst the expression of the
Drosophila homologue of 4E-BP, Thor, was significantly upregulated suggesting that
mitochondrial dysfunction triggers nuclear transcriptional changes which result in a
downregulation of the mTOR pathway.
In order to validate this work in vivo, I investigated levels of Thor expression in motor
neuron cell bodies in the larval VNC and levels of Ilp3 expression in neurosecretory cells in
the larval CNS. Ilp3 was also expressed at low levels throughout the VNC, although not at
levels which were easily quantifiable.
5.5.1. The transcription factor sima mediates the downregulation of
the mTOR pathway upon mitochondrial dysfunction.
In section 5.4.1, mitochondrial dysfunction, induced via overexpression of TFAM or
expression of mitoXhoI, was shown to trigger an upregulation of Thor in Drosophila larval
motor neurons. Similarly, in section 5.4.2, expression levels of Ilp3 were found to be
significantly reduced in Drosophila overexpressing TFAM and expressing mitoXhoI, thereby
validating the microarray results in in vivomodels of mitochondrial dysfunction.
Since several of the genes which were found to be differentially regulated upon
mitochondrial dysfunction in the microarray were also transcription targets of the
transcription factor sima, the Drosophila homologue of HIF1α, I also investigated its
involvement in vivo. Overexpression of sima in an otherwise wild-type background resulted
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in downregulated levels of Ilp3 and upregulated levels of Thor, suggesting that sima is an
upstream inhibitor of the mTOR pathway.
The next step was therefore to further investigate whether sima is in fact responsible for
the differential regulation of Ilp3 and Thor in the context of mitochondrial dysfunction. The
knockdown of sima in larvae overexpressing TFAM resulted in Thor expression being
restored to control levels. Therefore, sima is necessary to trigger an upregulation of Thor in
response to mitochondrial dysfunction. Knockdown of sima was, on the other hand, not
sufficient to restore Ilp3 expression levels in larvae with mitochondrial dysfunction.
5.5.2. Sima knockdown is not sufficient to restore Ilp3 expression
levels upon mitochondrial dysfunction.
Eight insulin-like peptides and one insulin receptor (dInR) have been identified in
Drosophila (Fernandez et al., 1995; Brogiolo et al., 2001; Gronke et al., 2010; Colombani et
al., 2012; Garelli et al., 2012). Ilps 1, 2, 3 and 5 are secreted by the 14 brain insulin
producing cells (IPCs) in the larval central brain, in both a systemic and paracrine fashion,
acting to induce growth and differentiation (Geminard et al., 2009; Nassel et al., 2013).
The regulation of the secretion of the different Ilps in response to environmental and
systemic stimuli is not well elucidated. Certainly, Ilp release acts in response to nutrient
availability. After feeding, elevated glucose and amino acid levels in the circulation are
sensed by the fat body which, as a consequence, releases signals into the hemolymph.
These signals then reach the brain and the IPCs, which in turn regulate secretion of the Ilps
(Geminard et al., 2009). The expression and functionality of the different Ilps appears to be
quite complex and they appear to exert a certain degree of functional redundancy, with Ilps
compensating for each other’s expression levels. Furthermore, studies also suggest that Ilps
themselves might provide feedback onto the brain IPCs. Overexpression of Ilp6 has been
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shown to lead to reduced levels of Ilp2 and Ilp5 (Bai et al., 2012), whilst knockdown of Ilp2
leads to increased levels of Ilp3 and Ilp5mRNA (Broughton et al., 2008).
Therefore, since Ilp expression is regulated by a multitude of factors, it is not surprising that
knockdown of sima was not sufficient to restore Ilp3 expression upon mitochondrial
dysfunction. In order to better understand the consequences of Ilp regulation upon
mitochondrial dysfunction, one must investigate the expression levels of other Ilps to
identify any compensatory regulation. Furthermore, one must also note that feeding
behaviour was not monitored in the mitochondrial dysfunction models described in this
study. It would be of interest to investigate whether differential regulation of Ilp expression
is a direct consequence of mitochondrial dysfunction and regulation by sima, or whether
mitochondrial dysfunction is causing a disturbance to the feeding behaviour or to the
nutrient-sensing pathway to the IPCs, thereby indirectly causing a reduced Ilp3 expression.
Another important note to take into consideration is that the different Ilps expressed in the
IPCs are independently transcriptionally regulated.  Could different stress responses, such
as mitochondrial dysfunction, trigger a differential transcription regulation of one Ilp versus
the other? If this were the case would the differential regulation be beneficial because of a
particular affinity for the one known dInR, or could it be because the differentially
regulated Ilp could exert a function which is beneficial to the organism in response to the
insult?
5.5.3. Mitochondrial dysfunction triggers a downregulation of cap-
dependent mRNA translation
Overexpression of TFAM and knockdown of ATPSyn-Cf6 both triggered a transcriptional
upregulation of Thor, encoding Drosophila 4E-BP1, which was further shown to be
upregulated in vivo in response to expression of mitoXhoI. This suggests that mitochondrial
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dysfunction triggers a downregulation of the mTOR pathway resulting in downregulated
cap-dependent translation.
Under normal physiological conditions, activated mTOR will act to inhibit 4E-BP1 via
phosphorylation, which will allow for cap-dependent mRNA translation to proceed. If mTOR
is inhibited, 4E-BP1 will be hypophosphorylated, allowing it to bind to eIF4E, thereby
inhibiting the formation of the eIF4F complex which is required for protein synthesis
(Figure 5.9). Therefore, essentially, downregulation of the mTOR pathway and consequent
upregulation of active 4E-BP1, results in decreased protein synthesis.
Figure 5.9 Active mTORC1 phosphorylates 4E-BP, promoting 5’ cap-dependent mRNA translation
mTORC1 controls 4E-BP phosphorylation thereby regulating its binding to eIF4E. (A) When mTORC1
is active, it phosphorylates 4E-BP, rendering it unable to bind to eIF4E. EIF4E is therefore free to bind
to eIF4G, which upon binding with the other components, mitogen-activated protein kinase-
interacting kinase 1 (Mnk1), and the RNA helicase eIF4A, completes the eIF4F complex at the 5’ cap.
Translation is now able to be initiated. (B) When mTORC1 is inactive, 4E-BP becomes
hypophosphorylated and can bind to eIF4E. EIF4E is therefore now dissociated from the rest of the
eIF complex and translation cannot proceed (Buchkovich et al., 2008).
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How does this relate to the context of mitochondrial dysfunction in neurodegeneration? If
the initial retrograde response to mitochondrial dysfunction involves an upregulation of
sima and a subsequent downregulation of cap-dependent mRNA translation, one would
think that this is a stress response mechanism which aims to minimise activity which
requires a high degree of energy expenditure whilst maintaining a minimal neuronal
activity. Inhibition of this response via downregulation of sima, resulted in 4E-BP1 levels
being restored to control levels and rescue of climbing and wing inflation ability. Therefore
sima knockdown restores cap-dependent protein translation, whilst also promoting
locomotor activity as well as CCAP neuronal activity. Further work is required to
understand whether downregulation of HIF1α could be used therapeutically to treat
mitochondrial dysfunction in the context of neurodegeneration, or whether restoration of
an enhanced neuronal activity would actually be more harmful than beneficial in a
prolonged mitochondrial dysfunction scenario. This is further discussed in section 6.
217
6. Conclusions and general discussion
6.1. Summary of findings
The brain is the most energy demanding organ in the human body and is therefore highly
reliant on efficient mitochondrial function and ATP production. Mitochondrial dysfunction
is linked to an array of diseases and is commonly associated with neurodegenerative
diseases including AD and PD.
In this thesis, a SNP in mitochondrial transcription factor A, TFAM SNP rs2306604 A>G, is
shown to be associated with an increased risk of PD in males. Furthermore, this association
was even greater in males who were diagnosed with PDD. No such association was found
with DLB, a form of dementia which develops shortly after the onset of motor symptoms in
PD. This is the first study which reports a genetic association that might distinguish PDD
from DLB, and further confirms the importance of TFAM and mitochondrial function in
neuronal integrity.
In order to investigate the role of neuronal mitochondrial dysfunction in
neurodegeneration, TFAM overexpression and expression of the mitochondrially-targeted
restriction enzyme mitoXhoI, were used to induce mitochondrial dysfunction in Drosophila
melanogaster. Microarray gene expression analysis revealed that mitochondrial
dysfunction in third instar larvae post-mitotic neurons triggered a mitochondrial retrograde
response. This response included a metabolic shift demonstrated by upregulated glycolysis
as well as a downregulation of the mTOR pathway, resulting in elevated expression of the
cap-dependent translation repressor 4E-BP1. The transcription factor HIF1α was found to
play a critical role in modulating the mTOR pathway response; HIF1α knockdown restored
4E-BP1 expression to control levels and rescued climbing and wing inflation phenotypes,
following mitochondrial dysfunction.
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In conclusion, mitochondrial dysfunction in Drosophila triggers a mitochondrial retrograde
response which induces a downregulation of cap-dependent mRNA translation, modulated
by the transcription factor HIF1α.
6.2. General discussion
Parkinson’s disease (PD) is a devastating neurodegenerative disease that affects 1 in 20
people over the age of 85. It is characterised by reduced motor function due to a
dopaminergic deficit in the substantia nigra. PD patients however, also exhibit a set of non-
motor symptoms including cognitive decline, which may lead to PDD in approximately 80%
of cases (Buter et al., 2008). To date, there is no known cure for PD or PDD and the
treatments available are solely symptomatic.
PDD symptoms show considerable similarity to those exhibited in another form of
dementia, dementia with Lewy bodies (DLB). The two are in fact commonly misdiagnosed
at clinical presentation, and there is little known regarding factors which may differentiate
between the two. Currently, the two dementia forms are distinguished primarily based on
the temporal onset of cognitive decline in relation to motor symptoms. This ‘one year rule’
diagnosis, as it is commonly known, states that patients who exhibit cognitive decline
within the same year of motor symptoms are diagnosed as having DLB, whilst those who
exhibit cognitive decline at a later stage are classified as PDD patients (McKeith, 2006).
As in other neurodegenerative diseases, several studies provide evidence of mitochondrial
dysfunction contributing to the onset and progression of PD. Perhaps the most convincing
piece of evidence is the decrease in activity of ETC complex I which has been repeatedly
observed in PD patients (Parker et al., 1989; Schapira et al., 1990a; Shoffner et al., 1991).
However, not much is known regarding the role of mitochondrial dysfunction during the
onset of cognitive decline in PD patients and whether mitochondrial function is
differentially affected in PDD compared to DLB.
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Autere and colleagues have provided evidence that polymorphisms in mtDNA-encoded
Complex I genes may exert a susceptibility to PD, but that this risk is mostly dependent on
the number of non-synonymous substitutions in these genes in the various mtDNA lineages
(Autere et al., 2004). They found that there is a greater presence of non-synonymous
substitutions in mtDNA-encoded Complex I genes in the haplogroup supercluster JTWIX
compared to other clusters and that this group exhibits an increased risk of PD and
advancement to PDD. In fact, this study revealed a greater number of amino acid
replacements in these genes in the JTWIX group which may lead to a greater decline in
Complex I activity and an increased risk of progression of PD onto PDD. Furthermore, in
mtDNA, polymorphisms are routinely accompanied by other polymorphisms. Therefore,
the increased risk of pathology could be due to a combination of polymorphisms occurring
together rather than directly due to a single mutation. In fact, there are several lines of
evidence which show that combinations of otherwise harmless individual mtDNA
polymorphisms in a particular lineage may increase susceptibility to complex diseases when
present together (Wallace et al., 1999; Chinnery et al., 2000; Ruiz-Pesini et al., 2000).
MtDNA works in conjunction with the nuclear genome to maintain cellular hometostasis.
Therefore, coordinated interplay between mitochondrial and nuclear factors is
indispensable for functional mitochondrial activity. Several studies have also assessed the
risk attributed to polymorphisms in nuclear genes which have roles in mitochondrial
function and biogenesis including the transcription factor TFAM. Studies discussed all
throughout this thesis have highlighted the necessity of TFAM for efficient mitochondrial
function. Homozygous TFAM mutant mice, which were devoid of mtDNA, died in utero in a
1998 study carried out by Larsson and colleagues (Larsson et al., 1998). Therefore, it is not
surprising that no pathogenic TFAM mutations have been identified in AD or PD patients.
One would assume that mutations in such a crucial factor for mtDNA stability would lead to
much earlier symptoms, and presumably earlier lethality. Any alterations in TFAM
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associated with AD and PD must therefore only result in a weak functional consequence, as
individuals carrying the mutation would have survived well into adulthood with relatively
efficient mitochondrial function.
A SNP in intron 4 of the TFAM transcript, TFAM SNP rs2306604 A>G has, however, been
shown to be significantly associated with a higher risk of AD (Bertram et al., 2007; Laumet
et al., 2010). Results obtained from studies of this SNP in association with PD, however,
have not been very robust; GWAS and meta-analysis have found no association of the SNP
with an increased risk of PD, (Belin et al., 2007; Alvarez et al., 2008b; Pankratz et al., 2009;
Simon-Sanchez et al., 2009; Lill et al., 2012) whilst one study suggested that rs2306604 G/G
is an independent risk factor for PD (Gaweda-Walerych et al., 2010). The study presented
in this thesis is the first reported investigation of the association of TFAM rs2306604 A>G
with PD and PDD.
Results presented in Chapter 2 suggest that this SNP exhibits significant association with PD
in males but not in females, and that it is the A/A genotype that presents itself as the risk
factor for disease development, as is found in AD cases. Furthermore, results obtained
from this cohort study suggest that the association is much greater in PDD patients with
the rs2306604 A>G SNP being much more strongly associated in PDD males than controls.
This association was not significant in DLB cases. Therefore, this study is the first to imply
there might be genetic polymorphisms which might distinguish PDD from DLB. This
suggests that there might be a genetic predisposition which plays a role in determining the
temporal onset of cognitive decline following presentation of motor symptoms.
It is important to note that this study does not take into account mtDNA genetic
background of the cohort cases. As discussed above, mtDNA lineages are important in
determining mitochondrial function as well as affecting the expression of nuclear genes
which regulate mitochondrial function, such as TFAM. Therefore, additional study is
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required to investigate whether the fact that TFAM SNP rs2306604 A>G is associated with
PDD but not with DLB is due to an underlying difference in mtDNA background, or whether
it is a distinguishing feature which is independent of mtDNA lineage.
Additionally, studies have suggested that the combined presence of TFAM rs2306604 SNP
G/G and parkin variant, PARK2 G/G V380L present an increased risk of PD in a
mitochondrial HV cluster background (Gaweda-Walerych et al., 2010; Gaweda-Walerych et
al., 2012). Again, this confirms that there are multiple factors which are to be taken into
account when analysing SNP genetic associations and there might be a multitude of factors
which contribute to the result obtained in this study. Unfortunately, due to unavailability of
additional information, the association study was thereby limited to the data presented in
chapters 2 and 3.
PDD patients in the cohort studies also had a significantly lower mtDNA copy number in the
pre-frontal cortex compared to controls, and this mtDNA reduction was even greater than
in PD patients. This was an interesting finding, considering that little is known regarding the
role of mtDNA copy number in PD progression to PDD. A reduction in mtDNA levels in the
prefrontal cortex is similarly observed in AD cases (Rodriguez-Santiago et al., 2001). This
further supports the hypothesis that AD and PDD exhibit similar neuropathological
characteristics and that mitochondrial dysfunction in this brain region might be indicative
of a general form of cognitive decline.
Interestingly, we found no association between mtDNA copy number and rs2306604
genotype in the cohort used, suggesting that TFAM SNP rs2306604 A>G does not influence
mtDNA copy number. TFAM SNP rs2306604 A>G was also found to bear no effect on
mitochondrial-associated protein levels. According to the statistical analyses used, any
changes observed in these parameters were purely due to the different diagnosis and not
due to the rs2306604 genotype of the individual. Alternatively, such an association might
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exist but is not traceable utilising the methods we used for measurement of mtDNA copy
number and protein levels. Analysing levels in whole brain tissue homogenate in fact, might
have provided misleading results as it could be diluting an effect, thereby masking an
association. Measurement of mtDNA and protein levels in individual neurons from the
prefrontal cortex might provide a clearer identification of such an association.
Previous studies have suggested that the presence of this SNP could lead to an alternative
splice form of TFAM, leading to the generation of a truncated 22kDa form of the protein.
Western blot analysis carried out in this thesis only revealed the presence of the mature
24kDa form of the protein, suggesting that this truncated form is not present within any of
the cohort cases, or that it is not traceable using the technique we utilised, as discussed in
section 3.5.3. The functional consequences of in vivo presence of TFAM SNP rs2306604 A>G
therefore remain unknown.
It is important to note that PD pathogenesis may result from a particular genetic
predisposition, environmental factors as well as changes associated with ageing.
Mitochondrial dysfunction is only one of the molecular mechanisms associated with PD.
Inflammation, impairment of the ubiquitin-proteosome system, impairment of the protein
folding system and abnormalities in cellular transport are additional mechanisms which are
associated with PD and which could equally contribute to disease progression.
Individual association studies may bring something new to the field in terms of uncovering
new potential therapeutic avenues and identifying genetic risk factors. However, in order
for robust reliable statistical power to be inferred from these studies, there needs to be a
much greater case number utilised. Furthermore, the need for exhaustive clinical,
demographic and lifestyle information is imperative. Recent studies have highlighted that
caffeine intake, smoking and exposure to mitochondrial toxins might all be contributing to
risk of the disease. It would therefore be crucial to have such information available as it
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could shed light on confounding factors that might be interfering with the results obtained
from the study. As argued by Gaweda-Walerych et al., a holistic approach, comprising all of
the factors available, including mitochondrial dynamics and bioenergetic data, oxidative
stress information, as well as a clearly understood mtDNA genetic background, would be
the best way of carrying out and interpreting association studies (Gaweda-Walerych and
Zekanowski, 2013). This might be the only way to ultimately determine whether specific
genetic variants might be causing a susceptibility to PD or PDD risk and whether their
identification could be useful in establishing methods of therapy that are based on these
genetic markers. Therefore, I propose that a higher number of cases as well as more
comprehensive medical history information would be required to further extend the study
outlined in this thesis, and to better apprehend the involvement of TFAM SNP rs2306604
A>G in different forms of neurodegeneration.
Ultimately, human post-mortem tissue studies serve to obtain correlative data and
determine genetic associations. In vivo models are required to better understand the role
of mitochondrial biogenesis, dynamics and overall function in the progression of the
disease. Indeed, mitochondrial dysfunction has been investigated in several
neurodegenerative disease models, which have been covered in detail in sections 1.10 and
1.12. However, the initial response of neurons to mitochondrial dysfunction and the
downstream mechanism which elicits neuronal death is still not well understood. Since
mitochondrial dysfunction and synapse loss appear to be early hallmarks of
neurodegenerative disease, mitochondria might well be an efficient therapeutic target. If
mitochondrial dysfunction is an early symptom that might lead to a downward spiral, then
trying to understand this mechanism could uncover the truth behind the process of
neurodegeneration.
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Recently generated mouse models of mitochondrial dysfunction include the MitoPark
mouse, in which TFAM is conditionally knocked out in dopaminergic neurons. This animal
exhibits adult-onset parkinsonian phenotypes including loss of motor ability and tremors,
neuronal loss in the substantia nigra, as well as intraneuronal inclusions (Ekstrand et al.,
2007). Similarly, the expression of a mitochondrially targeted endonuclease – mito-PstI in
mouse dopaminergic neurons, generated parkinsonian like phenotypes. As in mitoPark
mice, motor ability was reduced, dopamine levels were reduced and there was neuronal
loss in the substantia nigra (Pickrell et al., 2011). Furthermore, both models exhibited
reduced levels of mtDNA copy number.
TFAM is a major regulator of mtDNA transcription and replication, which controls mtDNA
copy number in cells. As discussed in section 1.7.2, TFAM binds to mtDNA and is
responsible for its bending into a particular conformation, and ratios of TFAM to mtDNA
are particularly important in maintaining optimal efficiency of transcription and replication
of the genome. MtDNA decline is generally observed upon TFAM knockdown, consistent
with the fact that TFAM is required for mtDNA transcription and replication. Subsequently,
studies have shown that TFAM overexpression might attenuate certain mitochondrial
dysfunction phenotypes observed in neurodegenerative disorders. For example, TFAM
overexpression has been shown to reduce oxidative damage induced by β-amyloid
treatment in SH-SY5Y cells (Xu et al., 2009).  Similarly, in a mouse model of ALS,
overexpression of human TFAM was found to reduce oxidative stress and motor neuron
cell death and generally delayed onset of disease (Morimoto et al., 2012).
However, as previously argued, the beneficial aspects of TFAM overexpression are highly
dependent on cell type, model organism and most importantly on an efficient balance of
TFAM to mtDNA. Studies have shown that TFAM overexpression in mice results in an
increased proportion of mtDNA deletions and reduced respiration in muscle and heart
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tissue (Ylikallio et al., 2010). Consistent with these findings, data presented in this thesis
suggests that excess TFAM in Drosophila does not alter mtDNA copy number, however, it
does result in the suppression of mitochondrial gene expression, as levels of a
mitochondrial-encoded protein were significantly reduced. As also previously argued
(section 4.5.1), one must note that due to the highly dynamic nature of mitochondrial
processes, the over-expression of several mitochondrial proteins could result in an
alteration of mitochondrial gene expression. Therefore, a caveat of this study is that no
‘unreactive’ mitochondrial-targeted control was used to validate this tool. The expression
of mitochondrial-targeted constructs such as mitoGFP or other mitochondrial proteins,
could help determine whether the mitochondrial dysfunction observed is due to alterations
of TFAM or whether it is simply due to alterations in the general balance of mitochondrial
proteins.
In this thesis, an additional tool for inducing mitochondrial dysfunction - expression of a
mitochondrially-target restriction enzyme mitoXhoI, which cuts mtDNA at the CoI site,
resulted in linearization of mtDNA. MtDNA undergoes transcription as two polycistronic
mRNAs. Therefore, linearization of the genome leads to reduced transcription of
mitochondrially-encoded genes, leading to mitochondrial dysfunction.
In order to better understand the initial role of mitochondrial dysfunction in
neurodegeneration at the cellular and functional level, we triggered mitochondrial
dysfunction specifically in Drosophila motor neurons and investigated the NMJ, which has
been repeatedly praised as the ideal structure for studying synaptic mechanisms (Katz,
1996; Ribchester, 2009). Overexpression of TFAM and expression of the mitochondrially-
targeted restriction enzyme mitoXhoI, resulted in a severe loss of mitochondria at the
synapses and behavioural defects. A third model of mitochondrial dysfunction, knockdown
of coupling factor 6 of ATP synthase, which targets the respiratory chain, was also utilised.
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Microarray gene expression analysis on larvae overexpressing TFAM and ATPSyn-Cf6 dsRNA
revealed a differential regulation of hundreds of nuclear genes. Approximately half of the
genes that were differentially regulated differed depending on whether mitochondrial
dysfunction was induced by overexpression of TFAM or knockdown of ATPSyn-Cf6. This
confirmed that different forms of mitochondrial dysfunction do affect nuclear gene
expression differently. A previous study, investigating changes in nuclear transcription
upon mtDNA loss (ρo cells) or the presence of a 3243 A>G mutation also identified
differences in the retrograde response depending on the specific mitochondrial insult
(Jahangir Tafrechi et al., 2005). Similarly, a later study also identified a differential response
in transcription dependent on a 3243 A>G mutation load in mtDNA, which is a mutation
associated with maternally inherited diabetes and deafness (MIDD) as well as the
neuromuscular MELAS syndrome (van den Ouweland et al., 1992; Jacobs, 2003). The study
found that nuclear gene expression changes differently according to mtDNA 3243A>G
heteroplasmy in transmitochondrial cybrids (Picard et al., 2014). The possibility of
interference due to previously discussed issues of karyotype instability in cybrids (section
1.12.1) was excluded for several reasons. Firstly, changes in cybrid nuclear DNA genes were
non-random in relation to mtDNA 3243A>G heteroplasmy. Secondly, transcriptional gene
expression phases were found to be independent of clonal origins of the 143B (TK-) nuclei.
Lastly, the 3243G heteroplasmic mtDNAs were transferred from 143B (TK-) cybrids into SH-
SY5Y neuroblastoma cybrids and similar gene expression profiles were obtained (Picard et
al., 2014). Similar to findings obtained in the Picard study, differences in compensatory
retrograde response have also been reported depending on which components of the TCA
cycle are mutated in yeast (McCammon et al., 2003). Together with my work, these studies
confirm that different forms of mitochondrial dysfunction do affect nuclear gene
expression differently.
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The microarray carried out in this study, however, revealed that there was also a set of 142
genes which were commonly differentially regulated, suggesting that there is a series of
genes whose regulation is commonly conserved in different cases of mitochondrial
dysfunction. I therefore focused on identifying this conserved mitochondrial retrograde
mechanism.
Analysis of the microarray data revealed a conspicuous upregulated expression of glycolytic
genes in response to both forms of mitochondrial dysfunction. As discussed in section
4.5.3, this is a commonly reported phenomenon that has been observed in yeast,
Drosophila and mammalian systems, and is a method by which the organism compensates
for loss of mitochondrial activity by shifting from oxidative phosphorylation to aerobic
glycolysis. Additionally, differential regulation of the Insulin-like growth factor 1
receptor/mechanistic target of rapamycin (IGF-1/mTOR) pathway was also apparent, with
mitochondrial dysfunction causing a downregulated expression of two of the eight Ilps; Ilp1
and Ilp3 and an upregulation of the mTOR downstream factor, Thor, the Drosophila
homologue of 4E-BP1.
In yeast, the organism most thoroughly studied in respect to mitochondrial retrograde
signalling, mTOR complex 1 (mTORC1) is known to be inactivated in response to
mitochondrial dysfunction. Indeed, recruitment of retrograde factors RTG1, RTG2 and RTG3
inhibits mTOR signals, downregulating the pathway activity. An additional study carried out
in yeast has shown that treatment with a protonophore or mutations in the mitochondrial
genome trigger a downregulation of mTORC1 (Kawai et al., 2011). Several further studies
have demonstrated a link between the TOR pathway and RTG proteins (Komeili et al., 2000;
Dilova et al., 2002; Dilova et al., 2004; Giannattasio et al., 2005), including a 2010 study
which thoroughly investigated the mTORC1 interaction network in yeast, and established
several links with the mitochondrial retrograde pathway (Breitkreutz et al., 2010). mTOR
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signalling is a highly conserved pathway and its inactivation upon mitochondrial
dysfunction is indicative of evolutionary conservation in the mitochondrial retrograde
signalling pathway.
mTOR signalling plays a key role in protein synthesis, cell growth, synaptic plasticity and
function, and is a key player in maintaining cellular homeostasis. However, mTOR
hyperactivity is known to be detrimental and causes cognitive decline in several animal
models (Ehninger et al., 2008; Puighermanal et al., 2009; Ehninger, 2013). Indeed, diabetes,
known to cause an increase in mTOR activity, is known to be a risk factor for AD, via an
mTOR mediated mechanism (Ma et al., 2013b; Orr et al., 2014). Additionally, mTOR
signalling has been found to be elevated in AD patients, and increased mTOR activity has
also been shown to increase tau levels and phosphorylation in Drosophila and mice
(Khurana et al., 2006; Caccamo et al., 2013; Tang et al., 2013). A recent study carried out on
an AD mouse model has identified that a reduction in mTOR signalling restores gene
expression to wild-type levels in the mouse hippocampus as well as reducing Aβ aggregates
and improving memory function (Caccamo et al., 2014). Indeed accumulation of Aβ is
sufficient to cause an increase in mTOR activity (Caccamo et al., 2011). Additional studies
have also shown that treatment with Rapamycin, an mTOR inhibitor, alleviates AD
symptoms in animal models (Harrison et al., 2009; Spilman et al., 2010). What’s more,
reduction in mTOR activity is thought to cause an increase in lifespan in several animal
species (Lamming et al., 2013). A recent report has also identified that a reduced activity of
the mTOR downstream factor, eukaryotic initiation factor 2 α-subunit (eIF2α) ameliorates
AD-like pathology and improves memory (Ma et al., 2013a; Caccamo et al., 2014). Similarly
in 2009, Tain et al., showed that overexpression of Thor can suppress dopaminergic
degeneration in a Drosophila model of Parkinson’s disease, leading the authors to suggest
that pharmacological stimulation of 4E-BP activity could be a potential therapeutic strategy
against PD (Tain et al., 2009).
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Taken together, these findings suggest that downregulation of mTOR and reduction in
protein translation might be a neuroprotective mechanism which could be an initial
response to mitochondrial dysfunction, as an attempt to protect against neuronal death.
Does this neuroprotective mitochondrial retrograde response fail in a longterm scenario of
mitochondrial dysfunction, resulting in a hyperactivity of the mTORC1 pathway, leading to
neurodegeneration symptoms and consequent neuronal death? Additionally, what are the
transcription factors responsible for modulating this initial response, including the
downregulation of the mTORC1 pathway?
Mitochondrial retrograde studies carried out in yeast identified Rtg1 and Rtg3 as
transcription factors which regulate this response (Butow and Avadhani, 2004). However,
these factors are not conserved in other species. In mammalian cells, mitochondrial
dysfunction activates a series of transcription factors including nuclear factor of activated
T-cells (NFAT), CAAT/enhancer binding protein δ (C/EBPδ), cAMP-responsive element
binding protein (CREB), and a novel IκBβ-dependent nuclear factor κB (NFκB) c-Rel/p50
(Amuthan et al., 2001; Biswas et al., 2005; Guha et al., 2007). In this study I have identified
sima, the Drosophila ortholog of HIF1α, as a transcriptional regulator of the mitochondrial
retrograde response, which was found to be required for the downregulation of Ilp3 and
the upregulation of Thor upon mitochondrial dysfunction. Additional studies have also
implicated HIF1α in the regulation of mRNA translation (Wouters et al., 2005; Koritzinsky et
al., 2006; Liu et al., 2006). In conditions of hypoxia which stimulate HIF1α, protein synthesis
is reduced, via an upregulation of 4E-BP, in preference to an upregulation of stress-
combating techniques which includes an upregulation of chaperones, antioxidants and
transcription factors (Lin et al., 2014). Furthermore, when PINK1 is recruited to
mitochondria in response to mitochondrial dysfunction, 4E-BP1 levels are upregulated and
this occurs via activation of HIF1α (Lin et al., 2014).
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There are several reasons which justify the proposition of HIF1α as an important
transcription factor mediating the mitochondrial retrograde response. Firstly, oxygen is the
final electron acceptor in the mitochondrial ETC, and HIF1α activity is based upon levels of
ambient oxygen. Therefore, it makes sense that HIF1α responds upon changes in
mitochondrial efficiency. Secondly, HIF1α controls the expression of cytochrome oxidase
genes which comprise complex IV of the ETC. Lastly, HIF1α plays a major role in regulating
glycolytic activity and indeed, HIF1α is known to upregulate several glycolytic genes
including Impl3 expression, a gene encoding for lactate dehydrogenase, which is also
upregulated in the microarray analysis described in this thesis (Bruick and McKnight, 2001;
Freije et al., 2012).
It is important to note that studies have implicated a role of HIF1α in regulating
mitochondrial ROS signalling (Majmundar et al., 2010; Young and Simon, 2012).
Contrastingly, other studies suggest that there are additional ROS-responsive pathways
which act in initiating a mitochondrial retrograde response that are independent of HIF1α
(Chae et al., 2013). Furthermore, other studies have suggested that conversely,
mitochondria are important regulators of HIF1α stability by regulating intracellular oxygen
availability, and that mitochondrially-generated ROS are an important redox signal
integrating mitochondrial function with the rest of the cell (Murphy, 2009). A study
published by Chandel et al., in 1998 was the first to report that HIF1-DNA binding and
consequent HIF1 mediated transcription requires mitochondrial generated ROS (Chandel et
al., 1998). A later study, reported in 2007 further showed that ROS generated by
mitochondrial ETC complex III is required for the transduction of a hypoxia signal and for
stabilisation of HIF1α (Bell et al., 2007). This study also suggested that mitochondrial
oxygen consumption plays no role in modulating the hypoxic signal. A later in vitro study,
however, found contrasting evidence to the Bell study, showing that ETC inhibitors
targeting different complexes of the respiratory chain decreased HIF1α stability to a similar
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degree (Chua et al., 2010). Furthermore, the study found that there was no effect on HIF1α
when ROS levels were increased or decreased, and that re-establishing mitochondrial
oxygen consumption upon inhibition of complex III restored HIF1α stabilisation (Chua et al.,
2010). The study therefore concluded that mitochondrial oxygen consumption rate is the
main determinant of HIF1α stability in hypoxic conditions.
As stated in section 4.4.3, most glutathione was present in a reduced state in the
mitochondrial matrix of the described models of induced mitochondrial dysfunction,
compared to a wildtype scenario. Further work will be required to determine whether ROS
are acting as a retrograde signal in this system. The results outlined in chapter 5 of this
thesis confirm the role of HIF1α in mediating the mitochondrial retrograde response,
suggesting that HIF1α could be modulating the mitochondrial retrograde pathway
independent of any alterations in ROS levels. Alterations in HIF1α stability might therefore
be due to alterations in mitochondrial oxygen consumption, as suggested by Chua et al.
(Chua et al., 2010).
Knockdown of sima in flies having mitochondrial dysfunction was found to inhibit the
mitochondrial retrograde response which triggers downregulation cap-dependent mRNA
translation. Furthermore, sima knockdown also rescues climbing ability and wing inflation
phenotypes in the context of mitochondrial dysfunction. This suggests that knockdown of
sima restores motor neuronal and CCAP neuronal activity. Surely, this implies that sima
knockdown is neuroprotective and should be investigated as a potential avenue for
therapeutic treatment of neurodegeneration. However, one must also keep in mind that
increased neuronal activity and restoration of cap-dependent translation might not be
energetically sustainable in the long term. Therefore, if mitochondria continue to be
dysfunctional for a prolonged period of time, there needs to be a mechanism which is able
to counteract this dysfunction for the same timeframe. If the stress response mechanism is
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only beneficial in the short term, then this is what ultimately leads to neuronal death
occurring anyway.
It is unknown, however, how does this metabolic switch triggered by HIF1α would apply to
the neurodegenerative diseases that are associated with mitochondrial dysfunction. The
SNpc, predominantly affected in PD, appears to be more energy-dependent than other
brain areas and is richer in metabolism-related and mitochondrial-associated genes. The
Snpc also expresses more hypoxia-related genes (Lin et al., 2014). Therefore, in the case of
PD, is this brain region more sensitive to a bioenergetic deficit? This might suggest that the
SNpc is particularly responsive to mitochondrial dysfunction, and subsequent alterations in
HIF1α levels. This strengthens the need of further investigation into the potential role of
HIFα as a therapeutic agent for PD and other neurodegenerative diseases.
Considering the multi-branched nature of the mTOR pathway and its many inputs and
outputs and considering the heterogeneity of the mitochondrial network, it is not
surprising that variations and different degrees of mitochondrial dysfunction lead to a great
variety of symptoms and pathologies and that this also suggests a probable variation in
retrograde triggers. Therefore, the role of mTORC1 in mitochondrial dysfunction is
probably not a clear cut process – the downregulation of translation might be an instinctual
sudden stress response which might be altered over time with possibly elevated levels of
mitochondrial dysfunction. Additionally, as previously argued, mtDNA and nuclear DNA
background play a huge role in determining the retrograde response to mitochondrial
dysfunction, thereby adding additional parameters to take into consideration and further
complicating the process.
Ultimately, the mitochondrial retrograde response is a highly complex process. Therefore,
while some aspects might be conserved in the different neurodegenerative disorders,
others might vary greatly depending on the individual and the degree of mitochondrial
233
dysfunction. It is therefore imperative for more research to be carried out to better
understand what factors are required to initiate this retrograde response, and how its
activation or inhibition could worsen or alleviate symptoms pertaining to diseases which
are associated with mitochondrial dysfunction.
6.3. Future directions
This thesis presents convincing evidence which further supports a role of mitochondrial
dysfunction in neurodegeneration. However, additional work is required to better
understand the mechanisms underlying all aspects of the studies outlined. Brief
descriptions of the future work which I deem to be required for this purpose are listed
below.
1. Measuring mitochondrial-associated protein levels and Complex I activity, and
associations with TFAM SNP rs2306604 A>G, in other brain regions apart from the pre-
frontal cortex.
2. Investigating the frequency of TFAM SNP rs2306604 A>G in additional PD and PDD cases,
which would strengthen the statistical power of any significant associations.
3. Investigating the presence of TFAM SNP rs2306604 A>G in PD and PDD, in combination
with additional polymorphisms. This would help to further elucidate whether the presence
of TFAM SNP rs2306604 A>G as a lone polymorphism is sufficient to induce greater risk for
PD and PDD, or whether the risk is increased by a combination of polymorphisms.
4. Polysomal profiling at different developmental stages in Drosophila mitochondrial
dysfunction would need to be carried out in order to follow changes in mRNA translation
upon mitochondrial dysfunction. Additionally, this assay could be used to investigate
alterations in mRNA translation rates upon inhibition of the mitochondrial retrograde
response by sima knockdown.
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5. HIF1α acts in combination with HIF1β to form a heterodimeric complex which binds to
hypoxia responsive elements in the genome, in response to hypoxia. It would be of interest
to investigate whether Tango, the Drosophila homologue of HIF1β, is also required in
modulating the mitochondrial retrograde response. Monitoring of Thor-lacZ expression
upon knockdown or overexpression of tgo would indicate its requirement on mRNA
translation regulation. Similarly, climbing and wing inflation assays would indicate the
effect of altering tgo expression levels on neuronal activity.
6. Since neurodegeneration is an age-related process, it would be important to establish
the role of sima in aged fly models of mitochondrial dysfunction compared to aged wild-
type control flies. Lifespan assays would need to be carried out in order to investigate
whether knockdown of sima, and subsequent upregulated mRNA translation and neuronal
activity, ameliorates or aggravates health-span. Furthermore this would help to better
establish the role of the mitochondrial retrograde mechanism throughout ageing and
progression of disease, and could outline different coping mechanisms in the larval and
adult stages of the fly models. This could shed some light on different metabolic responses
to initial versus prolonged mitochondrial dysfunction.
7. How does HIF1α involvement in the mitochondrial retrograde mechanism translate in
human examples of neurodegeneration? One way of investigating this, is to carry out
western blot analysis on PD and PDD cases and analyse protein levels of 4E-BP1 and HIF1α.
Unfortunately, this would only provide information about levels of these proteins of
interest at the progressive end of the disease; however, it would still be of major interest to
observe whether there are significant changes in these protein levels upon progression
from PD to PDD.
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8. An investigation into the mechanism underlying the mitochondrial retrograde response
upon mitochondrial dysfunction in the CNS. Use of a genetic screen in vitro as well as in
vivo in Drosophila could identify novel regulators of this retrograde response.
9. Finally, I conclude that investigating the effects of alterations in HIF1α levels on the
mitochondrial retrograde signalling pathway in rodent models of mitochondrial
dysfunction, would be the next step in unfolding this mechanism in a mammalian system.
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Appendix 1. Full list of demographic and clinical information of cases

















096/02 Y Control M 87 AG
101/97 Y Control F 83 A
122/94 Y Control F 72 AG
123/03 Y Control M 64 0 0 AG
144/94 Y Control F 86 A
161/00 Y Control M 60 AG
163/90 Y Control F 91 A
178/95 Y Control F 63 G
181/94 Y Control M 75 G
185/04 Y Control M 80 1 A
185/96 Y Control M 87 A
188/96 Y Control F 82 A
191/94 Y Control F 94 AG
196/94 Y Control M 95 AG
288/99 Y Control F 62 G
64/96 Y Control F 72 1 G
843/84 Y Control M 76 AG
922/88 Y Control F 84 AG
96/02 Y Control M 87 AG
97/97 Y Control M 72 1 A
A011/06 Y Control F 82 0 2 AG
A047/02 Y Control F 87 A
A048/09 Y Control M 81 G
A049/03 Y Control M 79 AG
A063/10 Y Control F 90 AG
A124/04 Y Control M 59 AG
A133/95 Y Control M 85 G
A134/00 Y Control M 86 0 2 AG
A136/10 Y Control F 89 G
A145/02 Y Control M 55 AG
A153/01 Y Control M 71 0 0 AG
A153/04 Y Control M 71 AG
A170/00 Y Control F 68 0 0 AG
A185/04 Y Control M 80 1 4 A
A219/97 Y Control F 76 0 0 A
A223/96 Y Control M 80 0 0 AG
A239/03 Y Control M 78 0 1 G
A239/95 Y Control F 79 1 3 AG
A283/96 Y Control M 77 0 1 AG
A308/09 Y Control M 66 AG

















A316/95 Y Control M 80 0 1 G
A33/96 Y Control F 96 0 2 A
A359/08 Y Control F 80 AG
A401/97 Y Control M 85 0 3 G
A47/02 Y Control F 87 0 0 A
A61/96 Y Control M 65 0 0 AG
A94/95 Y Control F 80 0 1 A
P001 N Control F 81 AG
P002 N Control F 74 AG
P003 N Control M 74 A
P004 N Control M 77 AG
P005 N Control F 84 AG
P006 N Control F 70 G
P007 N Control M 82 G
P008 N Control F 76 AG
P009 N Control F 70 G
P010 N Control M 76 G
P011 N Control F 90 AG
P012 N Control F 70 G
P014 N Control F 84 A
P015 N Control F 71 AG
P016 N Control M 76 G
P017 N Control M 83 AG
P018 N Control F 82 A
P019 N Control F 69 AG
P020 N Control M 84 AG
P022 N Control F 75 AG
P023 N Control M 73 AG
P024 N Control F 86 A
P025 N Control M 73 G
P026 N Control M 75 AG
P027 N Control F 84 AG
P028 N Control F 79 A
P029 N Control M 72 AG
P030 N Control M 82 AG
P031 N Control M 80 A
P032 N Control F 73 AG
P033 N Control M 72 AG
P034 N Control F 71 AG
P035 N Control F 70 AG

















P037 N Control F 87 G
P038 N Control F 73 AG
P039 N Control M 68 AG
P040 N Control F 67 AG
P041 N Control F 83 A
P042 N Control F 80 A
P043 N Control M 89 G
P044 N Control F 86 AG
P045 N Control F 77 AG
P046 N Control F 67 G
P048 N Control F 77 A
P050 N Control M 65 G
P051 N Control F 72 A
P052 N Control M 71 G
P053 N Control M 75 G
P055 N Control F 72 A
P056 N Control F 70 AG
P057 N Control M 78 AG
P058 N Control F 65 A
P059 N Control F 84 G
P061 N Control M 67 A
P062 N Control F 70 AG
P063 N Control F 84 G
P064 N Control M 88 A
P065 N Control F 82 A
P066 N Control F 67 A
P067 N Control F 80 A
P068 N Control F 77 A
P070 N Control F 81 AG
P071 N Control M 71 G
P072 N Control F 71 AG
P073 N Control F 71 A
P074 N Control F 81 AG
P076 N Control F 72 AG
P077 N Control F 73 AG
P079 N Control M 74 AG
P080 N Control M 65 A
P083 N Control F 78 AG
P084 N Control M 66 G
P085 N Control F 81 A

















P087 N Control F 72 G
P088 N Control F 77 A
P089 N Control F 79 A
P090 N Control F 67 G
P094 N Control M 80 AG
P095 N Control F 84 AG
P097 N Control F 71 G
P098 N Control F 71 AG
P099 N Control M 72 AG
P100 N Control F 60 AG
P101 N Control F 74 AG
P102 N Control F 81 AG
P103 N Control F 75 A
P104 N Control F 85 AG
P105 N Control F 72 AG
P106 N Control F 65 G
P107 N Control M 67 G
P108 N Control F 72 A
004/03 Y DLB F 69 1 2 G
007/03 Y DLB F 88 3 3 A
016/01 Y DLB F 81 G
019/98 Y DLB M 79 0 AG
020/00 Y DLB M 74 3 4 AG
024/99 Y DLB M 88 5 A
040/97 Y DLB F 85 5 6 AG
047/98 Y DLB M 73 AG
050/95 Y DLB F 81 3 2 A
060/98 Y DLB F 77 3 A
061/98 Y DLB F 83 A
075/97 Y DLB F 82 5 AG
080/01 Y DLB M 92 3 4 AG
113/03 Y DLB M 77 1 3 A
125/97 Y DLB M 86 A
129/03 Y DLB M 79 1 4 G
133/90 Y DLB M 67 1 G
136/98 Y DLB M 77 AG
143/97 Y DLB M 63 3 6 AG
153/96 Y DLB F 79 5 2 G
192/96 Y DLB M 79 5 AG
290/99 Y DLB F 85 G

















D124 N DLB F 69 AG
D126 N DLB M 68 AG
D129 N DLB M 72 G
D13 N DLB M 77 AG
D134 N DLB F 80 AG
D136 N DLB M 72 AG
D14 N DLB F 81 G
D140 N DLB F 80 G
D147 N DLB M 73 AG
D156 N DLB M A
D160 N DLB M 73 G
D162 N DLB F 76 A
D165 N DLB F 84 AG
D171 N DLB M 69 A
D173 N DLB M 77 AG
D174 N DLB M 76 AG
D177 N DLB M 86 G
D182 N DLB F 82 AG
D186 N DLB F 77 G
D189 N DLB M 79 A
D26 N DLB M 78 G
D37 N DLB M 70 A
D44 N DLB M 64 AG
D51 N DLB M 71 G
D66 N DLB F 84 AG
D7 N DLB F 58 G
D80 N DLB F 79 A
D81 N DLB M 72 AG
D85 N DLB M 69 A
D87 N DLB F 71 AG
D93 N DLB F 92 AG
D95 N DLB M 66 G
M04 N DLB F 82 A
M07 N DLB F 81 AG
M22 N DLB M 81 AG
M23 N DLB F 72 AG
M26 N DLB F 74 G
M27 N DLB M 77 AG
M33 N DLB F 73 A
M36 N DLB F 76 A

















M46 N DLB F 68 A
M47 N DLB F 80 AG
M49 N DLB M 69 A
M54 N DLB F 70 G
M56 N DLB F 74 AG
M57 N DLB F 81 A
M59 N DLB M 71 A
M67 N DLB F 75 A
017/99 Y PDD M 76 A
111/03 Y PDD M 81 A
183/96 Y PDD M 85 A
20020080 Y PDD M 70 0 1 2 A
20050099 Y PDD M 89 1 2 3 A
A143/00 Y PDD F 89 0 1 0 A
D118 N PDD M 64 A
D178 N PDD M 80 A
D183 N PDD M 74 A
D34 N PDD M 70 A
M11 N PDD F 79 A
M15 N PDD F 81 A
M34 N PDD M 69 A
M37 N PDD F 68 A
M40 N PDD F 63 A
M64 N PDD F 73 A
M66 N PDD F 73 A
PD002 Y PDD M 84 0 0 3 A
PD014 Y PDD M 79 1 A
PD067 Y PDD M 83 0 A
PD081 Y PDD M 73 0 A
PD099 Y PDD M 82 1 A
PD102 Y PDD M 81 1 1 A
ST02/01 Y PDD M 82 0 1 2 A
ST04/01 Y PDD F 85 3 2 3 A
ST10/02 Y PDD M 82 1 1 3 A
ST13/02 Y PDD F 81 1 1 A
ST14/02 Y PDD M 78 2 2 A
ST17/02 Y PDD M 72 0 1 A
ST19/02 Y PDD F 84 0 1 2 A
ST20/02 Y PDD F 84 2 1 3 A
ST22/02 Y PDD F 79 3 1 2 A

















ST25/04 Y PDD F 86 1 1 A
ST30/04 Y PDD M 86 0 0 A
123/97 Y PDD F 76 AG
151/98 Y PDD M 64 AG
183/91 Y PDD M 79 AG
20030103 Y PDD F 73 1 2 3 AG
20030134 Y PDD M 75 1 2 3 AG
D74 N PDD F 55 AG
M14 N PDD F 74 AG
M20 N PDD F 82 AG
M31 N PDD F 75 AG
M32 N PDD M 79 AG
M50 N PDD M 81 AG
M55 N PDD F 79 AG
M58 N PDD F 76 AG
PD013 Y PDD M 78 0 1 2 AG
PD063 Y PDD F 80 0 0 AG
PD093 Y PDD F 81 1 AG
ST03/01 Y PDD M 75 1 1 3 AG
ST09/02 Y PDD M 78 3 3 2 AG
ST11/02 Y PDD F 73 1 1 AG
ST12/02 Y PDD F 80 0 1 2 AG
ST15/02 Y PDD F 88 0 1 AG
ST16/02 Y PDD M 80 0 1 AG
ST18/02 Y PDD M 79 1 1 1 AG
ST23/03 Y PDD F 82 2 1 3 AG
20040022 Y PDD M 79 1 2 3 G
20040076 Y PDD M 76 0 1 3 G
20040105 Y PDD M 68 3 3 3 G
20050096 Y PDD M 73 0 0 2 G
D154 N PDD M 69 G
D94 N PDD F 78 G
M05 N PDD M 69 G
M21 N PDD F 81 G
M28 N PDD F 80 G
M29 N PDD F 76 G
M39 N PDD F 82 G
M44 N PDD F 71 G
ST01/01 Y PDD F 83 2 1 3 G
ST21/03 Y PDD F 83 3 1 3 G

















PD022 Y PD F 76 A
PD023 Y PD M 82 1 1 2 A
PD036 Y PD M 76 0 1 A
PD050 Y PD F 82 A
PD051 Y PD M 80 0 1 2 A
PD086 Y PD F 87 0 1 1 A
PD106 Y PD M 75 2 1 1 A
PD109 Y PD M 72 0 1 1 A
PD114 Y PD M 61 2 1 2 A
PD132 Y PD M 78 1 1 2 A
PD154 Y PD F 79 2 1 2 A
PD160 Y PD M 65 0 1 2 A
PD184 Y PD M 71 0 1 2 A
PD354 Y PD F 89 1 1 A
PD356 Y PD F 86 A
PD368 Y PD F 83 A
PD423 Y PD F 66 A
PD436 Y PD M 80 A
PD074 Y PD M 85 AG
PD175 Y PD M 87 0 1 2 AG
PD187 Y PD M 71 AG
PD197 Y PD F 80 0 1 2 AG
PD201 Y PD M 87 AG
PD203 Y PD F 84 1 1 2 AG
PD204 Y PD F 86 2 1 2 AG
PD216 Y PD M 78 1 1 2 AG
PD239 Y PD M 81 2 1 2 AG
PD275 Y PD M 79 1 1 AG
PD305 Y PD M 86 1 1 AG
PD317 Y PD M 70 AG
PD348 Y PD M 78 1 1 AG
PD377 Y PD F 84 AG
PD398 Y PD M 74 AG
PD009 Y PD F 86 G
PD032 Y PD M 89 0 1 1 G
PD121 Y PD M 69 3 3 2 G
PD183 Y PD M 69 2 2 3 G
PD387 Y PD M 82 G
PD416 Y PD F 85 G
PD007 Y PD M 78 unknown


















































































































































































































004/03 19 10 10 0 0 45 6.66
007/03 18 4 4 0 0 16 6.45
016/01 31 6.26
019/98 25 3 2 -1 1 26 6.66
020/00 4 4 3 -1 1 6 6.23
024/99 0 2 0 -1.5 1.5 24 6.13
040/97 16 1 0 -1 1 48 6.48
047/98 5 5 0 0 58 7.6
050/95 12 2 0 -2 2 23 6.41
060/98 5 2 1 -1 1 48 6.48
061/98 0 1 0 -1 1 33 6.21
075/97 1 5 0 -5 5 75 6.73
080/01 12 9 9 0 0 20 6
113/03 12 5 5 0 0 59 6.5
125/97 9 60 6.84
129/03 22 8 19 11 64 6.32
133/90 3 3 0 0 24 5.88
136/98 19 2 15 13 33 6.23
143/97 36 6.91
153/96 23 4 4 0 64 6.48
192/96 6 1 -5.5 5.5 16 6.73
























































































20020080 16 5 12 7 0 17 6.19
20050099 4 3 16 13 0 64 5.99












PD002 1 9 8 6.41
PD014 3 12 9 21 6.71
PD067 2 9 7 10 6.83
PD081 0 9 9 19 6.51
PD099 4 11 7 10 6.73
PD102 7 25 18 16
ST02/01 16 1 15 14 0 37 6.45
ST04/01 2 4 8 4 0 6.81
ST10/02 20 1 4 3 0 24 6.44
ST13/02 26 0 28 6.85
ST14/02 5 0 24 6.48
ST17/02 27 0 9 6.9
ST19/02 0 27 6.18
ST20/02 3 2 16 14 0 36 6.36
ST22/02 12 2 7 5 0 24 7.19


















ST25/04 11 7 21 14 0 24 6.3




20030103 5 4 10 6 0 30 5.83









PD013 7 24 17 20 6.08
PD063 1 13 12 10 6.73
PD093 3 14 11 22
ST03/01 16 1 13 12 0 36 6.31
ST09/02 9 1 9 8 0 72 6.8
ST11/02 25 0 60 6.68
ST12/02 29 1 6 5 0 28 6.34
ST15/02 13 0 72 5.9
ST16/02 20 0 26 6.58
ST18/02 10 5 16 11 0 30 6.8
ST23/03 6 2 14 12 0 33 6.74
20040022 9 14 5 0 30 6.78
20040076 7 11 4 0 17 6.45
20040105 9 6 8 2 0 11 6.15









ST01/01 12 4 19 15 0 24 6.63
ST21/03 14 2 26 24 0 24 6.45


















PD022 10 14 6.55
PD023 7 28 6.54
PD036 10 10 6.88
PD050 14 6.46
PD051 5 7 6.77
PD086 9 22 6.76
PD106 8 3 6.63
PD109 6 9 6.4
PD114 2 12 6.73
PD132 10 11 6.69
PD154 24 19 6.85
PD160 6 14 6.6
PD184 7 24 6.57
PD354 11 8 6.7
PD356 9 19 6.79
PD368 30 14 6.58
PD423 13 19 6.99
PD436 8 6.71
PD074 9 17 6.49
PD175 19 15 6.61
PD187 8 11 6.58
PD197 22 15 6.43
PD201 7 19 6.52
PD203 18 19
PD204 18 5 6.53
PD216 8 21 6.67
PD239 6 8 6.4
PD275 15 22 6.5
PD305 8 20 6.71
PD317 16 24
PD348 6 31 6.81
PD377 4 15 6.53
PD398 24 12 6.71
PD009 15 6 6.43
PD032 3 16 6.52
PD121 4 9 6.74
PD183 19 22 6.59
PD387 19 14 6.62
PD416 12 17 6.77
PD007 10 22
PD229 18 7 6.56
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Appendix 2. Microarray and gene ontology (GO) analysis
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Appendix 2.1 List of genes that were significantly differentially regulated upon TFAM
overexpression.
transcript_
cluster_id Gene Symbol Gene Title p-value Fold change
18154670
dom ///
snoRNA:Me28S-G2596 domino /// ncRNA 0.001216175 8.24603
18137346 snoRNA:Psi18S-640g ncRNA 0.000575468 5.62505
18207604 CG15784
CG15784 gene product from transcript
CG15784-RA 0.000193688 5.51706
18141748 CG31918
CG31918 gene product from transcript
CG31918-RA 0.000214553 3.70455
18173921 ImpL3 Ecdysone-inducible gene L3 0.001970607 3.58449
18138001 Thor
CG8846 gene product from transcript
CG8846-RA 0.00270655 3.235
18161305 CG13430
CG13430 gene product from transcript
CG13430-RA 0.001199013 3.11299
18150198 CG18343
CG18343 gene product from transcript
CG18343-RA 0.000415337 3.04329
18149383 CG2064
CG2064 gene product from transcript
CG2064-RA 0.000297723 2.80085
18190022 CG31157
CG31157 gene product from transcript
CG31157-RB 0.003184809 2.46274
18142755 FucTB
CG4435 gene product from transcript
CG4435-RA 0.000696815 2.45558
18198470 TFAM mitochondrial transcription factor A 9.31E-06 2.34985
18155337 CG42694




protein 1 0.000108027 2.15547
18154142 Vkor Vitamin-K epoxide reductase 0.008863742 1.87653
18137376 snoRNA:Psi18S-525c ncRNA 0.004784562 1.86948
18168863 CG7607
CG7607 gene product from transcript
CG7607-RA 0.002469362 1.8693
18154342 snoRNA:Psi28S-3316a ncRNA 0.001249277 1.80242
18217993 snoRNA:Me28S-U3344b ncRNA 0.001281285 1.69847
18156120 cv-2 crossveinless 2 0.001654013 1.69341
18168794 blos4 BLOC-1 subunit 4 0.005306561 1.68943
18163719 CG34232
CG34232 gene product from transcript
CG34232-RA 0.003414842 1.58253
18159512 CG7637
CG7637 gene product from transcript
CG7637-RA 0.001649847 1.54785
18142869 CG5846
CG5846 gene product from transcript
CG5846-RA 0.006010311 1.54681
18150644 Arc2
CG13941 gene product from transcript
CG13941-RA 0.003126833 1.54564
18136839 Ada1-2
CG31866 gene product from transcript
CG31866-RA 0.002951174 1.54478
18142919 CG5727
CG5727 gene product from transcript
CG5727-RA 0.006773993 1.54257
18133690 mRpL28 mitochondrial ribosomal protein L28 0.003165487 1.52601
288
18134171 CG7191
CG7191 gene product from transcript
CG7191-RA 0.002290588 1.51138
18142886 CG31714
CG31714 gene product from transcript
CG31714-RB 0.008882207 1.5066
18191725 Rbp1 RNA-binding protein 1 0.001865953 1.50202
18185768 CG14715
CG14715 gene product from transcript
CG14715-RA 0.004138754 1.50177
18131365 Trf TBP-related factor 0.006783743 1.49161
18203018 mRpL37 mitochondrial ribosomal protein L37 0.000612093 1.48775
18153306 Tret1-1 Trehalose transporter 1-1 0.006335764 1.48552
18132916 CG2789
CG2789 gene product from transcript
CG2789-RA 0.001765072 1.48408
18205028 CR41608 ribosomal RNA 0.000910637 1.47645
18171959 loj logjam 0.006072274 1.47212
18165272 CG17684
CG17684 gene product from transcript
CG17684-RC 0.002510032 1.46805
18204860 ND3 NADH dehydrogenase subunit 3 0.006319813 1.45411
18158130 Dgp-1
CG5729 gene product from transcript
CG5729-RA 8.42E-05 1.45384
18154666 snoRNA:Me28S-A2589b ncRNA 0.001301827 1.44864
18144739 CG31683
CG31683 gene product from transcript
CG31683-RA 0.001055888 1.44807
18136832 Qtzl Quetzalcoatl 0.001102121 1.43038
18140864 CG18095
CG18095 gene product from transcript
CG18095-RB 0.001969727 1.42731
18142747 borr borealin-related 0.001573783 1.4251
18187053 CG7342
CG7342 gene product from transcript
CG7342-RB 0.005556996 1.42067
18191773 Xrp1
CG17836 gene product from transcript
CG17836-RB 0.003401172 1.41121
18169539 CG17029
CG17029 gene product from transcript
CG17029-RA 0.00024886 1.40792
18208447 CG2076
CG2076 gene product from transcript
CG2076-RA 0.00097162 1.40643
18172683 Bet1
CG14084 gene product from transcript
CG14084-RB 0.002689554 1.40435
18157874 Inos
CG11143 gene product from transcript
CG11143-RA 0.000662356 1.40422
18150034 CG12942
CG12942 gene product from transcript
CG12942-RA 0.004580837 1.40386
18172840 Exn Ephexin 0.002232586 1.40107
18170573 CG11425
CG11425 gene product from transcript
CG11425-RA 0.001026525 1.395
18156255 ix intersex 0.004650343 1.39117
18176893 CG8111
CG8111 gene product from transcript
CG8111-RA 0.002876667 1.38303
18182365 E(spl) Enhancer of split 0.009645258 1.37837
18149377 CG2065
CG2065 gene product from transcript
CG2065-RA 2.85E-05 1.37834
18203582 CG43448
CG43448 gene product from transcript
CG43448-RA 0.001968114 1.36591
18131618 His3.3A /// His3.3B Histone H3.3A /// Histone H3.3B 0.006127948 1.36157
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18170738 GNBP1 Gram-negative bacteria binding protein 1 0.002172055 1.35968
18200063 CG11882
CG11882 gene product from transcript
CG11882-RA 0.007331665 1.35229
18178466 CG14057
CG14057 gene product from transcript
CG14057-RA 0.003384012 1.33997
18131738 Acer Angiotensin-converting enzyme-related 0.005730108 1.33373
18195594 RpL35A Ribosomal protein L35A 0.001482247 1.33139
18149426 CG1882
CG1882 gene product from transcript
CG1882-RA 0.005315602 1.3218
18132393 Taf10 TBP-associated factor 10 0.000333316 1.31896
18161743 CG3501
CG3501 gene product from transcript
CG3501-RA 0.009024873 1.31185
18144062 Taf13 TBP-associated factor 13 0.008836609 1.29969
18148328 Nrk Neurospecific receptor kinase 0.008766055 1.2966
18135748 Pomp
CG9324 gene product from transcript
CG9324-RA 3.46E-05 1.29456
18140409 NTPase
CG3059 gene product from transcript
CG3059-RD 0.004505528 1.29295
18188448 CG5913
CG5913 gene product from transcript
CG5913-RA 0.002634422 1.29038
18131668 RpS21 Ribosomal protein S21 0.005511447 1.28886
18216191 CG6123
CG6123 gene product from transcript
CG6123-RB 0.007905125 1.28815
18198589 CG7044
CG7044 gene product from transcript
CG7044-RA 0.002534054 1.28767
18172710 CG42588
CG42588 gene product from transcript
CG42588-RA 0.007284208 1.27362
18171088 CR32027 ncRNA 0.000862496 1.26807
18135200 CG16820
CG16820 gene product from transcript
CG16820-RA 0.006627346 1.26453
18168685 CG8329




methylenetetrahydrofolate dehydrogenase 0.007290833 1.24683
18140339 dnt doughnut on 2 0.000555652 1.24252
18148476 san separation anxiety 0.00244481 1.24111
18134302 Scgalpha Sarcoglycan alpha 0.002640796 1.23919
18138091 LanB1
CG7123 gene product from transcript
CG7123-RA 0.000536162 1.23891
18161255 CG16868
CG16868 gene product from transcript
CG16868-RA 0.003669986 1.23605
18208208 Rbm13 RNA-binding motif protein 13 0.003848889 1.23157
18154964 CG42360
CG42360 gene product from transcript
CG42360-RA 0.001283464 1.22981
18178217 CG5830
CG5830 gene product from transcript
CG5830-RA 0.002265748 1.2283
18211098 CG42240
CG42240 gene product from transcript
CG42240-RA 0.002310454 1.22618
18156673 dpn deadpan 0.002935974 1.22555
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18142473 mon2
CG8683 gene product from transcript
CG8683-RB 0.002327515 1.22338
18169736 beg bad egg 0.007281212 1.22323
18152609 Pask PAS kinase 0.008913397 1.22304
18198845 CG4813
CG4813 gene product from transcript
CG4813-RA 0.007749747 1.2221
18133663 CG3036
CG3036 gene product from transcript
CG3036-RA 0.002624977 1.2205
18142912 CG5731
CG5731 gene product from transcript
CG5731-RA 0.00569152 1.21338
18135030 CG14945
CG14945 gene product from transcript
CG14945-RB 0.002934221 1.21086
18172671 CG42575
CG42575 gene product from transcript
CG42575-RA 0.00052047 1.20832
18197160 Ravus
CG15889 gene product from transcript
CG15889-RA 0.009772333 1.20247
18203521 vret vreteno 0.000489586 1.20105
18186795 sll slalom 0.001986136 1.19695
18134652 eEF1delta
CG4912 gene product from transcript
CG4912-RB 6.00E-05 1.19541
18217846 snoRNA:Psi18S-1854c ncRNA 0.007834201 1.19416
18217826 snoRNA:Psi28S-1192b ncRNA 0.003257402 1.19306
18152066 CG10306
CG10306 gene product from transcript
CG10306-RA 0.009807127 1.19119
18133694 CG3792
CG3792 gene product from transcript
CG3792-RA 0.004678829 1.18934
18166977 Rev1
CG12189 gene product from transcript
CG12189-RA 0.001348521 1.18882
18176446 CG10671
CG10671 gene product from transcript
CG10671-RB 0.004946807 1.1875
18166227 tap target of Poxn 0.000430786 1.18613
18193002 e ebony 0.000280314 1.18362
18194868 Irp-1B Iron regulatory protein 1B 0.004115626 1.18148
18134667 CG4957
CG4957 gene product from transcript
CG4957-RA 0.007974996 1.17479
18175769 CG2277
CG2277 gene product from transcript
CG2277-RA 0.009551461 1.17452
18171399 CG32250
CG32250 gene product from transcript
CG32250-RA 0.003810554 1.17446
18163882 snoRNA:Or-CD1 ncRNA 0.005321113 1.17121
18139237 l(2)37Cc lethal (2) 37Cc 0.00468869 1.17026
18161902 Rrp4
CG3931 gene product from transcript
CG3931-RA 0.008791764 1.166
18195800 MAGE
CG10059 gene product from transcript
CG10059-RA 0.009854643 1.16379
18164958 Eaf /// mir-4977
ELL-associated factor /// mir-4977 stem
loop 0.007504492 1.16312
18185658 CG4820
CG4820 gene product from transcript
CG4820-RB 0.008969043 1.15982
18188294 Nup358 Nucleoporin 358 0.003028192 1.15963
18184683 CG1236
CG1236 gene product from transcript
CG1236-RA 0.007954358 1.15883
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18183587 sima similar 0.005544955 1.15856
18166516 Trn Transportin 0.0064983 1.15722
18169870 mRpS26 mitochondrial ribosomal protein S26 0.0074742 1.15672
18190421 CG31472
CG31472 gene product from transcript
CG31472-RA 0.005420729 1.15631
18161975 Upf3
CG11184 gene product from transcript
CG11184-RB 0.003284819 1.15594
18168404 CG6745
CG6745 gene product from transcript
CG6745-RA 0.000305255 1.15495
18212651 shtd shattered 0.007109925 1.15442
18148606 bonsai
CG4207 gene product from transcript
CG4207-RA 0.007766797 1.15064
18179141 mRpL15 mitochondrial ribosomal protein L15 0.005618132 1.14976
18149778 CG12140
CG12140 gene product from transcript
CG12140-RA 0.0097342 1.14878
18181501 CG42863
CG42863 gene product from transcript
CG42863-RB 0.008660875 1.14835
18202403 Ino80
CG31212 gene product from transcript
CG31212-RA 0.000386794 1.14525
18149710 Updo
CG1818 gene product from transcript
CG1818-RA 0.000709967 1.14443
18160444 CG8314
CG8314 gene product from transcript
CG8314-RA 0.007198857 1.14274
18143758 Atac2 ATAC complex component 2 0.00074219 1.14129
18131069 ref(2)P refractory to sigma P 0.001678822 1.13932
18153776 CG30349
CG30349 gene product from transcript
CG30349-RA 0.006824619 1.13918
18211291 CG5010
CG5010 gene product from transcript
CG5010-RA 0.001078923 1.13761
18214386 lin-52
CG15929 gene product from transcript
CG15929-RA 0.009150359 1.13411
18183605 Hmu Hemomucin 0.001656483 1.13236
18142469 RpL36A Ribosomal protein L36A 0.005787647 1.13184
18140791 Rpn11
CG18174 gene product from transcript
CG18174-RA 0.008534965 1.13181
18202368 ALiX ALG-2 interacting protein X 0.000657961 1.13079
18202099 pncr002:3R putative noncoding RNA 002:3R 0.002366496 1.13027
18191841 scaRNA:mgU2-25 ncRNA 0.000322539 1.1268
18198619 CG3337
CG3337 gene product from transcript
CG3337-RA 0.001437471 1.12652
18169698 TSG101 tumor suppressor protein 101 0.002786764 1.12584
18203499 snRNA:U4atac:82E small nuclear RNA U4atac at 82E 0.009193095 1.12555
18160209 RpS23 Ribosomal protein S23 0.005443141 1.12516
18176994 CG7185
CG7185 gene product from transcript
CG7185-RB 0.006356462 1.1241
18165468 LanB2 Laminin B2 0.003413521 1.12392
18138532 CG43403
CG43403 gene product from transcript
CG43403-RA 0.007341784 1.12189
18209746 Hs3st-B Heparan sulfate 3-O sulfotransferase-B 0.006096256 1.12106
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18182995 Gnf1 Germ line transcription factor 1 0.008253461 1.11708
18195012 Noa36
CG10009 gene product from transcript
CG10009-RA 0.005345982 1.11672
18160466 casp caspar 0.008548242 1.116
18218410 Megalin
CG42611 gene product from transcript
CG42611-RA 0.007663898 1.11558
18147971 RpL11 Ribosomal protein L11 0.001875604 1.11026
18192983 Dl Delta 0.004007629 1.10785
18140503 Taf10b TBP-associated factor 10b 0.007752123 1.10747
18132113 beta'Cop beta'-coatomer protein 0.00260211 1.10668
18155317 CG42678
CG42678 gene product from transcript
CG42678-RG 0.004533447 1.10435
18208543 CG11699
CG11699 gene product from transcript
CG11699-RA 0.006352381 1.10384
18184014 gukh GUK-holder 0.002384124 1.10109
18158284 Spn4 Serine protease inhibitor 4 0.009500507 1.10025
18216945 mRpL14 mitochondrial ribosomal protein L14 0.005031468 1.09863
18197221 yellow-e2
CG17044 gene product from transcript
CG17044-RB 0.008753208 1.09802
18143402 CG9934
CG9934 gene product from transcript
CG9934-RB 0.002349179 1.09698
18138997 ck crinkled 0.004652414 1.09596
18193803 Crc Calreticulin 0.001438407 1.09328
18140014 RpL9 Ribosomal protein L9 0.003567168 1.089
18145550 snoRNA:Psi28S-2996 ncRNA 0.000602456 1.08799
18132619 dao down and out 0.003371475 1.08626
18186631 pad poils au dos 0.005977259 1.08298
18208551 CG11696
CG11696 gene product from transcript
CG11696-RA 0.009257201 1.0818
18156226 Hsc70-5 Heat shock protein cognate 5 0.009666787 1.08172
18141733 CG31650
CG31650 gene product from transcript
CG31650-RF 0.008275916 1.08113
18134672 CG4968
CG4968 gene product from transcript
CG4968-RA 0.004429893 1.07783
18137260 His2A:CG33853 ///
CG33853 gene product from transcript
CG33853-RA 0.000575401 1.07699
18152039 CG10321
CG10321 gene product from transcript
CG10321-RA 0.008358105 1.07699
18136473 His2A:CG31618 ///
CG31618 gene product from transcript
CG31618-RA 0.000431063 1.07624
18159807 CG8858
CG8858 gene product from transcript
CG8858-RA 0.004689175 1.07537
18199652 CG6073
CG6073 gene product from transcript
CG6073-RA 0.000906437 1.07465
18165998 RpS4 Ribosomal protein S4 0.008137342 1.07153
18185234 Tcp-1eta
CG8351 gene product from transcript
CG8351-RA 0.00438848 1.06535
18149451 CG2906
CG2906 gene product from transcript
CG2906-RE 0.00044902 1.06486
18150006 CG12325
CG12325 gene product from transcript
CG12325-RA 0.008055326 1.06255
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18219234 kl-3 male fertility factor kl3 0.004181665 1.05968
18181860 scaRNA:pUf68-a ncRNA 0.001229777 1.05922
18202281 CG34293
CG34293 gene product from transcript
CG34293-RA 0.003821104 1.05285
18204046 Rad23
CG1836 gene product from transcript
CG1836-RB 0.003041165 1.05263
18146459 gho ghost 0.00303588 1.05171
18172904 CG42676
CG42676 gene product from transcript
CG42676-RD 0.008179293 1.05052
18167940 CG4769
CG4769 gene product from transcript
CG4769-RA 0.008929421 1.04681
18200552 CstF-50
CG2261 gene product from transcript
CG2261-RA 0.009409992 1.02657
18173529 Notum /// mir-4941
CG13076 gene product from transcript
CG13076-RB 0.001575277 0.966293
18135708 Arc-p34
CG10954 gene product from transcript
CG10954-RA 0.006590619 0.952418
18201562 Unc-115a /// Unc-115b
CG31352 gene product from transcript
CG31352-RA 0.005011536 0.94748
18138279 CG43051
CG43051 gene product from transcript
CG43051-RB 8.61E-05 0.94549
18144790 RluA-1
CG31719 gene product from transcript
CG31719-RA 0.009845629 0.940391
18158303 ced-6
CG11804 gene product from transcript
CG11804-RD 0.000153626 0.937225
18169211 CG10741
CG10741 gene product from transcript
CG10741-RB 0.007445609 0.920592
18183735 Ice
CG7788 gene product from transcript
CG7788-RA 0.00508727 0.917428
18185865 CG17639
CG17639 gene product from transcript
CG17639-RA 0.002758188 0.916263
18202739 E(var)3-9 Enhancer of variegation 3-9 0.00046223 0.915395
18169918 MYPT-75D
CG6896 gene product from transcript
CG6896-RA 0.009220406 0.908841
18162975 CG30375
CG30375 gene product from transcript
CG30375-RA 0.001918266 0.908442
18151744 CG11044
CG11044 gene product from transcript
CG11044-RA 0.009865918 0.90175
18132017 KdelR KDEL receptor 0.005627271 0.901146
18194562 Rab1 Rab-protein 1 0.003899471 0.894818
18202306 CG34353
CG34353 gene product from transcript
CG34353-RB 0.001084427 0.894219
18214141 CG14810
CG14810 gene product from transcript
CG14810-RB 0.004573251 0.890755
18184679 CG1239
CG1239 gene product from transcript
CG1239-RA 0.003527111 0.887632
18136572 CG31661
CG31661 gene product from transcript
CG31661-RA 0.007504383 0.878268
18150655 Dh44-R1 Diuretic hormone 44 receptor 1 0.004838241 0.87768
18158501 CG9430
CG9430 gene product from transcript
CG9430-RB 0.001798084 0.874502
18144474 CG13773




CG6983 gene product from transcript
CG6983-RA 0.000253572 0.873876
18154202 Yu ncRNA 0.006841689 0.872302
18135349 CG15141
CG15141 gene product from transcript
CG15141-RA 0.003168971 0.87041
18200711 CG17193
CG17193 gene product from transcript
CG17193-RB 0.006929341 0.869666
18136885 CG31928
CG31928 gene product from transcript
CG31928-RA 0.009896456 0.863918
18151296 CG4975 /// CG4984
CG4975 gene product from transcript
CG4975-RC 0.004469496 0.8632
18149161 CG3270
CG3270 gene product from transcript
CG3270-RA 0.007457679 0.859796
18158990 Mal-A7 Maltase A7 0.009089439 0.85928
18180785 snoRNA:Or-CD11a ncRNA 0.003869643 0.85926
18177236 pall pallbearer 0.006548162 0.858546
18189532 CG18672
CG18672 gene product from transcript
CG18672-RB 0.002410554 0.854864
18153198 Uhg1 U snoRNA host gene 1 0.007311613 0.852241
18141388 CG3117
CG3117 gene product from transcript
CG3117-RB 0.002587046 0.851631
18134661 CG4953
CG4953 gene product from transcript
CG4953-RA 0.003357879 0.849528
18190590 CG33110
CG33110 gene product from transcript
CG33110-RA 0.00789783 0.843445
18142114 Tsp Thrombospondin 0.007679562 0.843309
18189951 CG31104
CG31104 gene product from transcript
CG31104-RA 0.008487416 0.840469
18173527
CG4641 /// mir-4940 ///
nwk
CG4641 gene product from transcript
CG4641-RA 0.00580685 0.84012
18161416 CG4030
CG4030 gene product from transcript
CG4030-RA 0.000869827 0.829569
18208082 CG15330
CG15330 gene product from transcript
CG15330-RA 0.005826931 0.828649
18151269 HPS4 Hermansky-Pudlak Syndrome 4 ortholog 0.009916421 0.824848
18198913 CG17111
CG17111 gene product from transcript
CG17111-RB 0.006784088 0.823458
18142760 jp junctophilin 0.001120585 0.819984
18163038 CG30403
CG30403 gene product from transcript
CG30403-RB 0.008754219 0.818053
18153463 CG30093
CG30093 gene product from transcript
CG30093-RA 0.004704774 0.814056
18203546 CR43435 ncRNA 2.05E-05 0.813473
18151018 CG6262
CG6262 gene product from transcript
CG6262-RB 0.008909545 0.812102
18169001 CG14125
CG14125 gene product from transcript
CG14125-RA 0.000745845 0.809274
18163176 CG30486
CG30486 gene product from transcript
CG30486-RB 0.004406818 0.807686
18150301 Cpr49Af Cuticular protein 49Af 0.006460296 0.807518
18146538 CG43153




CG30196 gene product from transcript
CG30196-RA 0.00131304 0.791375
18199546 alrm astrocytic leucine-rich repeat molecule 0.007206935 0.786217
18199996 CG9997
CG9997 gene product from transcript
CG9997-RA 0.002758496 0.781906
18208275 Gr8a Gustatory receptor 8a 0.006897148 0.776487
18136813 CR31845 ncRNA 0.005849643 0.774731
18199764 Cpr97Eb Cuticular protein 97Eb 0.003612836 0.774051
18152265 Obp59a Odorant-binding protein 59a 0.00101205 0.773675
18162410 Gr59c Gustatory receptor 59c 0.00026524 0.772871
18141438 CG12400
CG12400 gene product from transcript
CG12400-RA 0.001159771 0.771248
18153693 CG30280
CG30280 gene product from transcript
CG30280-RB 0.002378308 0.768438
18187120 CG4686
CG4686 gene product from transcript
CG4686-RA 0.000265788 0.765585
18188853 CG14527
CG14527 gene product from transcript
CG14527-RA 0.004489832 0.764418
18184717 CG1208
CG1208 gene product from transcript
CG1208-RB 0.005183712 0.763429
18208108 CG15337
CG15337 gene product from transcript
CG15337-RA 0.004026197 0.75891
18157969 Ady43A
CG1851 gene product from transcript
CG1851-RA 0.00403644 0.755935
18170188 Spn77Bb Serpin 77Bb 0.006060339 0.753598
18186801 CG14329
CG14329 gene product from transcript
CG14329-RA 0.000783602 0.743154
18217872 inaF-A
CG34322 gene product from transcript
CG34322-RA 0.001916919 0.722015
18176467 CG10635
CG10635 gene product from transcript
CG10635-RA 0.000306441 0.720365
18154829 Mlp60A Muscle LIM protein at 60A 0.004011238 0.71862
18147882 PebIII Ejaculatory bulb protein III 0.008960484 0.714332
18163021 CG30392
CG30392 gene product from transcript
CG30392-RA 0.004751544 0.710874
18137386 BG642163
CG34102 gene product from transcript
CG34102-RA 0.003132257 0.710612
18168307 ldbr lariat debranching enzyme 0.002333999 0.709086
18139593 Gyc32E Guanyl cyclase at 32E 0.007608087 0.7037
18176460 Uev1A
CG10640 gene product from transcript
CG10640-RA 0.002211696 0.700764
18144961 Cpr30F Cuticular protein 30F 0.007949721 0.696969
18210372 CG32551
CG32551 gene product from transcript
CG32551-RB 0.006371923 0.696004
18176606 CG10469
CG10469 gene product from transcript
CG10469-RA 0.000855532 0.693676
18145396 His4:CG31611 ///
CG31611 gene product from transcript
CG31611-RA 0.004083871 0.689378
18172510 Sfp79B Seminal fluid protein 79 0.002312923 0.683762
18166767 Rh50
CG7499 gene product from transcript
CG7499-RA 0.007696921 0.665234
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18161134 endoB endophilin B 0.000909184 0.648779
18203635 mir-4945 mir-4945 stem loop 0.007784818 0.627274
18153561 CG30197
CG30197 gene product from transcript
CG30197-RA 3.69E-06 0.60787
18170976 Ilp1 Insulin-like peptide 1 0.009023732 0.606509
18197461 CG6912
CG6912 gene product from transcript
CG6912-RA 0.006964493 0.569697
18178610 CG5506
CG5506 gene product from transcript
CG5506-RA 0.00536986 0.53232
18158274 mthl3 methuselah-like 3 0.001843841 0.52145
18154241 snoRNA:U31:54Eb ncRNA 0.000456861 0.468991
18154290 snoRNA:Or-CD4 ncRNA 0.002094688 0.432139
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Appendix 2.2 List of genes that were significantly differentially regulated upon ATPSyn-Cf6
RNAi




CG15784 gene product from
transcript CG15784-RA 6.03E-05 10.5969




G2596 domino /// ncRNA 0.00095617 8.56686
18137346
snoRNA:Psi18S-
640g ncRNA 0.00069359 8.13965
18173921 ImpL3 Ecdysone-inducible gene L3 0.00033932 7.97103
18138001 Thor
CG8846 gene product from
transcript CG8846-RA 0.000565 5.83231
18141748 CG31918
CG31918 gene product from
transcript CG31918-RA 0.00062151 4.37434
18190022 CG31157
CG31157 gene product from
transcript CG31157-RB 0.00046312 4.28967
18149383 CG2064
CG2064 gene product from




CG40648 gene product from
transcript CG40648-RB ///
CG43176 gene product from
transcript CG43176-RB 0.00317208 3.51624
18151892 CG9313
CG9313 gene product from
transcript CG9313-RA 0.00222925 2.88412
18161305 CG13430
CG13430 gene product from
transcript CG13430-RA 0.00159555 2.86149
18153306 Tret1-1 Trehalose transporter 1-1 0.00110164 2.81272
18150198 CG18343
CG18343 gene product from
transcript CG18343-RA 0.00207589 2.76453
18167718 CG14997
CG14997 gene product from
transcript CG14997-RB 0.00061028 2.68688
18136417 CG13245
CG13245 gene product from
transcript CG13245-RA 0.00348208 2.67462
18158130 Dgp-1
CG5729 gene product from
transcript CG5729-RA 0.00096629 2.62097
18160245 Arc1
Activity-regulated cytoskeleton
associated protein 1 6.11E-05 2.56448
18142755 FucTB
CG4435 gene product from
transcript CG4435-RA 0.00027521 2.50122
18171047 Gr64a Gustatory receptor 64a 0.00052089 2.47306
18156120 cv-2 crossveinless 2 1.17E-05 2.43755
18137364
snoRNA:Psi18S-
525i ncRNA 0.00115461 2.39906
18205551 Hex-A Hexokinase A 0.00302129 2.36947
18137376
snoRNA:Psi18S-
525c ncRNA 0.00304722 2.35583
18189641 CG18731
CG18731 gene product from
transcript CG18731-RA 0.00465534 2.3492
18150644 Arc2
CG13941 gene product from
transcript CG13941-RA 0.00311678 2.32007
18191837 CheB98a Chemosensory protein A 98a 0.00869434 2.19248
18180610 pncr009:3L putative noncoding RNA 009:3L 0.00602012 2.18646
18168863 CG7607
CG7607 gene product from








CG5946 gene product from
transcript CG5946-RB 0.00495456 2.1346
18192562 mir-4951 mir-4951 stem loop 0.0082785 2.04486
18205963 y yellow 0.00384956 2.01326
18149377 CG2065
CG2065 gene product from
transcript CG2065-RA 0.0060389 1.97465
18140864 CG18095
CG18095 gene product from
transcript CG18095-RB 0.00301527 1.90088
18137374
snoRNA:Psi18S-
525d ncRNA 0.00696082 1.878
18176479 blanks
CG10630 gene product from
transcript CG10630-RA 0.00189323 1.86689
18136832 Qtzl Quetzalcoatl 0.0001013 1.85172
18168794 blos4 BLOC-1 subunit 4 0.00618154 1.81667
18137362
snoRNA:Psi18S-
525j ncRNA 0.0092684 1.81412
18154342
snoRNA:Psi28S-
3316a ncRNA 0.00157657 1.76679
18187053 CG7342
CG7342 gene product from
transcript CG7342-RB 0.00138545 1.75682
18132916 CG2789
CG2789 gene product from
transcript CG2789-RA 0.00128501 1.74489
18144739 CG31683
CG31683 gene product from
transcript CG31683-RA 0.00728208 1.72951
18149279 Gadd45
CG11086 gene product from
transcript CG11086-RA 0.00288436 1.71983
18205073 Su(Ste):CR40820 ncRNA 0.00552004 1.71519
18191725 Rbp1 RNA-binding protein 1 0.00181542 1.71257
18135200 CG16820
CG16820 gene product from
transcript CG16820-RA 0.00256896 1.70397
18208447 CG2076
CG2076 gene product from
transcript CG2076-RA 0.0004414 1.68845
18154517 Rgk2
CG34390 gene product from
transcript CG34390-RA 0.00093715 1.67261
18185768 CG14715
CG14715 gene product from
transcript CG14715-RA 0.00069977 1.66363
18155337 CG42694
CG42694 gene product from
transcript CG42694-RA 0.00155381 1.66228
18184582 CG1113
CG1113 gene product from
transcript CG1113-RA 5.39E-05 1.65956
18144596 CG31600
CG31600 gene product from
transcript CG31600-RA 0.00438316 1.6591
18143153 Ast-C Allatostatin C 0.00827769 1.64893
18172683 Bet1
CG14084 gene product from
transcript CG14084-RB 0.00093655 1.64152
18144038 CG13962
CG13962 gene product from
transcript CG13962-RA 0.00568099 1.63233
18210964
snoRNA:Me18S-
G894 ncRNA 0.00887228 1.62661
18149426 CG1882
CG1882 gene product from
transcript CG1882-RA 0.0007392 1.62248
18180649
snoRNA:Me28S-





CG34232 gene product from
transcript CG34232-RA 0.00270732 1.60778
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18134171 CG7191
CG7191 gene product from
transcript CG7191-RA 0.00113077 1.60759
18176893 CG8111
CG8111 gene product from
transcript CG8111-RA 0.00039659 1.60559
18189765 bai baiser 0.0007726 1.5942
18172710 CG42588
CG42588 gene product from
transcript CG42588-RA 0.00054462 1.5874
18217993
snoRNA:Me28S-
U3344b ncRNA 0.00965921 1.58092
18191773 Xrp1
CG17836 gene product from
transcript CG17836-RB 0.00291055 1.5691
18170858
asparagine-
synthetase asparagine synthetase 0.00231 1.56638
18152327 asrij
CG13533 gene product from
transcript CG13533-RA 0.00205478 1.55215
18142747 borr borealin-related 0.00096301 1.54624
18165272 CG17684
CG17684 gene product from
transcript CG17684-RC 0.0029367 1.5456
18133927 frj farjavit 0.00677752 1.54303
18180900 Mst77F Male-specific transcript 77F 0.00246547 1.54054
18131052 numb
CG3779 gene product from
transcript CG3779-RB 0.00968873 1.52817
18216191 CG6123
CG6123 gene product from
transcript CG6123-RB 0.00513927 1.52813
18179471 CG7130
CG7130 gene product from
transcript CG7130-RA 0.00720837 1.51901
18204052 yellow-h
CG1629 gene product from





18172840 Exn Ephexin 0.00131918 1.50184
18197090 CG10126
CG10126 gene product from
transcript CG10126-RB 0.00437373 1.5015
18217838
snoRNA:Psi28S-
1135b ncRNA 0.00797287 1.49616
18208208 Rbm13 RNA-binding motif protein 13 0.00136745 1.49516
18200066 CG14509
CG14509 gene product from
transcript CG14509-RB 0.00536327 1.49368
18171021 Gr64b /// Gr64c
Gustatory receptor 64b ///
Gustatory receptor 64c 0.00131264 1.49319
18156910 l(2)not lethal (2) neighbor of tid 0.00315373 1.48761
18178217 CG5830
CG5830 gene product from
transcript CG5830-RA 0.00012407 1.47155
18150034 CG12942
CG12942 gene product from
transcript CG12942-RA 0.00363334 1.4572
18178119 CG7841
CG7841 gene product from
transcript CG7841-RA 0.00687607 1.45293
18132393 Taf10 TBP-associated factor 10 0.00309227 1.44266
18172671 CG42575
CG42575 gene product from
transcript CG42575-RA 0.00045101 1.4426
18156255 ix intersex 0.00538518 1.44083
18180012 CR32207 ncRNA 0.00897907 1.4405
18140409 NTPase
CG3059 gene product from
transcript CG3059-RD 0.00666035 1.44036
18178470 CG6512
CG6512 gene product from
transcript CG6512-RB 0.00374011 1.43897
300
18166086 CG32320
CG32320 gene product from
transcript CG32320-RC 0.00302906 1.43359
18209015 rab3-GEF
CG5627 gene product from
transcript CG5627-RC 0.00971081 1.43349
18154666
snoRNA:Me28S-
A2589b ncRNA 0.00444189 1.42975
18217830
snoRNA:Psi28S-









ncRNA /// ncRNA /// ncRNA ///
ncRNA 0.00909222 1.42741
18157867 CG8910
CG8910 gene product from
transcript CG8910-RA 0.00840028 1.42692
18142869 CG5846
CG5846 gene product from
transcript CG5846-RA 0.00712039 1.42139
18159512 CG7637
CG7637 gene product from
transcript CG7637-RA 2.37E-05 1.42004
18170573 CG11425
CG11425 gene product from
transcript CG11425-RA 0.0003724 1.41948
18197424 CG17304
CG17304 gene product from
transcript CG17304-RA 0.00609519 1.41464
18136243 TepIV Thiolester containing protein IV 0.00584729 1.40373
18196583 Tpc1
Thiamine pyrophosphate carrier
protein 1 0.00161826 1.39494
18142600 CG7627
CG7627 gene product from
transcript CG7627-RB 0.00835849 1.3903
18203582 CG43448
CG43448 gene product from
transcript CG43448-RA 0.00130302 1.38434
18138870 aub aubergine 0.00814965 1.38431
18168870 CG14141
CG14141 gene product from
transcript CG14141-RA 0.00293094 1.37882
18139237 l(2)37Cc lethal (2) 37Cc 0.00496437 1.37379
18135748 Pomp
CG9324 gene product from
transcript CG9324-RA 0.00041795 1.37123
18193002 e ebony 0.00381131 1.36759
18217834
snoRNA:Psi28S-
1135d ncRNA 0.00124629 1.36645




CG9510 gene product from
transcript CG9510-RC 0.00611554 1.3467
18155416 mi minus 0.00234087 1.34232
18170738 GNBP1
Gram-negative bacteria binding
protein 1 0.00183648 1.34025
18172193 CG34455
CG34455 gene product from
transcript CG34455-RC 0.00020333 1.33589
18206438 Hsp60 Heat shock protein 60 0.00714319 1.33496
18198589 CG7044
CG7044 gene product from
transcript CG7044-RA 0.0016562 1.33324
18195692 CG2017
CG2017 gene product from
transcript CG2017-RA 0.00081963 1.32884
18185466 CG8417
CG8417 gene product from
transcript CG8417-RA 0.00319293 1.32724
18161743 CG3501
CG3501 gene product from





CG42630 gene product from
transcript CG42630-RA ///
Mitochondrial Transcription
Factor B1 0.00220474 1.32219




CG34317 gene product from
transcript CG34317-RA 0.00716466 1.30453
18179703 HBS1
CG1898 gene product from
transcript CG1898-RA 0.00431613 1.30101
18180817
snoRNA:Psi28S-
1837a ncRNA 0.00445381 1.288
18213482 CG2658
CG2658 gene product from
transcript CG2658-RB 0.00268513 1.28711
18176868 CG7506
CG7506 gene product from
transcript CG7506-RA 0.00656835 1.27949
18142912 CG5731
CG5731 gene product from
transcript CG5731-RA 0.00738243 1.27094
18174479 Rac1
CG2248 gene product from
transcript CG2248-RA 0.00109148 1.26839
18144062 Taf13 TBP-associated factor 13 0.00682681 1.26757
18156673 dpn deadpan 0.00138788 1.26742
18131618 His3.3A /// His3.3B Histone H3.3A /// Histone H3.3B 0.00139008 1.26602
18171088 CR32027 ncRNA 0.00024312 1.26497
18143847 CG10623
CG10623 gene product from
transcript CG10623-RA 0.00311502 1.26129
18134022 CG3476
CG3476 gene product from
transcript CG3476-RA 0.00571236 1.2585
18164468 CG42732
CG42732 gene product from
transcript CG42732-RH 0.00753201 1.25835
18143613 CG13284
CG13284 gene product from




1377b Ribosomal protein S7 /// ncRNA 0.00680026 1.25585
18197845 ns1 nucleostemin 1 0.00309263 1.25524




CG33649 gene product from
transcript CG33649-RA /// DNA
polymerase gamma 35kD 0.00909722 1.24865
18131668 RpS21 Ribosomal protein S21 0.0009991 1.24853
18195594 RpL35A Ribosomal protein L35A 0.00332662 1.24103
18177312 iPLA2-VIA
calcium-independent
phospholipase A2 VIA 0.00670401 1.23893
18154251
snoRNA:Me28S-
A3407a ncRNA 0.00613538 1.23656
18177554 CG11652
CG11652 gene product from
transcript CG11652-RA 0.00504862 1.23559
18199573 CG4730
CG4730 gene product from
transcript CG4730-RA 0.00943814 1.23485
18134302 Scgalpha Sarcoglycan alpha 0.0018049 1.23211
18189252 dj-1beta
CG1349 gene product from
transcript CG1349-RA 0.0012515 1.22836
18134652 eEF1delta
CG4912 gene product from
transcript CG4912-RB 7.57E-06 1.22819





18167150 pex10 peroxin 10 0.00876471 1.224
18147760 Cct5 T-complex Chaperonin 5 0.00821256 1.22208
18133656 CG3008
CG3008 gene product from
transcript CG3008-RA 0.00306654 1.21796
18153973 CG30493
CG30493 gene product from
transcript CG30493-RB 0.00162682 1.21512
18131069 ref(2)P refractory to sigma P 0.00077173 1.21195
18195800 MAGE
CG10059 gene product from
transcript CG10059-RA 0.00238993 1.21033
18199695 CG6425
CG6425 gene product from
transcript CG6425-RA 0.00425993 1.20876
18162584 CG30022
CG30022 gene product from
transcript CG30022-RB 0.00211952 1.20863
18176446 CG10671
CG10671 gene product from
transcript CG10671-RB 0.00265446 1.20623
18176903 CG7565
CG7565 gene product from
transcript CG7565-RA 0.00152064 1.20286
18161255 CG16868
CG16868 gene product from
transcript CG16868-RA 0.00114234 1.2
18144167 Mtp
Microsomal triacylglycerol
transfer protein 0.00669395 1.19753
18168832 CG7638
CG7638 gene product from
transcript CG7638-RA 0.00293392 1.194
18173983 sti sticky 0.00694341 1.19397
18209406 CG4872
CG4872 gene product from
transcript CG4872-RA 0.00972829 1.19077
18202403 Ino80
CG31212 gene product from
transcript CG31212-RA 0.00096217 1.18948
18211291 CG5010
CG5010 gene product from
transcript CG5010-RA 0.0013282 1.18921
18215857 Anxb11 Annexin B11 0.0090365 1.18819
18183166 ppan peter pan 0.00768755 1.18775
18168404 CG6745
CG6745 gene product from
transcript CG6745-RA 0.00262462 1.18726
18149710 Updo
CG1818 gene product from
transcript CG1818-RA 0.00185684 1.18709
18184429 CG9791
CG9791 gene product from
transcript CG9791-RC 0.00301038 1.18611
18160444 CG8314
CG8314 gene product from
transcript CG8314-RA 0.00719811 1.18408





CG1662 gene product from
transcript CG1662-RA 0.009885 1.17947
18185658 CG4820
CG4820 gene product from
transcript CG4820-RB 0.00818575 1.17384
18133694 CG3792
CG3792 gene product from
transcript CG3792-RA 0.0048409 1.17191
18172723 BHD Birt-Hogg-Dube homolog 0.00447945 1.17091
18148801 Adam
CG12131 gene product from
transcript CG12131-RA 0.00960811 1.16681
18181128 Vti1
CG3279 gene product from
transcript CG3279-RA 0.00757214 1.16538








CG12189 gene product from
transcript CG12189-RA 0.00022847 1.15824
18198545 CG3822
CG3822 gene product from
transcript CG3822-RA 0.00570564 1.15778
18171098 CG32038
CG32038 gene product from
transcript CG32038-RA 0.00624537 1.15746
18173198 Ect4
CG43119 gene product from
transcript CG43119-RI 0.00268206 1.15669
18168918 PCID2 PCI domain-containing protein 2 0.0029372 1.15495
18200680 granny-smith granny smith 0.00846738 1.15439
18200647 Ugt86Di
CG6658 gene product from
transcript CG6658-RA 0.00557256 1.15426
18178350 CG4573
CG4573 gene product from
transcript CG4573-RA 0.0061076 1.15069
18178624 Prestin
CG5485 gene product from
transcript CG5485-RA 0.00751566 1.14997
18138091 LanB1
CG7123 gene product from
transcript CG7123-RA 0.00103271 1.14679
18179951 Ndfip Nedd4 family interacting protein 0.00510313 1.14499
18198619 CG3337
CG3337 gene product from
transcript CG3337-RA 0.00157063 1.14388
18139077 Eno Enolase 0.00278226 1.14032
18167629 IntS10 Integrator 10 0.00520661 1.13987
18200852 Spec2
CG14672 gene product from
transcript CG14672-RA 0.00519965 1.13968
18191841 scaRNA:mgU2-25 ncRNA 0.00219448 1.13847
18199548 CG4553
CG4553 gene product from
transcript CG4553-RA 0.00838847 1.13349
18150646 Tfb1
CG8151 gene product from
transcript CG8151-RB 0.00480318 1.13328
18213842 CG13364
CG13364 gene product from
transcript CG13364-RA 0.00796648 1.13032
18218609 CG42854
CG42854 gene product from
transcript CG42854-RA 0.00298705 1.12967
18187225 Srp14
Signal recognition particle
protein 14 0.00966718 1.12933
18145550
snoRNA:Psi28S-
2996 ncRNA 0.00736528 1.1287
18195950 CG2747
CG2747 gene product from
transcript CG2747-RD 0.00499733 1.12542
18183720 RpS20 Ribosomal protein S20 0.00145545 1.1235
18174496 RpS9 Ribosomal protein S9 0.00074463 1.11832
18169698 TSG101 tumor suppressor protein 101 0.00377256 1.11832
18206908 Crag
Calmodulin-binding protein
related to a Rab3 GDP/GTP
exchange protein 0.00349223 1.11757
18216512 CG12702
CG12702 gene product from
transcript CG12702-RA 0.00671461 1.11718
18179216 CG11396
CG11396 gene product from
transcript CG11396-RA 0.00046612 1.11695
18141576 CG3702
CG3702 gene product from
transcript CG3702-RA 0.00078896 1.11157
18161975 Upf3
CG11184 gene product from
transcript CG11184-RB 0.00845278 1.10988
18217347 Rab9Fb Rab GTPase 9Fb 0.00608404 1.10913
18147971 RpL11 Ribosomal protein L11 0.0050975 1.10583
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18138004 wb wing blister 0.00256153 1.10399
18184118 CG11970
CG11970 gene product from
transcript CG11970-RA 0.00262973 1.10346
18201535 CG31320
CG31320 gene product from
transcript CG31320-RA 0.00746204 1.10315
18192983 Dl Delta 0.00737701 1.10056
18202744 CG12163
CG12163 gene product from
transcript CG12163-RB 0.00576503 1.10012
18176994 CG7185
CG7185 gene product from
transcript CG7185-RB 0.00124625 1.08631
18202368 ALiX ALG-2 interacting protein X 0.00751174 1.08523
18156419 sub subito 0.00331387 1.079
18150743 pcs parcas 0.00973699 1.07868
18169390 CG6859
CG6859 gene product from
transcript CG6859-RA 0.00560458 1.07861
18206728 CG11412
CG11412 gene product from
transcript CG11412-RC 0.00781226 1.07719
18137618 l(2)37Cd lethal (2) 37Cd 0.00064376 1.07103
18184106 rha
CG11908 gene product from
transcript CG11908-RA 0.00394443 1.06965
18200820 CG18766
CG18766 gene product from
transcript CG18766-RB 0.00837091 1.06713
18140954 Spn27A Serpin 27A 0.00351791 1.06012
18195295 Snap24 Synapse protein 24 0.00035428 1.05726
18175627 Tudor-SN
CG7008 gene product from
transcript CG7008-RA 8.11E-05 1.05531
18188169 Trf4-2
CG17462 gene product from
transcript CG17462-RA 0.00268128 1.05424
18172904 CG42676
CG42676 gene product from
transcript CG42676-RD 0.00339452 1.0464
18147725 Dcp-1 Death caspase-1 0.00239293 1.04464
18158416 SCAP SREBP cleavage activating protein 0.00394888 1.04304
18217114 Stim Stromal interaction molecule 0.00984113 1.03939
18205430 dwg deformed wings 0.00139099 1.02453
18193931 pll pelle 0.00641721 0.975716




CG31352 gene product from
transcript CG31352-RA ///
CG31332 gene product from
transcript CG31332-RD 0.00463604 0.962239
18148900 CSN7
COP9 complex homolog subunit
7 0.0060013 0.956608
18208148 Trf4-1
CG11265 gene product from
transcript CG11265-RE 0.00813735 0.955724
18192319 lute
CG43226 gene product from
transcript CG43226-RC 0.00661157 0.947304
18209615 CG6106
CG6106 gene product from
transcript CG6106-RA 0.00172427 0.945839
18169918 MYPT-75D
CG6896 gene product from




18182528 ort ora transientless 0.00370002 0.927295
18162975 CG30375
CG30375 gene product from
transcript CG30375-RA 0.00098599 0.926502
18188844 CG1647 CG1647 gene product from 0.0086378 0.904734
305
transcript CG1647-RA
18181251 CG42638 /// trpml





CG10741 gene product from
transcript CG10741-RB 0.00489654 0.899898
18168169 sec63
CG8583 gene product from
transcript CG8583-RA 0.0034034 0.897385
18202739 E(var)3-9 Enhancer of variegation 3-9 0.00016396 0.896784
18178107 Best3 Bestrophin 3 0.00838554 0.894136
18135414 CG5783
CG5783 gene product from
transcript CG5783-RA 0.00377317 0.893372
18131918 SA Stromalin 0.00950391 0.892258
18199795 CG5984
CG5984 gene product from




CG12546 gene product from
transcript CG12546-RA ///
CG14452 gene product from
transcript CG14452-RA 0.00933525 0.884581
18208454 CG18292
CG18292 gene product from
transcript CG18292-RA 0.00883178 0.878065
18177236 pall pallbearer 0.00449977 0.876039
18183735 Ice
CG7788 gene product from




CG4975 gene product from
transcript CG4975-RC /// CG4984
gene product from transcript
CG4984-RD 0.0044309 0.868863
18133960 Tango1
Transport and Golgi organization
1 0.00635577 0.867038
18146561 CG43271
CG43271 gene product from
transcript CG43271-RA 0.00709926 0.866657
18190590 CG33110
CG33110 gene product from
transcript CG33110-RA 0.00824954 0.862701
18174438 Con Connectin 0.00108219 0.861287
18203667 CR43633 ncRNA 0.0071896 0.858526
18170822 exex extra-extra 0.00768239 0.857871
18213573 CG3081
CG3081 gene product from
transcript CG3081-RA 0.00308284 0.857812
18177541 CG11660
CG11660 gene product from
transcript CG11660-RA 0.00540736 0.856129
18134661 CG4953
CG4953 gene product from
transcript CG4953-RA 0.00247443 0.852556
18213037 CG15865
CG15865 gene product from
transcript CG15865-RA 0.00235208 0.851414
18212788 Yp2 Yolk protein 2 0.00519328 0.846374
18155451 CG42753
CG42753 gene product from
transcript CG42753-RA 0.00280996 0.846061
18152302 CG13532
CG13532 gene product from
transcript CG13532-RA 0.00831944 0.844791
18160593 CG15710
CG15710 gene product from
transcript CG15710-RA 0.00444053 0.842452
18176606 CG10469
CG10469 gene product from
transcript CG10469-RA 0.00454781 0.842121
18144474 CG13773
CG13773 gene product from
transcript CG13773-RA 0.00502971 0.838801
18198913 CG17111 CG17111 gene product from 0.00620576 0.837542
306
transcript CG17111-RB
18142760 jp junctophilin 0.00014847 0.836092
18179124 CG13248
CG13248 gene product from
transcript CG13248-RA 0.00911344 0.8353
18188368 CG5111
CG5111 gene product from
transcript CG5111-RA 0.00711398 0.833873
18151739 CG11041
CG11041 gene product from
transcript CG11041-RB 0.00960347 0.83343
18141765 CG7742
CG7742 gene product from
transcript CG7742-RA 0.00374987 0.832256
18141159 CG5126
CG5126 gene product from
transcript CG5126-RA 0.00263721 0.831834
18135349 CG15141
CG15141 gene product from
transcript CG15141-RA 0.0021022 0.830719
18209672 Pvf1 PDGF- and VEGF-related factor 1 0.00307256 0.830278
18195203 CG2082
CG2082 gene product from
transcript CG2082-RO 0.00890957 0.828343
18203136 CG42789
CG42789 gene product from
transcript CG42789-RA 0.00459018 0.827865
18201884 dpr11
CG33202 gene product from
transcript CG33202-RB 0.00664696 0.82226
18156074 Amy-p Amylase proximal 0.00814662 0.818545
18162410 Gr59c Gustatory receptor 59c 0.00852015 0.817033
18179191 cmpy crimpy 0.00178677 0.81592
18162802 CG30196
CG30196 gene product from
transcript CG30196-RA 0.00031754 0.80735
18181428 CG42764
CG42764 gene product from
transcript CG42764-RB 0.00763566 0.802441
18198922 CG13830
CG13830 gene product from
transcript CG13830-RD 0.00188221 0.802181





CG4386 gene product from
transcript CG4386-RA 0.00460361 0.797008
18181599 CG43085
CG43085 gene product from
transcript CG43085-RA 0.00685298 0.792418
18163038 CG30403
CG30403 gene product from
transcript CG30403-RB 0.00806516 0.78629
18136813 CR31845 ncRNA 0.00707127 0.78252
18141282 CG9967
CG9967 gene product from
transcript CG9967-RA 0.00817463 0.78131
18208108 CG15337
CG15337 gene product from
transcript CG15337-RA 0.00444608 0.781075
18199996 CG9997
CG9997 gene product from
transcript CG9997-RA 0.00043183 0.780029
18186801 CG14329
CG14329 gene product from
transcript CG14329-RA 0.00029947 0.778517
18138259 mir-932 mir-932 stem loop 0.00577106 0.778265
18165176 CG40191
CG40191 gene product from
transcript CG40191-RC 5.62E-05 0.775788
18133006 CG4577
CG4577 gene product from
transcript CG4577-RA 0.00056071 0.775572
18165134 rl rolled 0.00981922 0.774677
18188326 CG11878
CG11878 gene product from
transcript CG11878-RA 0.00376345 0.773014
18172510 Sfp79B Seminal fluid protein 79 0.00698367 0.769735
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18182945 Ccp84Ad
CG2341 gene product from
transcript CG2341-RA 0.00340661 0.768953
18144721 CG31677
CG31677 gene product from
transcript CG31677-RA 0.00921253 0.76771
18144961 Cpr30F Cuticular protein 30F 0.0008396 0.762671
18162910 CG30355
CG30355 gene product from
transcript CG30355-RA 0.00464086 0.762407
18203546 CR43435 ncRNA 3.68E-05 0.759067
18179679 CG18808
CG18808 gene product from
transcript CG18808-RA 0.00162533 0.745906
18175772 CG9186
CG9186 gene product from
transcript CG9186-RB 0.00441964 0.742348
18135911 CG3262
CG3262 gene product from
transcript CG3262-RD 0.0040742 0.741251
18184717 CG1208
CG1208 gene product from
transcript CG1208-RB 0.00880127 0.740908
18146538 CG43153
CG43153 gene product from
transcript CG43153-RA 0.00592774 0.738891
18208275 Gr8a Gustatory receptor 8a 0.0052984 0.735824
18165215 Yeti
CG40218 gene product from
transcript CG40218-RA 0.00577918 0.726886
18161134 endoB endophilin B 0.0050366 0.714497
18170976 Ilp1 Insulin-like peptide 1 0.0084955 0.711269
18211888 CR43461 ncRNA 0.00867789 0.710874
18210372 CG32551
CG32551 gene product from
transcript CG32551-RB 0.00167094 0.709824
18168307 ldbr lariat debranching enzyme 0.00245015 0.709398
18188457 CG14540
CG14540 gene product from
transcript CG14540-RA 0.00098635 0.704872
18176460 Uev1A
CG10640 gene product from
transcript CG10640-RA 0.00056549 0.703522
18193731 Takr86C Tachykinin-like receptor at 86C 0.00059545 0.696583





CG14321 gene product from
transcript CG14321-RA 0.00247061 0.691595
18137386 BG642163
CG34102 gene product from
transcript CG34102-RA 0.00255612 0.68677
18153561 CG30197
CG30197 gene product from
transcript CG30197-RA 0.0077143 0.672047
18186402 CG3987
CG3987 gene product from
transcript CG3987-RA 0.00406746 0.66688
18217872 inaF-A
CG34322 gene product from
transcript CG34322-RA 0.00227378 0.662167
18202229 CG34148
CG34148 gene product from
transcript CG34148-RA 0.00752868 0.660471
18187120 CG4686
CG4686 gene product from




CG31086 gene product from
transcript CG31086-RB ///
CG31323 gene product from
transcript CG31323-RA 0.00516557 0.649454
18157969 Ady43A
CG1851 gene product from
transcript CG1851-RA 0.00070362 0.649214
18178610 CG5506
CG5506 gene product from
transcript CG5506-RA 0.00832784 0.647671
18143158 Ast-CC Allatostatin double C 0.00416383 0.64646
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18159092 CG8216
CG8216 gene product from
transcript CG8216-RA 0.00038131 0.635721
18171921 CG34002
CG34002 gene product from
transcript CG34002-RB 0.00613068 0.628173
18149246 Tsp42El Tetraspanin 42El 0.00710957 0.615843
18137535 CG34351
CG34351 gene product from
transcript CG34351-RC 0.00878067 0.61506
18137557 CG34381
CG34381 gene product from
transcript CG34381-RB 2.70E-05 0.614294
18190260 CG31323
CG31323 gene product from
transcript CG31323-RA 0.00899695 0.60462
18197509 CG6654
CG6654 gene product from
transcript CG6654-RA 0.00311757 0.594878
18158274 mthl3 methuselah-like 3 0.0001988 0.584942
18166767 Rh50
CG7499 gene product from
transcript CG7499-RA 0.00072599 0.569184
18186662 Gyc-89Da Guanylyl cyclase at 89Da 0.002398 0.558076
18197611 CG14871
CG14871 gene product from
transcript CG14871-RB 0.00681125 0.541112
18176817 pst pastrel 0.00108573 0.540126
18154290 snoRNA:Or-CD4 ncRNA 0.00840178 0.527594
18154336
snoRNA:Psi28S-
3316d ncRNA 0.00963706 0.514913
18179739 Ilp3 Insulin-like peptide 3 0.00043264 0.499792
18197461 CG6912
CG6912 gene product from
transcript CG6912-RA 0.00023605 0.0827881
309
Appendix 2.3 List of genes that were commonly regulated upon TFAM overexpression and
ATPSyn-Cf6 RNAi
TFAM o/e ATPSyn-Cf6 RNAi
transcript








S-G2596 domino /// ncRNA 0.001216175 8.24603 0.000956175 8.56686
18137346
snoRNA:Psi18










RA 0.000214553 3.70455 0.000621511 4.37434
18173921 ImpL3
Ecdysone-inducible




































associated protein 1 0.000108027 2.15547 6.11E-05 2.56448
18137376
snoRNA:Psi18




CG7607-RA 0.002469362 1.8693 9.01E-05 2.17674
18154342
snoRNA:Psi28




S-U3344b ncRNA 0.001281285 1.69847 0.009659213 1.58092
18156120 cv-2 crossveinless 2 0.001654013 1.69341 1.17E-05 2.43755






















CG7191-RA 0.002290588 1.51138 0.001130766 1.60759
18191725 Rbp1
RNA-binding protein





RA 0.004138754 1.50177 0.000699772 1.66363
18203018 mRpL37
mitochondrial
ribosomal protein L37 0.000612093 1.48775 0.000188217 1.61239
18153306 Tret1-1
Trehalose transporter













CG5729-RA 8.42E-05 1.45384 0.000966286 2.62097
18154666
snoRNA:Me28





RA 0.001055888 1.44807 0.007282082 1.72951





RB 0.001969727 1.42731 0.003015274 1.90088
























RA 0.004580837 1.40386 0.003633341 1.4572





RA 0.001026525 1.395 0.000372403 1.41948


























related 0.005730108 1.33373 0.004335039 1.2255
18195594 RpL35A
Ribosomal protein




CG1882-RA 0.005315602 1.3218 0.000739204 1.62248
18132393 Taf10
TBP-associated factor




CG3501-RA 0.009024873 1.31185 0.006109095 1.32455
18144062 Taf13
TBP-associated factor

























RA 0.007284208 1.27362 0.000544616 1.5874









folate dehydrogenase 0.007290833 1.24683 0.000876472 1.50605









RA 0.003669986 1.23605 0.001142343 1.2
18208208 Rbm13
RNA-binding motif




CG5830-RA 0.002265748 1.2283 0.000124072 1.47155






























transcript CG10671RB 0.004946807 1.1875 0.002654463 1.20623
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18193002 e ebony 0.000280314 1.18362 0.003811313 1.36759































CG8314-RA 0.007198857 1.14274 0.007198113 1.18408




CG5010-RA 0.001078923 1.13761 0.001328196 1.18921
18202368 ALiX
ALG-2 interacting
protein X 0.000657961 1.13079 0.007511745 1.08523
18191841
scaRNA:mgU2




CG3337-RA 0.001437471 1.12652 0.001570632 1.14388
18169698 TSG101
tumor suppressor




CG7185-RB 0.006356462 1.1241 0.001246255 1.08631
18209746 Hs3st-B
Heparan sulfate 3-O
sulfotransferase-B 0.006096256 1.12106 0.005104865 1.15955
18147971 RpL11
Ribosomal protein
L11 0.001875604 1.11026 0.005097498 1.10583
18192983 Dl Delta 0.004007629 1.10785 0.007377014 1.10056
18216945 mRpL14
mitochondrial
ribosomal protein L14 0.005031468 1.09863 0.001921077 1.18015
18145550
snoRNA:Psi28













RA /// CG31332 gene
product from
transcript CG31332-









CG7788-RA 0.00508727 0.91742 0.000496423 0.87298
18202739 E(var)3-9
Enhancer of




























CG4984-RD 0.004469496 0.8632 0.004430902 0.86883














RB 0.006784088 0.82348 0.006205757 0.83752





RB 0.008754219 0.81803 0.008065165 0.78629















CG9997-RA 0.002758496 0.78196 0.000431832 0.78009
18208275 Gr8a Gustatory receptor 8a 0.006897148 0.77487 0.005298401 0.73584
18136813 CR31845 ncRNA 0.005849643 0.77471 0.007071271 0.78252
18162410 Gr59c
Gustatory receptor
































RA 0.003132257 0.71062 0.002556117 0.68677
18168307 ldbr
lariat debranching





RA 0.002211696 0.70074 0.000565487 0.70352










RA 0.000855532 0.69366 0.004547806 0.84211
18172510 Sfp79B
Seminal fluid protein




CG7499-RA 0.007696921 0.66524 0.000725993 0.56914






RA 3.69E-06 0.60787 0.007714296 0.67207








CG5506-RA 0.00536986 0.53232 0.00832784 0.64761
18158274 mthl3 methuselah-like 3 0.001843841 0.52145 0.000198802 0.58492
18154290
snoRNA:Or-
CD4 ncRNA 0.002094688 0.43219 0.008401781 0.52754
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Appendix 2.4 GO functional clustering chart for the most enriched genes in larvae
overexpressing TFAM












































































































CG7637, SIMA, BORR, NOA36,
HIS2A:CG33832,
HIS2A:CG33835 234 1.4681

































organelle lumen 18 0.67441 0.05277352
MRPS26, TAF10B, CG7185,
CG7637, RRP4, BONSAI, TRF, IX,
TAF10, TAF13, DOM, MRPL28,
NOA36, MRPL15, MRPL14,
CG31650, EAF, CSTF-50 98 1.581
GO:0043233~or
ganelle lumen 18 0.67441 0.05277352
MRPS26, TAF10B, CG7185,
CG7637, RRP4, BONSAI, TRF, IX,
TAF10, TAF13, DOM, MRPL28,
NOA36, MRPL15, MRPL14,
CG31650, EAF, CSTF-50 98 1.581
GO:0031974~m
embrane-
enclosed lumen 18 0.67441 0.06482678
MRPS26, TAF10B, CG7185,
CG7637, RRP4, BONSAI, TRF, IX,
TAF10, TAF13, DOM, MRPL28,
NOA36, MRPL15, MRPL14,









CPR30F, RPL11, RPS23 155 1.6804
GO:0030529~rib
onucleoprotein





MRPL37, RPL11, RPS23 98 1.804
cytoplasm 14 0.52454 0.05106217
TAF10B, IMPL3, TCP-1ETA,
MLP60A, ARC-P34, UPDO,
INOS, TAF10, BORR, SAN, CED-
6, CG8858, CG10306, CK 234 1.7811
GO:0006350~tra
nscription 14 0.52454 0.08273623
TAF10B, INO80, TAP, SIMA,
TRF, IX, TAF10, TAF13, DOM,
DPN, E(SPL), CG13773, GNF1,
EAF 148 1.6357
ribosomal
protein 12 0.44961 1.24E-04
MRPS26, RPL35A, RPL36A,
MRPL28, MRPL15, MRPL14,
RPL9, BONSAI, MRPL37, RPL11,
RPS23, RPS4 234 4.2398
GO:0005840~rib
osome 12 0.44961 0.0012175
MRPS26, RPL35A, RPL36A,
MRPL28, MRPL15, MRPL14,
RPL9, BONSAI, MRPL37, RPL11,
RPS23, RPS4 98 3.1508
320
GO:0005811~lip






























regulation 12 0.44961 0.09043216
TAF10B, TAF10, DOM, DPN,
E(SPL), GNF1, TAP, INO80,
SIMA, TRF, EAF, IX 234 1.72
Transcription 12 0.44961 0.09704439
TAF10B, TAF10, DOM, DPN,
E(SPL), GNF1, TAP, INO80,
SIMA, TRF, EAF, IX 234 1.6937
GO:0033279~rib
osomal subunit 11 0.41214 0.00162793
MRPS26, RPL35A, RPL36A,
MRPL28, MRPL15, MRPL14,





ribosome 11 0.41214 0.00240841
MRPS26, RPL35A, RPL36A,
MRPL28, MRPL15, MRPL14,


































in 10 0.37467 5.88E-04
MRPS26, RPL36A, MRPL28,
MRPL14, RPL9, CG7637,
BONSAI, RPL11, RPS23, RPS4 234 4.2344
GO:0044427~ch






























Appendix 2.5 GO functional clustering chart for the most enriched genes in larvae
expressing ATPSyn-Cf6 dsRNA

















HIS2A:CG33826, HIS2A:CG33820, KL-3, INO80,
HIS4:CG33873, HIS2A:CG31618, RPS4,
HIS4:CG33875, HIS2A:CG33862, HIS3.3B,









BONSAI, ARC-P34, HIS4:CG33891, TRF,
HIS4:CG33893, SAN, MRPL15, MRPL14, HIS4R,
RPL9, HIS2A:CG33844, HIS4:CG33901,
HIS2A:CG33841, HIS2A:CG33847, RPS23,
MRPS26, HIS2A:CG33829, CG7637, BORR,
MRPL28, NOA36, RAVUS, LIN-52,












HIS2A:CG33826, HIS2A:CG33820, KL-3, INO80,
HIS4:CG33873, HIS2A:CG31618, RPS4,
HIS4:CG33875, HIS2A:CG33862, HIS3.3B,









BONSAI, ARC-P34, HIS4:CG33891, TRF,
HIS4:CG33893, SAN, MRPL15, MRPL14, HIS4R,
RPL9, HIS2A:CG33844, HIS4:CG33901,
HIS2A:CG33841, HIS2A:CG33847, RPS23,
MRPS26, HIS2A:CG33829, CG7637, BORR,
MRPL28, NOA36, RAVUS, LIN-52,














HIS4:CG33885, IX, TAF10, HIS2A:CG33850,
DOM, GNF1, HIS2A:CG33856, HIS2A:CG33859,
HIS2A:CG33853, HIS2A:CG33808,
HIS4:CG33895, HIS2A:CG33838, HIS4:CG33897,
RBP1, HIS4:CG33899, HIS4:CG33891, TRF, LDBR,
HIS4:CG33893, DPN, HIS4R, HIS2A:CG33844,
HIS4:CG33901, HIS2A:CG33841,
HIS2A:CG33847, REF(2)P, HIS2A:CG33829,
CG7185, CG7637, SIMA, BORR, NOA36,













HIS4:CG33885, INOS, DOM, HIS2A:CG33850,
CG8858, GNF1, HIS2A:CG33856, NRK,
HIS2A:CG33859, HIS2A:CG33853,
HIS2A:CG33808, HIS4:CG33895,
HIS2A:CG33838, HSC70-5, HIS4:CG33897, RBP1,
HIS4:CG33899, HIS4:CG33891, HIS4:CG33893,
CED-6, DPN, HIS4R, HIS2A:CG33844,
HIS4:CG33901, HIS2A:CG33841,
HIS2A:CG33847, REF(2)P, HIS2A:CG33829,
CG7185, BORR, HIS2A:CG33832, MTHL3,







MRPS26, TAF10B, CG7185, CG7637, RRP4,
BONSAI, TRF, IX, TAF10, TAF13, DOM, MRPL28,









MRPS26, TAF10B, CG7185, CG7637, RRP4,
BONSAI, TRF, IX, TAF10, TAF13, DOM, MRPL28,









MRPS26, TAF10B, CG7185, CG7637, RRP4,
BONSAI, TRF, IX, TAF10, TAF13, DOM, MRPL28,










MRPS26, RPL35A, RPL36A, CPR97EB, BONSAI,
RPS4, SCGALPHA, CPR49AF, MRPL28, MRPL15,








MRPS26, RPL35A, RPL36A, CG7637, BONSAI,
RPS4, SNRNA:U4ATAC:82E, MRPL28, MRPL15,





TAF10B, IMPL3, TCP-1ETA, MLP60A, ARC-P34,
UPDO, INOS, TAF10, BORR, SAN, CED-6,







TAF10B, INO80, TAP, SIMA, TRF, IX, TAF10,






MRPS26, RPL35A, RPL36A, MRPL28, MRPL15,







MRPS26, RPL35A, RPL36A, MRPL28, MRPL15,
































TAF10B, TAF10, DOM, DPN, E(SPL), GNF1, TAP,





TAF10B, TAF10, DOM, DPN, E(SPL), GNF1, TAP,







MRPS26, RPL35A, RPL36A, MRPL28, MRPL15,











MRPS26, RPL35A, RPL36A, MRPL28, MRPL15,




















HIS4:CG33893, SAN, HIS4R, HIS2A:CG33844,
HIS4:CG33901, HIS2A:CG33841,
HIS2A:CG33847, HIS2A:CG33829, BORR,







MRPS26, RPL36A, MRPL28, MRPL14, RPL9,












HIS4:CG33893, HIS2A:CG33862, SAN, HIS3.3B,







HIS2A:CG33850, RAVUS, NOA36, LIN-52, GNF1,
HIS2A:CG33856, HIS2A:CG33859,
HIS2A:CG33832, HIS2A:CG33808,
HIS2A:CG33853, HIS2A:CG33835 98 2.009742168
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Appendix 2.6 GO functional clustering chart for the genes which are commonly most
enriched in larvae overexpressing TFAM or expressing ATPSyn-Cf6 dsRNA


















only 2 0.44643 0.05154
CG2064,
CG2065 6 31.7179487











MTHL3, ACER 115 2.07576212
